Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:nucleoside phosphate
go back to main search page
Accession:CHEBI:25608 term browser browse the term
Definition:A nucleobase-containing molecular entity that is a nucleoside in which one or more of the sugar hydroxy groups has been converted into a mono- or poly-phosphate. The term includes both nucleotides and non-nucleotide nucleoside phosphates.
Synonyms:related_synonym: NMP;   nucleoside phosphates
 xref: kegg.compound:C01329
 cyclic_relationship: has_functional_parent CHEBI:33838


show annotations for term's descendants           Sort by:
2'-deoxycytosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Deoxycytidine Monophosphate] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
2'-deoxyguanosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 2'-deoxyguanosine 5'-phosphate] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions 		ISO Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein 		CTD PMID:20339114 PMID:20655299 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 increases transport
multiple interactions
affects uptake 		ISO ABCC4 protein results in increased transport of Cyclic AMP
Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog] 		CTD PMID:11856762 PMID:28587784 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 multiple interactions ISO [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases abundance ISO ADIPOQ protein results in increased abundance of Cyclic AMP CTD PMID:18931039 NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169 		JBrowse link
G Adm adrenomedullin multiple interactions
increases abundance 		EXP ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]
ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP 		CTD PMID:10374718 PMID:17306419 NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371 		JBrowse link
G Adra1b adrenoceptor alpha 1B multiple interactions ISO ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:12649302 NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347 		JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions
increases abundance
affects abundance 		ISO
EXP 		[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP
ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] 		CTD PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 More... NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
increases chemical synthesis
increases abundance
affects abundance 		EXP
ISO 		[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]
ADRB2 protein results in increased abundance of Cyclic AMP
ADRB2 protein affects the abundance of Cyclic AMP 		CTD PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 More... NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803 		JBrowse link
G Adrb3 adrenoceptor beta 3 multiple interactions
affects abundance 		ISO 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP
ADRB3 protein affects the abundance of Cyclic AMP 		CTD PMID:10952688 PMID:14730417 NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420 		JBrowse link
G Ahcyl1 adenosylhomocysteinase-like 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] CTD PMID:19414516 NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
decreases expression 		EXP
ISO 		AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
Cyclic AMP results in decreased expression of AHR protein 		CTD PMID:12859982 PMID:32781018 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA CTD PMID:16036225 NCBI chr 9:95,213,763...95,216,509
Ensembl chr 9:95,213,374...95,219,451 		JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] CTD PMID:19414516 NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ank2 ankyrin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] CTD PMID:19414516 NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259 		JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions
increases expression 		ISO N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] CTD PMID:12542607 NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685 		JBrowse link
G Aqp5 aquaporin 5 multiple interactions ISO Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein CTD PMID:15536076 NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] CTD PMID:19414516 NCBI chr15:25,455,478...25,556,569
Ensembl chr15:25,455,297...25,556,534 		JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator multiple interactions EXP Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] CTD PMID:12859982 NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546 		JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions ISO [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein CTD PMID:25191754 NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487 		JBrowse link
G Atf5 activating transcription factor 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] CTD PMID:19414516 NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183 		JBrowse link
G Avp arginine vasopressin multiple interactions ISO [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:20683494 NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522 		JBrowse link
G Avpr2 arginine vasopressin receptor 2 multiple interactions
increases abundance 		ISO [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP
AVPR2 protein results in increased abundance of Cyclic AMP 		CTD PMID:20683494 PMID:33638691 NCBI chr  X:156,785,009...156,787,477
Ensembl chr  X:156,785,139...156,787,477 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase increases activity
multiple interactions 		ISO
EXP 		Cyclic AMP results in increased activity of BRAF protein
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein 		CTD PMID:21693435 NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:69,342,813...69,476,931 		JBrowse link
G C13h1orf115 similar to human chromosome 1 open reading frame 115 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C13H1ORF115 mRNA] CTD PMID:19414516 NCBI chr13:98,953,841...98,963,577
Ensembl chr13:98,953,843...98,963,810 		JBrowse link
G C1qtnf5 C1q and TNF related 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] CTD PMID:19414516 NCBI chr 8:53,347,754...53,349,912
Ensembl chr 8:53,347,711...53,349,912 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases abundance
multiple interactions 		ISO
EXP 		CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP
CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]
Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP] 		CTD PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Carm1 coactivator-associated arginine methyltransferase 1 multiple interactions
increases phosphorylation 		ISO [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr 8:28,373,370...28,418,056
Ensembl chr 8:28,373,362...28,418,056 		JBrowse link
G Cckbr cholecystokinin B receptor multiple interactions ISO CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] CTD PMID:11880531 NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] CTD PMID:9863660 NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] CTD PMID:19414516 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions EXP
ISO 		[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] CTD PMID:21693435 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Cd3e CD3 epsilon subunit of T-cell receptor complex decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3E protein CTD PMID:2824607 NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876 		JBrowse link
G Cd3g CD3 gamma subunit of T-cell receptor complex decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3G protein CTD PMID:2824607 NCBI chr 8:54,177,572...54,184,087
Ensembl chr 8:54,177,977...54,183,918 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP
ISO 		[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] CTD PMID:21693435 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases response to substance ISO CEBPB protein results in increased susceptibility to Cyclic AMP CTD PMID:23097472 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity 		ISO
EXP 		Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides]
CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
Cyclic AMP results in increased activity of CFTR protein
Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form] 		CTD PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 More... NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Cga glycoprotein hormones, alpha polypeptide multiple interactions
affects secretion
increases abundance 		EXP
ISO 		[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA
CGA protein affects the secretion of Cyclic AMP
CGA protein results in increased abundance of Cyclic AMP
[CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] 		CTD PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 More... NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:54,235,019...54,295,464 		JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] CTD PMID:19414516 NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:129,100,041...129,161,081 		JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions EXP
ISO 		[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] 		CTD PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions ISO (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CTD PMID:17558435 PMID:27429655 NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961 		JBrowse link
G Cntn1 contactin 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA CTD PMID:33713149 NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391 		JBrowse link
G Cp ceruloplasmin multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] CTD PMID:19414516 NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP [Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] CTD PMID:12859982 PMID:22676303 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crebbp CREB binding protein multiple interactions ISO CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:20360387 NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions ISO
EXP 		[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]] 		CTD PMID:2153673 PMID:20702571 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Crhr1 corticotropin releasing hormone receptor 1 multiple interactions ISO [CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CTD PMID:20702571 NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466 		JBrowse link
G Crp C-reactive protein multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] CTD PMID:22117073 NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514 		JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Cyclic AMP results in increased expression of CSF3 protein CTD PMID:7540958 NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860 		JBrowse link
G Csk C-terminal Src kinase multiple interactions ISO CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] CTD PMID:1699227 NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274 		JBrowse link
G Cstb cystatin B multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] CTD PMID:19414516 NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199 		JBrowse link
G Ctsa cathepsin A multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] CTD PMID:19414516 NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:173,988,460...173,995,539 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression
multiple interactions 		ISO Cyclic AMP results in increased expression of CYP11A1 mRNA
Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein
myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA] 		CTD PMID:25576683 PMID:28668616 PMID:29228121 NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 multiple interactions
increases expression 		ISO N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA] CTD PMID:22172629 NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions
increases expression 		ISO [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein
Cyclic AMP results in increased expression of CYP17A1 mRNA 		CTD PMID:23084589 PMID:25576683 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases expression
multiple interactions 		ISO Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] 		CTD PMID:29228121 PMID:31953017 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA CTD PMID:32781018 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions 		ISO
EXP 		Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] 		CTD PMID:12859982 PMID:32781018 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp51 cytochrome P450, family 51 increases expression ISO Cyclic AMP results in increased expression of CYP51 mRNA CTD PMID:25576683 NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression
decreases activity 		EXP Cyclic AMP results in decreased expression of CYP7B1 mRNA
Cyclic AMP results in decreased activity of CYP7B1 protein 		CTD PMID:12029625 NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804 		JBrowse link
G Dap death-associated protein multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] CTD PMID:19414516 NCBI chr 2:83,910,113...83,962,673
Ensembl chr 2:83,910,060...83,962,673 		JBrowse link
G Ddt D-dopachrome tautomerase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] CTD PMID:19414516 NCBI chr20:12,883,025...12,886,121 JBrowse link
G Disc1 DISC1 scaffold protein multiple interactions ISO Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] CTD PMID:16293762 NCBI chr19:69,911,548...70,120,970
Ensembl chr19:69,911,976...70,120,970 		JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 affects response to substance ISO DKK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650 		JBrowse link
G Dld dihydrolipoamide dehydrogenase increases abundance EXP DLD protein results in increased abundance of Cyclic AMP CTD PMID:25981801 NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354 		JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA CTD PMID:33713149 NCBI chr10:55,239,397...55,267,780
Ensembl chr10:55,236,869...55,265,839 		JBrowse link
G Drd1 dopamine receptor D1 multiple interactions ISO
EXP 		A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]
[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]] 		CTD PMID:8558425 PMID:15711596 NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166 		JBrowse link
G Drd2 dopamine receptor D2 multiple interactions ISO [Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] 		CTD PMID:11880531 PMID:17958328 NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339 		JBrowse link
G Drd4 dopamine receptor D4 multiple interactions ISO [3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] CTD PMID:15542745 NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458 		JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA CTD PMID:33713149 NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:17295779 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA CTD PMID:12767924 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Ehd2 EH-domain containing 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] CTD PMID:19414516 NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:85,768,667...85,786,943 		JBrowse link
G Endod1 endonuclease domain containing 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] CTD PMID:19414516 NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:19,490,615...19,520,007 		JBrowse link
G Eno2 enolase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] CTD PMID:19414516 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Epo erythropoietin increases expression EXP Cyclic AMP results in increased expression of EPO protein CTD PMID:18621143 NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725 		JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 increases expression EXP Cyclic AMP results in increased expression of ERRFI1 mRNA CTD PMID:1472065 NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
increases activity 		ISO [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of ESR1 mRNA; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of ESR1 mRNA]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:19766106 PMID:20360387 PMID:39892737 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] 		CTD PMID:19766106 PMID:20378682 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G F2r coagulation factor II (thrombin) receptor multiple interactions ISO [C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions ISO Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] CTD PMID:11804840 NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954 		JBrowse link
G F2rl3 F2R like thrombin or trypsin receptor 3 multiple interactions ISO [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr16:17,151,516...17,153,509
Ensembl chr16:17,151,516...17,153,823 		JBrowse link
G Fam20c FAM20C, golgi associated secretory pathway kinase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] CTD PMID:19414516 NCBI chr12:20,940,654...20,999,072
Ensembl chr12:20,940,654...20,998,318 		JBrowse link
G Fcgr2a Fc gamma receptor 2A multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] CTD PMID:19414516 NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394 		JBrowse link
G Fdx1 ferredoxin 1 multiple interactions
increases expression 		ISO myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] CTD PMID:28668616 NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:61,164,839...61,183,583 		JBrowse link
G Fig4 FIG4 phosphoinositide 5-phosphatase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] CTD PMID:19414516 NCBI chr20:46,183,225...46,306,686
Ensembl chr20:46,183,225...46,306,477 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression 		ISO [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA
Cyclic AMP results in increased expression of FOS mRNA 		CTD PMID:10064622 PMID:10711420 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Foxm1 forkhead box M1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA CTD PMID:33713149 NCBI chr 4:163,325,628...163,338,100
Ensembl chr 4:163,325,614...163,337,172 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]
FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] 		CTD PMID:26847930 PMID:31953017 PMID:39892737 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions
increases abundance
increases secretion 		EXP
ISO 		2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]
FSHB protein results in increased secretion of Cyclic AMP
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]
[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] 		CTD PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 More... NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072 		JBrowse link
G Fshr follicle stimulating hormone receptor multiple interactions ISO [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] CTD PMID:26895433 NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:10,952,329...11,160,288 		JBrowse link
G Fzd10 frizzled class receptor 10 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA CTD PMID:33713149 NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions EXP
ISO 		[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein] 		CTD PMID:22676303 PMID:26847930 NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033 		JBrowse link
G Gabpb1 GA binding protein transcription factor subunit beta 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] CTD PMID:19414516 NCBI chr 3:134,333,339...134,380,239
Ensembl chr 3:134,333,339...134,361,344 		JBrowse link
G Gabra2 gamma-aminobutyric acid type A receptor subunit alpha 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA CTD PMID:33713149 NCBI chr14:37,451,218...37,587,458
Ensembl chr14:37,450,683...37,587,457 		JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] CTD PMID:19414516 NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810 		JBrowse link
G Gcg glucagon multiple interactions
increases chemical synthesis
increases abundance 		ISO
EXP 		[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
GCG protein results in increased chemical synthesis of Cyclic AMP
Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP 		CTD PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533 		JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions ISO 3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:19647008 PMID:33713149 NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA CTD PMID:33713149 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Ghrh growth hormone releasing hormone multiple interactions ISO [GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP CTD PMID:22308467 NCBI chr 3:166,412,763...166,432,519
Ensembl chr 3:166,412,764...166,431,880 		JBrowse link
G Gip gastric inhibitory polypeptide multiple interactions ISO [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216 		JBrowse link
G Gipr gastric inhibitory polypeptide receptor multiple interactions ISO [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr 1:87,932,316...87,956,084
Ensembl chr 1:87,932,623...87,942,492 		JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA CTD PMID:33713149 NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:65,042,237...65,054,540 		JBrowse link
G Glipr2 GLI pathogenesis-related 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] CTD PMID:19414516 NCBI chr 5:62,966,163...62,998,016
Ensembl chr 5:62,966,195...62,998,716 		JBrowse link
G Glp1r glucagon-like peptide 1 receptor multiple interactions ISO
EXP 		[danuglipron results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP; [GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP; [Liraglutide results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
[Exenatide results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP 		CTD PMID:18669601 PMID:25191754 PMID:39395609 NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,973,352...9,011,654 		JBrowse link
G Gnai2 G protein subunit alpha i2 multiple interactions ISO [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:20713914 NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:117,167,045...117,187,622 		JBrowse link
G Gnal G protein subunit alpha L multiple interactions ISO [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP CTD PMID:15598656 NCBI chr18:62,892,257...63,032,510
Ensembl chr18:62,892,226...63,043,129 		JBrowse link
G Gnas GNAS complex locus multiple interactions ISO [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP 		CTD PMID:11895442 PMID:15598656 PMID:23022524 NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions ISO [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP 		CTD PMID:17963371 PMID:23022524 NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:83,311,246...83,315,608 		JBrowse link
G Gpc3 glypican 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] CTD PMID:19414516 NCBI chr  X:136,789,770...137,157,598
Ensembl chr  X:136,789,770...137,157,639 		JBrowse link
G Greb1l GREB1 like retinoic acid receptor coactivator multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] CTD PMID:19414516 NCBI chr18:1,665,468...1,902,291
Ensembl chr18:1,766,214...1,900,178 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA CTD PMID:33713149 NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616 		JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA CTD PMID:33713149 NCBI chr 3:28,501,836...28,528,754
Ensembl chr 3:28,501,836...28,528,754 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA CTD PMID:33713149 NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378 		JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA CTD PMID:33713149 NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570 		JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions ISO [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] CTD PMID:25191754 NCBI chr 1:211,010,259...211,031,013
Ensembl chr 1:211,009,978...211,031,015 		JBrowse link
G Grn granulin precursor multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] CTD PMID:19414516 NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] CTD PMID:20056751 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gtpbp2 GTP binding protein 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] CTD PMID:19414516 NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441 		JBrowse link
G Gypc glycophorin C multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] CTD PMID:19414516 NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,434,922...24,440,053 		JBrowse link
G H2bc21 H2B clustered histone 21 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of H2BC21 mRNA] CTD PMID:19414516 NCBI chr 2:186,469,452...186,471,899 JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions
decreases abundance 		ISO [3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
HCAR2 protein results in decreased abundance of Cyclic AMP 		CTD PMID:17124637 PMID:19223991 PMID:20655299 NCBI chr12:38,387,163...38,389,149
Ensembl chr12:38,387,230...38,389,391 		JBrowse link
G Hdac2 histone deacetylase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] CTD PMID:19414516 NCBI chr20:42,101,815...42,126,486
Ensembl chr20:42,102,861...42,126,311 		JBrowse link
G Hdac6 histone deacetylase 6 affects abundance ISO HDAC6 protein affects the abundance of Cyclic AMP CTD PMID:28887310 NCBI chr  X:17,222,538...17,244,373
Ensembl chr  X:17,222,856...17,244,370 		JBrowse link
G Hes3 hes family bHLH transcription factor 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA CTD PMID:33713149 NCBI chr 5:168,076,337...168,082,270
Ensembl chr 5:168,077,093...168,078,987 		JBrowse link
G Hivep2 HIVEP zinc finger 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] CTD PMID:19414516 NCBI chr 1:10,176,880...10,376,089
Ensembl chr 1:10,179,402...10,376,089 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions ISO Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] CTD PMID:18602936 NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758 		JBrowse link
G Hoxb1 homeo box B1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA CTD PMID:33713149 NCBI chr10:81,827,915...81,830,404
Ensembl chr10:81,827,915...81,830,404 		JBrowse link
G Hp haptoglobin multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] CTD PMID:22117073 NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518 		JBrowse link
G Hrh1 histamine receptor H 1 multiple interactions ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] CTD PMID:2419744 NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:149,120,039...149,208,248 		JBrowse link
G Hrh2 histamine receptor H 2 increases abundance
multiple interactions 		ISO HRH2 protein results in increased abundance of Cyclic AMP
[Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] 		CTD PMID:9187264 PMID:9681472 PMID:15843518 NCBI chr17:10,371,083...10,412,979
Ensembl chr17:10,371,083...10,391,041 		JBrowse link
G Hrh3 histamine receptor H3 multiple interactions EXP [imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:21276809 NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:187,569,175...187,574,259 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression ISO Cyclic AMP results in increased expression of HSD3B1 mRNA CTD PMID:25576683 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression ISO Cyclic AMP results in increased expression of HSD3B2 mRNA CTD PMID:18490834 NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions ISO [JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11356925 PMID:20580787 NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760 		JBrowse link
G Htr1b 5-hydroxytryptamine receptor 1B multiple interactions ISO HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11134654 NCBI chr 8:91,395,405...91,414,815
Ensembl chr 8:91,052,432...91,418,583 		JBrowse link
G Htr6 5-hydroxytryptamine receptor 6 increases abundance
multiple interactions 		ISO HTR6 protein results in increased abundance of Cyclic AMP
Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP] 		CTD PMID:11406289 NCBI chr 5:156,579,901...156,595,147
Ensembl chr 5:156,579,901...156,595,147 		JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 increases abundance
multiple interactions 		ISO HTR7 results in increased abundance of Cyclic AMP
[3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] 		CTD PMID:10720076 PMID:14578406 PMID:19509219 NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:243,049,081...243,173,230 		JBrowse link
G Htra1 HtrA serine peptidase 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] CTD PMID:19414516 NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein CTD PMID:32781018 NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328 		JBrowse link
G Ier3 immediate early response 3 multiple interactions
affects response to substance 		EXP
ISO 		2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA]
IER3 protein affects the susceptibility to Cyclic AMP
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]] 		CTD PMID:19414516 PMID:20713914 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Ifng interferon gamma multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] CTD PMID:32781018 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 protein; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] CTD PMID:31953017 PMID:32446389 PMID:32781018 PMID:39892737 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] CTD PMID:19414516 NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390 		JBrowse link
G Il12a interleukin 12A multiple interactions ISO Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] CTD PMID:15843518 NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] CTD PMID:15843518 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il15ra interleukin 15 receptor subunit alpha multiple interactions
decreases expression 		ISO [Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] CTD PMID:22117073 NCBI chr17:71,712,141...71,742,072
Ensembl chr17:71,712,141...71,742,149 		JBrowse link
G Il17re interleukin 17 receptor E multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] CTD PMID:19414516 NCBI chr 4:148,160,384...148,173,830
Ensembl chr 4:148,159,475...148,173,827 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases abundance 		ISO 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA] 		CTD PMID:8904084 PMID:17709599 PMID:22117073 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il1rn interleukin 1 receptor antagonist multiple interactions
increases expression 		ISO Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] CTD PMID:22117073 NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732 		JBrowse link
G Il4 interleukin 4 increases chemical synthesis
multiple interactions 		ISO IL4 protein results in increased chemical synthesis of Cyclic AMP
Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP] 		CTD PMID:12230500 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il6 interleukin 6 increases expression EXP Cyclic AMP analog results in increased expression of IL6 mRNA CTD PMID:10469353 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Inhba inhibin subunit beta A increases secretion ISO Cyclic AMP results in increased secretion of INHBA protein CTD PMID:20074812 NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508 		JBrowse link
G Inhbe inhibin subunit beta E multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA CTD PMID:33713149 NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP
ISO 		[Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] 		CTD PMID:4306506 PMID:26847930 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] CTD PMID:19414516 NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043 		JBrowse link
G Irf6 interferon regulatory factor 6 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] CTD PMID:19414516 NCBI chr13:107,200,876...107,220,083
Ensembl chr13:107,200,731...107,220,049 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] CTD PMID:19414516 NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA CTD PMID:10711420 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] CTD PMID:19414516 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kif15 kinesin family member 15 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] CTD PMID:19414516 NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202 		JBrowse link
G Kng1 kininogen 1 increases abundance EXP KNG1 results in increased abundance of Cyclic AMP CTD PMID:15750287 NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148 		JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] CTD PMID:19414516 NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159 		JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA CTD PMID:33713149 NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929 		JBrowse link
G Lep leptin increases abundance
multiple interactions
increases expression 		ISO LEP protein results in increased abundance of Cyclic AMP
3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA] 		CTD PMID:11342529 PMID:27381457 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions
increases abundance
increases chemical synthesis
affects secretion 		EXP
ISO 		5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]
CGB3 protein results in increased chemical synthesis of Cyclic AMP; LHB protein results in increased chemical synthesis of Cyclic AMP
LHB protein affects the secretion of Cyclic AMP
[LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP] 		CTD PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions ISO [CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] 		CTD PMID:19766106 PMID:20378682 NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061 		JBrowse link
G Lipe lipase E, hormone sensitive type increases activity ISO Cyclic AMP results in increased activity of LIPE protein CTD PMID:7155675 NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117 		JBrowse link
G Lmna lamin A/C multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] CTD PMID:19414516 NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072 		JBrowse link
G Lurap1l leucine rich adaptor protein 1-like multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] CTD PMID:19414516 NCBI chr 5:100,402,921...100,455,479
Ensembl chr 5:100,407,483...100,455,478 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] CTD PMID:19414516 NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584 		JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein CTD PMID:33713149 NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459 		JBrowse link
G Mc2r melanocortin 2 receptor multiple interactions ISO [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA CTD PMID:23084589 NCBI chr18:64,279,878...64,291,775
Ensembl chr18:64,277,360...64,291,881 		JBrowse link
G Msantd3 Myb/SANT DNA binding domain containing 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] CTD PMID:19414516 NCBI chr 5:67,661,551...67,687,971
Ensembl chr 5:67,661,912...67,684,384 		JBrowse link
G Ndufb11 NADH:ubiquinone oxidoreductase subunit B11 increases phosphorylation
multiple interactions 		ISO Cyclic AMP results in increased phosphorylation of NDUFB11 protein
Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] 		CTD PMID:17904600 NCBI chr  X:4,126,317...4,128,575
Ensembl chr  X:4,126,245...4,128,566 		JBrowse link
G Ngf nerve growth factor multiple interactions
increases expression 		EXP [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA
Cyclic AMP results in increased expression of NGF mRNA 		CTD PMID:2174743 PMID:2853697 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Nog noggin multiple interactions ISO NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] CTD PMID:23137853 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Npl N-acetylneuraminate pyruvate lyase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] CTD PMID:19414516 NCBI chr13:68,205,602...68,247,940
Ensembl chr13:68,205,603...68,247,999 		JBrowse link
G Nr0b1 nuclear receptor subfamily 0, group B, member 1 decreases expression
multiple interactions 		ISO Cyclic AMP results in decreased expression of NR0B1 mRNA
Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] 		CTD PMID:19822634 NCBI chr  X:54,707,658...54,711,786
Ensembl chr  X:54,707,639...54,712,083 		JBrowse link
G Ntan1 N-terminal asparagine amidase multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] CTD PMID:19414516 NCBI chr10:2,618,239...2,633,185
Ensembl chr10:2,618,235...2,633,810 		JBrowse link
G Oat ornithine aminotransferase increases activity
multiple interactions
increases expression 		EXP Cyclic AMP results in increased activity of OAT protein
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] 		CTD PMID:2824512 PMID:2827574 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO [7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP CTD PMID:11413242 NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756 		JBrowse link
G Or51a41 olfactory receptor family 51 subfamily A member 41 multiple interactions ISO [pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP] CTD PMID:15598656 NCBI chr 1:166,866,293...166,867,300
Ensembl chr 1:166,866,293...166,867,300 		JBrowse link
G Or5d18 olfactory receptor family 5 subfamily D member 18 multiple interactions ISO [[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP CTD PMID:12767924 PMID:15716417 NCBI chr 3:93,972,754...93,973,695
Ensembl chr 3:93,972,754...93,973,695 		JBrowse link
G Or6e1 olfactory receptor family 6 subfamily E member 1 multiple interactions ISO [citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP 		CTD PMID:15598656 NCBI chr15:31,703,919...31,704,863
Ensembl chr15:31,703,919...31,704,863 		JBrowse link
G Os9 OS9, endoplasmic reticulum lectin multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] CTD PMID:19414516 NCBI chr 7:64,802,517...64,829,185
Ensembl chr 7:64,802,103...64,829,070 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 increases expression
multiple interactions 		EXP
ISO 		Cyclic AMP results in increased expression of PCK1 mRNA
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] 		CTD PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 More... NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561 		JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions
increases hydrolysis 		ISO Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10373451 NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:54,317,732...54,764,051 		JBrowse link
G Pde11a phosphodiesterase 11A increases hydrolysis ISO PDE11A protein results in increased hydrolysis of Cyclic AMP CTD PMID:10725373 NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:81,320,822...81,680,612 		JBrowse link
G Pde4b phosphodiesterase 4B multiple interactions ISO [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP
[Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] 		CTD PMID:16293762 PMID:21266552 PMID:21854221 NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:122,135,174...122,598,267 		JBrowse link
G Pde7a phosphodiesterase 7A multiple interactions
increases hydrolysis 		ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10618442 PMID:10814504 NCBI chr 2:103,631,655...103,723,057
Ensembl chr 2:103,634,594...103,722,890 		JBrowse link
G Pde7b phosphodiesterase 7B increases hydrolysis
multiple interactions 		ISO PDE7B protein results in increased hydrolysis of Cyclic AMP
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 		CTD PMID:10618442 PMID:10814504 PMID:10872825 NCBI chr 1:16,994,072...17,312,828
Ensembl chr 1:17,002,286...17,312,456 		JBrowse link
G Pde8a phosphodiesterase 8A multiple interactions
increases metabolic processing
increases hydrolysis 		ISO Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]
PDE8A protein results in increased hydrolysis of Cyclic AMP
Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] 		CTD PMID:9671792 PMID:12681444 NCBI chr 1:144,575,203...144,698,216
Ensembl chr 1:144,575,428...144,698,215 		JBrowse link
G Pde8b phosphodiesterase 8B multiple interactions
increases metabolic processing
increases hydrolysis 		ISO 9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] CTD PMID:9784418 PMID:12681444 NCBI chr 2:28,009,841...28,244,050
Ensembl chr 2:28,011,359...28,244,327 		JBrowse link
G Pde9a phosphodiesterase 9A increases hydrolysis ISO PDE9A protein results in increased hydrolysis of Cyclic AMP CTD PMID:9624146 NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,471,167...9,564,286 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions
affects abundance 		ISO 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] CTD PMID:28887310 NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145 		JBrowse link
G Pebp1 phosphatidylethanolamine binding protein 1 multiple interactions ISO PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:26670611 NCBI chr12:44,946,307...44,967,890
Ensembl chr12:44,963,675...44,971,780 		JBrowse link
G Pfn2 profilin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] CTD PMID:19414516 NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:144,205,636...144,222,936 		JBrowse link
G Pgr progesterone receptor multiple interactions ISO [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PGR mRNA; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PGR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] CTD PMID:37552060 PMID:39892737 NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271 		JBrowse link
G Pkia cAMP-dependent protein kinase inhibitor alpha multiple interactions ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] CTD PMID:29669941 NCBI chr 2:96,306,181...96,380,959
Ensembl chr 2:96,306,184...96,321,262 		JBrowse link
G Pla2g4a phospholipase A2 group 4A increases expression
multiple interactions 		EXP Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein] 		CTD PMID:22187434 NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641 		JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases abundance 		EXP
ISO 		[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
POMC protein modified form results in increased abundance of Cyclic AMP
Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP] 		CTD PMID:4306506 PMID:26586997 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Por cytochrome p450 oxidoreductase increases expression ISO Cyclic AMP results in increased expression of POR mRNA CTD PMID:25576683 NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions
increases expression 		ISO
EXP 		Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]
Cyclic AMP results in increased expression of PPARGC1A mRNA 		CTD PMID:18602936 PMID:22117073 PMID:22676303 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] CTD PMID:19414516 NCBI chr 1:213,594,416...213,596,527
Ensembl chr12:21,088,517...21,101,431
Ensembl chr 1:21,088,517...21,101,431 		JBrowse link
G Prkacb protein kinase cAMP-activated catalytic subunit beta multiple interactions
affects response to substance 		ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:238,300,127...238,386,315 		JBrowse link
G Prkar1a protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions ISO [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr10:95,120,537...95,139,028
Ensembl chr10:95,120,487...95,139,025 		JBrowse link
G Prkar2a protein kinase cAMP-dependent type II regulatory subunit alpha multiple interactions EXP Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] CTD PMID:11907174 NCBI chr 8:118,271,608...118,337,332
Ensembl chr 8:118,274,167...118,337,330 		JBrowse link
G Prkar2b protein kinase cAMP-dependent type II regulatory subunit beta multiple interactions EXP Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] CTD PMID:11907174 NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:54,291,151...54,381,411 		JBrowse link
G Prl prolactin multiple interactions
increases secretion 		EXP
ISO 		[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL protein; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cadmium inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
Cyclic AMP results in increased secretion of PRL protein 		CTD PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 More... NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217 		JBrowse link
G Prok1 prokineticin 1 affects response to substance ISO PROK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr 2:197,538,747...197,547,550
Ensembl chr 2:197,537,068...197,547,550 		JBrowse link
G Ptgdr2 prostaglandin D2 receptor 2 multiple interactions ISO [5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP CTD PMID:15563582 NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:216,995,629...217,022,393 		JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions ISO [Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr15:20,694,765...20,708,475
Ensembl chr15:20,696,013...20,708,950 		JBrowse link
G Ptger3 prostaglandin E receptor 3 multiple interactions ISO [Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP CTD PMID:10357836 NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:249,264,985...249,409,846 		JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions ISO [Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135 		JBrowse link
G Ptgir prostaglandin I2 receptor multiple interactions ISO [cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] CTD PMID:11895442 NCBI chr 1:86,707,690...86,710,073
Ensembl chr 1:86,707,503...86,711,874 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] CTD PMID:21873648 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Pth parathyroid hormone increases abundance EXP PTH protein results in increased abundance of Cyclic AMP CTD PMID:26851681 NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:176,943,102...176,946,034 		JBrowse link
G Pthlh parathyroid hormone-like hormone increases abundance ISO PTHLH protein results in increased abundance of Cyclic AMP CTD PMID:10600786 NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454 		JBrowse link
G Ptma prothymosin alpha increases abundance ISO PTMA protein results in increased abundance of Cyclic AMP CTD PMID:9147362 NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:94,624,196...94,628,276 		JBrowse link
G Rab3b RAB3B, member RAS oncogene family multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] CTD PMID:19414516 NCBI chr 5:128,859,034...128,926,087
Ensembl chr 5:128,841,716...128,926,086 		JBrowse link
G Ralgdsl1 ral guanine nucleotide dissociation stimulator like 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] CTD PMID:19414516 NCBI chr13:67,184,402...67,454,019
Ensembl chr13:67,184,402...67,454,019 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family increases activity ISO Cyclic AMP results in increased activity of RAP1A protein CTD PMID:24701590 NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808 		JBrowse link
G Rap1b RAP1B, member of RAS oncogene family multiple interactions EXP
ISO 		[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] CTD PMID:21693435 NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217 		JBrowse link
G Rbfox3 RNA binding fox-1 homolog 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein CTD PMID:33713149 NCBI chr10:104,218,940...104,655,863
Ensembl chr10:104,218,940...104,551,945 		JBrowse link
G Rbm12 RNA binding motif protein 12 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] CTD PMID:19414516 NCBI chr 3:165,069,744...165,089,994
Ensembl chr 3:165,042,878...165,090,021 		JBrowse link
G Rmdn3 regulator of microtubule dynamics 3 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] CTD PMID:19414516 NCBI chr 3:126,579,811...126,601,016
Ensembl chr 3:126,579,812...126,600,418 		JBrowse link
G S100b S100 calcium binding protein B multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein CTD PMID:33713149 NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081 		JBrowse link
G Scn2a sodium voltage-gated channel alpha subunit 2 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA CTD PMID:33713149 NCBI chr 3:70,710,862...70,845,569
Ensembl chr 3:70,710,954...70,845,279 		JBrowse link
G Sct secretin multiple interactions
increases abundance 		EXP Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] CTD PMID:6312992 NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246 		JBrowse link
G Sdc1 syndecan 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] CTD PMID:19414516 NCBI chr 6:37,282,041...37,304,503
Ensembl chr 6:37,297,010...37,304,500 		JBrowse link
G Slc17a6 solute carrier family 17 member 6 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA CTD PMID:33713149 NCBI chr 1:110,348,447...110,388,499
Ensembl chr 1:110,348,447...110,388,498 		JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein CTD PMID:33713149 NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:104,785,955...104,798,049 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 affects transport ISO SLC22A8 protein affects the transport of Cyclic AMP CTD PMID:11306713 NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588 		JBrowse link
G Slc2a5 solute carrier family 2 member 5 affects expression
multiple interactions 		ISO
EXP 		Cyclic AMP affects the expression of SLC2A5 mRNA
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein
[Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA 		CTD PMID:8037665 PMID:8554516 PMID:12820898 NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:165,866,172...165,894,038 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions EXP Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] CTD PMID:12612912 NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:11,628,862...11,645,402 		JBrowse link
G Smoc2 SPARC related modular calcium binding 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] CTD PMID:19414516 NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:63,935,647...64,064,955 		JBrowse link
G Snx33 sorting nexin 33 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] CTD PMID:19414516 NCBI chr 8:66,213,133...66,224,926
Ensembl chr 8:66,213,133...66,223,509 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] CTD PMID:23782265 NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] CTD PMID:20685861 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Srd5a1 steroid 5 alpha-reductase 1 increases expression ISO Cyclic AMP results in increased expression of SRD5A1 mRNA CTD PMID:25576683 NCBI chr 1:35,514,914...35,548,898
Ensembl chr 1:35,514,846...35,548,903 		JBrowse link
G Sst somatostatin multiple interactions ISO [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr11:90,461,546...90,462,823
Ensembl chr11:90,461,546...90,462,823 		JBrowse link
G Sstr2 somatostatin receptor 2 multiple interactions ISO [64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr10:99,163,353...99,170,519
Ensembl chr10:99,162,740...99,183,863 		JBrowse link
G St6gal2 ST6 beta-galactoside alpha-2,6-sialyltransferase 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] CTD PMID:19414516 NCBI chr 9:9,508,928...9,606,900
Ensembl chr 9:9,509,548...9,594,007 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression 		ISO [Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein]
Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein 		CTD PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Taar1 trace-amine-associated receptor 1 multiple interactions ISO [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP 		CTD PMID:19725810 NCBI chr 1:23,336,978...23,337,976
Ensembl chr 1:23,335,165...23,353,981 		JBrowse link
G Tas1r2 taste 1 receptor member 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] CTD PMID:19414516 NCBI chr 5:157,192,799...157,208,937
Ensembl chr 5:157,192,799...157,208,937 		JBrowse link
G Tax1bp1 Tax1 binding protein 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] CTD PMID:19414516 NCBI chr 4:83,152,549...83,208,463
Ensembl chr 4:83,110,062...83,209,657 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase multiple interactions ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA CTD PMID:32781018 NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA CTD PMID:33713149 NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111 		JBrowse link
G Tex14 testis expressed 14, intercellular bridge forming factor multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] CTD PMID:19414516 NCBI chr10:72,729,017...72,859,697
Ensembl chr10:72,728,985...72,853,064 		JBrowse link
G Tff1 trefoil factor 1 multiple interactions
increases expression 		ISO CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956 		JBrowse link
G Tgfb3 transforming growth factor, beta 3 multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946 		JBrowse link
G Tmsb15b2 thymosin beta 15B2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] CTD PMID:19414516 NCBI chr  X:105,090,980...105,093,094
Ensembl chr  X:105,090,980...105,093,094 		JBrowse link
G Tmtc4 transmembrane O-mannosyltransferase targeting cadherins 4 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] CTD PMID:19414516 NCBI chr15:106,406,795...106,463,226
Ensembl chr15:106,407,597...106,463,210 		JBrowse link
G Tnf tumor necrosis factor decreases expression
multiple interactions 		ISO Cyclic AMP results in decreased expression of TNF protein
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] 		CTD PMID:8550079 PMID:21266552 PMID:23566200 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfsf12 TNF superfamily member 12 decreases expression ISO Cyclic AMP results in decreased expression of TNFSF12 mRNA CTD PMID:22117073 NCBI chr10:54,902,616...54,912,628
Ensembl chr10:54,902,616...54,911,913 		JBrowse link
G Trpv4 transient receptor potential cation channel, subfamily V, member 4 increases expression
multiple interactions 		EXP Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein] 		CTD PMID:22187434 NCBI chr12:47,599,161...47,638,143
Ensembl chr12:47,599,035...47,638,143 		JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions
increases abundance 		ISO [Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21072367 PMID:21123444 NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984 		JBrowse link
G Tshr thyroid stimulating hormone receptor multiple interactions
increases abundance 		ISO [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21123444 NCBI chr 6:116,072,321...116,206,009
Ensembl chr 6:116,072,281...116,206,010 		JBrowse link
G Ttc6 tetratricopeptide repeat domain 6 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] CTD PMID:19414516 NCBI chr 6:80,872,055...81,103,170
Ensembl chr 6:80,889,487...81,103,163 		JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr19:68,365,687...68,374,741
Ensembl chr19:68,365,587...68,374,740 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] CTD PMID:19414516 NCBI chr 8:113,544,037...113,559,711
Ensembl chr 8:113,544,037...113,559,711 		JBrowse link
G Vash1 vasohibin 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] CTD PMID:19414516 NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689 		JBrowse link
G Vash2 vasohibin 2 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] CTD PMID:19414516 NCBI chr13:105,060,857...105,092,325
Ensembl chr13:105,060,857...105,092,275 		JBrowse link
G Vat1 vesicle amine transport 1 multiple interactions EXP 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] CTD PMID:19414516 NCBI chr10:86,889,793...86,897,411
Ensembl chr10:86,889,793...86,897,411 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] CTD PMID:10788502 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vip vasoactive intestinal peptide multiple interactions
increases abundance 		ISO
EXP 		[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP
alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]
VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP 		CTD PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:44,470,462...44,478,558 		JBrowse link
G Vipr2 vasoactive intestinal peptide receptor 2 multiple interactions ISO [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr 6:143,139,672...143,213,609
Ensembl chr 6:143,144,523...143,213,609 		JBrowse link
G Wnt5a Wnt family member 5A multiple interactions ISO WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] CTD PMID:20685861 NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860 		JBrowse link
G Zfp36l2 zinc finger protein 36, C3H type-like 2 increases abundance ISO ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP CTD PMID:24830504 NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653 		JBrowse link
3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc4 ATP binding cassette subfamily C member 4 increases export
increases transport
multiple interactions 		ISO ABCC4 protein results in increased export of Cyclic GMP
ABCC4 protein results in increased transport of Cyclic GMP
daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] 		CTD PMID:11856762 PMID:16156793 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Agt angiotensinogen multiple interactions
increases abundance 		EXP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
AGT protein modified form results in increased abundance of Cyclic GMP 		CTD PMID:11696475 PMID:28299329 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions EXP [PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr  X:116,914,320...116,918,504
Ensembl chr  X:116,913,656...116,918,745 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] CTD PMID:12891555 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] CTD PMID:17585900 NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Apoe apolipoprotein E decreases abundance ISO APOE gene mutant form results in decreased abundance of Cyclic GMP CTD PMID:11397713 NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855 		JBrowse link
G Bdkrb1 bradykinin receptor B1 multiple interactions EXP [bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973 		JBrowse link
G Bdkrb2 bradykinin receptor B2 multiple interactions EXP [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] CTD PMID:9388267 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] CTD PMID:25490417 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cct7 chaperonin containing TCP1 subunit 7 multiple interactions ISO CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] CTD PMID:24213632 NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973 		JBrowse link
G Edn1 endothelin 1 multiple interactions
increases abundance 		EXP Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Edn3 endothelin 3 multiple interactions
increases abundance 		EXP Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:183,980,668...184,005,329 		JBrowse link
G Epo erythropoietin multiple interactions ISO EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] CTD PMID:25041251 PMID:25490417 NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725 		JBrowse link
G Gch1 GTP cyclohydrolase 1 affects abundance
increases abundance
multiple interactions 		ISO GCH1 protein affects the abundance of Cyclic GMP
GCH1 gene mutant form results in increased abundance of Cyclic GMP
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] 		CTD PMID:21963838 PMID:25490417 NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412 		JBrowse link
G Gnrh1 gonadotropin releasing hormone 1 multiple interactions EXP [manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein CTD PMID:17110411 PMID:17290048 NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977 		JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
increases abundance 		ISO [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP]
GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP 		CTD PMID:22171090 PMID:24213632 PMID:25373139 NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737 		JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions ISO [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP CTD PMID:22171090 NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987 		JBrowse link
G Hmox2 heme oxygenase 2 affects abundance ISO HMOX2 affects the abundance of Cyclic GMP CTD PMID:16181104 NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800 		JBrowse link
G Il12rb2 interleukin 12 receptor subunit beta 2 increases expression ISO Cyclic GMP results in increased expression of IL12RB2 mRNA CTD PMID:12451176 NCBI chr 4:97,756,089...97,844,937
Ensembl chr 4:97,756,089...97,844,937 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases abundance 		EXP
ISO 		Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP] 		CTD PMID:11506125 PMID:14762100 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation 		ISO Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]
Cyclic GMP results in decreased phosphorylation of MAP2K1 protein 		CTD PMID:18225537 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases phosphorylation
multiple interactions 		ISO Cyclic GMP results in decreased phosphorylation of MAP2K2 protein
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] 		CTD PMID:18225537 NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases activity ISO Cyclic GMP analog results in increased activity of MAPK8 protein CTD PMID:11051267 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP [testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP CTD PMID:20463352 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions
increases abundance 		ISO
EXP 		NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP]
NOS3 protein results in increased abundance of Cyclic GMP 		CTD PMID:11504159 PMID:16891913 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases abundance 		ISO
EXP 		Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
NPPA protein results in increased abundance of Cyclic GMP
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] 		CTD PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 More... NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G Nppc natriuretic peptide C increases chemical synthesis
increases abundance
multiple interactions 		EXP NPPC protein results in increased chemical synthesis of Cyclic GMP
NPPC protein results in increased abundance of Cyclic GMP
Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP] 		CTD PMID:17629948 PMID:18222015 NCBI chr 9:94,767,986...94,772,186
Ensembl chr 9:94,767,986...94,772,186 		JBrowse link
G Pde10a phosphodiesterase 10A multiple interactions
increases hydrolysis 		ISO Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10373451 NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:54,317,732...54,764,051 		JBrowse link
G Pde11a phosphodiesterase 11A multiple interactions
increases hydrolysis 		ISO 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10725373 NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:81,320,822...81,680,612 		JBrowse link
G Pde1a phosphodiesterase 1A multiple interactions EXP PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] CTD PMID:11696475 NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212 		JBrowse link
G Pde5a phosphodiesterase 5A decreases abundance ISO PDE5A protein results in decreased abundance of Cyclic GMP CTD PMID:10422958 NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:213,542,923...213,684,298 		JBrowse link
G Pde9a phosphodiesterase 9A increases hydrolysis
multiple interactions 		ISO PDE9A protein results in increased hydrolysis of Cyclic GMP
zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP] 		CTD PMID:9624146 NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,471,167...9,564,286 		JBrowse link
G Pomc proopiomelanocortin affects abundance EXP POMC protein affects the abundance of Cyclic GMP CTD PMID:11193135 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Ptpn12 protein tyrosine phosphatase, non-receptor type 12 increases activity EXP Cyclic GMP results in increased activity of PTPN12 protein CTD PMID:12714323 NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,913,218...14,985,284 		JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] CTD PMID:21145922 NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases abundance 		EXP 7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] CTD PMID:16754782 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
increases abundance 		ISO N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] CTD PMID:18575783 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vim vimentin multiple interactions ISO VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] CTD PMID:11588525 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
G Xdh xanthine dehydrogenase multiple interactions EXP [Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] CTD PMID:17339839 NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350 		JBrowse link
3',5'-cyclic UMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccdc122 coiled-coil domain containing 122 affects binding ISO CCDC122 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr15:58,816,927...58,899,200
Ensembl chr15:58,816,873...58,879,592 		JBrowse link
G Celf1 CUGBP, Elav-like family member 1 affects binding ISO CELF1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:97,380,407...97,455,253
Ensembl chr 3:97,380,424...97,452,791 		JBrowse link
G Chlsn cholesin affects binding ISO CHLSN protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr12:20,298,968...20,402,890
Ensembl chr12:20,388,520...20,402,922 		JBrowse link
G Cirbp cold inducible RNA binding protein affects binding ISO CIRBP protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 7:10,184,515...10,189,623 JBrowse link
G Csde1 cold shock domain containing E1 affects binding ISO CSDE1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:193,234,546...193,271,301
Ensembl chr 2:193,243,526...193,271,301 		JBrowse link
G Cstf2t cleavage stimulation factor subunit 2, tau variant affects binding ISO CSTF2T protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:238,366,042...238,369,608
Ensembl chr 1:238,365,912...238,369,749 		JBrowse link
G Ddx21 DExD-box helicase 21 affects binding ISO DDX21 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr20:31,077,044...31,097,238
Ensembl chr20:31,077,045...31,097,238 		JBrowse link
G Ddx5 DEAD-box helicase 5 affects binding ISO DDX5 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300 		JBrowse link
G Ddx54 DEAD-box helicase 54 affects binding ISO DDX54 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr12:41,595,298...41,610,560
Ensembl chr12:41,595,555...41,611,053 		JBrowse link
G Dhx9 DExH-box helicase 9 affects binding ISO DHX9 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546 		JBrowse link
G Elavl1 ELAV like RNA binding protein 1 affects binding ISO ELAVL1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631 		JBrowse link
G Elavl4 ELAV like RNA binding protein 4 affects binding ISO ELAVL4 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:130,285,418...130,429,106
Ensembl chr 5:130,285,418...130,429,096 		JBrowse link
G Fau FAU ubiquitin like and ribosomal protein S30 fusion affects binding ISO FAU protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:212,779,429...212,781,028
Ensembl chr 1:212,779,473...212,781,026
Ensembl chr 1:212,779,473...212,781,026 		JBrowse link
G Fbxl19 F-box and leucine-rich repeat protein 19 affects binding ISO FBXL19 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:191,786,981...191,811,314
Ensembl chr 1:191,789,428...191,811,314 		JBrowse link
G Fubp3 far upstream element binding protein 3 affects binding ISO FUBP3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:35,253,216...35,302,282
Ensembl chr 3:35,253,306...35,302,280 		JBrowse link
G Gas2 growth arrest-specific 2 affects binding ISO GAS2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:110,587,952...110,721,572
Ensembl chr 1:110,717,312...110,718,541 		JBrowse link
G Hnrnpa0 heterogeneous nuclear ribonucleoprotein A0 affects binding ISO HNRNPA0 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr17:6,513,129...6,515,786
Ensembl chr17:6,512,629...6,516,127 		JBrowse link
G Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 affects binding ISO HNRNPA1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085 		JBrowse link
G Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 affects binding ISO HNRNPA2B1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 4:81,867,354...81,875,886
Ensembl chr 4:81,869,661...81,877,572 		JBrowse link
G Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3 affects binding ISO HNRNPA3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:80,984,470...80,999,413
Ensembl chr 3:80,985,969...80,996,043 		JBrowse link
G Hnrnpab heterogeneous nuclear ribonucleoprotein A/B affects binding ISO HNRNPAB protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:36,358,004...36,363,898
Ensembl chr10:36,358,006...36,364,307 		JBrowse link
G Hnrnpc heterogeneous nuclear ribonucleoprotein C affects binding ISO HNRNPC protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr15:27,253,098...27,282,779
Ensembl chr15:27,253,098...27,282,715 		JBrowse link
G Hnrnpd heterogeneous nuclear ribonucleoprotein D affects binding ISO HNRNPD protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr14:9,918,630...9,938,072
Ensembl chr14:9,919,739...9,938,066 		JBrowse link
G Hnrnpdl heterogeneous nuclear ribonucleoprotein D-like affects binding ISO HNRNPDL protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr14:9,861,716...9,867,945
Ensembl chr14:9,861,716...9,867,945 		JBrowse link
G Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 affects binding ISO HNRNPH1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906 		JBrowse link
G Hnrnpk heterogeneous nuclear ribonucleoprotein K affects binding ISO HNRNPK protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565 		JBrowse link
G Hnrnpl heterogeneous nuclear ribonucleoprotein L affects binding ISO HNRNPL protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:93,226,373...93,239,084
Ensembl chr 1:93,235,729...93,239,061 		JBrowse link
G Hnrnpm heterogeneous nuclear ribonucleoprotein M affects binding ISO HNRNPM protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 7:15,140,877...15,178,871
Ensembl chr 7:15,129,287...15,178,871 		JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R affects binding ISO HNRNPR protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:153,826,482...153,872,272
Ensembl chr 5:153,826,692...153,858,344 		JBrowse link
G Hnrnpu heterogeneous nuclear ribonucleoprotein U affects binding ISO HNRNPU protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr13:92,609,791...92,618,580
Ensembl chr13:92,605,216...92,618,612 		JBrowse link
G Kbtbd3 kelch repeat and BTB domain containing 3 affects binding ISO KBTBD3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:9,749,229...9,780,036
Ensembl chr 8:9,749,175...9,774,555 		JBrowse link
G Khsrp KH-type splicing regulatory protein affects binding ISO KHSRP protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 9:1,949,557...1,959,400
Ensembl chr 9:1,949,557...1,959,497 		JBrowse link
G Larp7 La ribonucleoprotein 7, transcriptional regulator affects binding ISO LARP7 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:218,672,145...218,687,332
Ensembl chr 2:218,672,208...218,687,308 		JBrowse link
G Lrpprc leucine-rich pentatricopeptide repeat containing affects binding ISO LRPPRC protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 6:15,612,638...15,695,113
Ensembl chr 6:15,612,655...15,695,116 		JBrowse link
G Ltv1 LTV1 ribosome biogenesis factor affects binding ISO LTV1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:9,385,834...9,398,557
Ensembl chr 1:9,385,830...9,398,677 		JBrowse link
G Matr3 matrin 3 affects binding ISO MATR3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr18:27,428,190...27,474,421
Ensembl chr18:27,432,179...27,470,421 		JBrowse link
G Mrpl57 mitochondrial ribosomal protein L57 affects binding ISO MRPL57 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr15:36,086,457...36,087,319
Ensembl chr15:36,086,457...36,087,298 		JBrowse link
G Mrps7 mitochondrial ribosomal protein S7 affects binding ISO MRPS7 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:101,342,642...101,345,790
Ensembl chr10:101,342,421...101,346,082 		JBrowse link
G Myef2 myelin expression factor 2 affects binding ISO MYEF2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:132,791,694...132,827,572
Ensembl chr 3:132,791,694...132,827,523 		JBrowse link
G Ncapg2 non-SMC condensin II complex, subunit G2 affects binding ISO NCAPG2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 6:143,484,651...143,561,850
Ensembl chr 6:143,485,944...143,560,249 		JBrowse link
G Ncl nucleolin affects binding ISO NCL protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:94,446,682...94,456,083 		JBrowse link
G Nono non-POU domain containing, octamer-binding affects binding ISO NONO protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr  X:70,594,116...70,611,976
Ensembl chr  X:70,593,888...70,611,979 		JBrowse link
G Ptbp1 polypyrimidine tract binding protein 1 affects binding ISO PTBP1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 7:10,493,199...10,502,957
Ensembl chr 7:10,493,200...10,502,957 		JBrowse link
G Ptbp3 polypyrimidine tract binding protein 3 affects binding ISO PTBP3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:79,108,376...79,194,533
Ensembl chr 5:79,108,376...79,194,508 		JBrowse link
G Raly RALY heterogeneous nuclear ribonucleoprotein affects binding ISO RALY protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:163,766,183...163,830,726
Ensembl chr 3:163,766,478...163,830,740 		JBrowse link
G Ralyl RALY RNA binding protein-like affects binding ISO RALYL protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:89,390,212...90,181,681
Ensembl chr 2:89,390,129...90,181,624 		JBrowse link
G Rbm14 RNA binding motif protein 14 affects binding ISO RBM14 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:211,476,298...211,535,077
Ensembl chr 1:211,523,972...211,535,065 		JBrowse link
G Rbm15 RNA binding motif protein 15 affects binding ISO RBM15 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:197,634,174...197,642,697
Ensembl chr 2:197,583,002...197,643,037 		JBrowse link
G Rbm15b RNA binding motif protein 15B affects binding ISO RBM15B protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:116,422,309...116,425,374
Ensembl chr 8:116,421,540...116,425,940 		JBrowse link
G Rbm22 RNA binding motif protein 22 affects binding ISO RBM22 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr18:56,283,807...56,294,615
Ensembl chr18:56,283,770...56,295,073 		JBrowse link
G Rbm24 RNA binding motif protein 24 affects binding ISO RBM24 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr17:18,481,893...18,494,440
Ensembl chr17:18,481,900...18,494,604 		JBrowse link
G Rbm3 RNA binding motif protein 3 affects binding ISO RBM3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr  X:17,020,863...17,024,341
Ensembl chr  X:17,020,864...17,024,841 		JBrowse link
G Rbm47 RNA binding motif protein 47 affects binding ISO RBM47 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr14:42,407,226...42,545,304
Ensembl chr14:42,466,335...42,543,163 		JBrowse link
G Rbm4b RNA binding motif protein 4B affects binding ISO RBM4B protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:211,477,337...211,487,428 JBrowse link
G Rbm7 RNA binding motif protein 7 affects binding ISO RBM7 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:57,728,413...57,734,833
Ensembl chr 8:57,728,423...57,734,968 		JBrowse link
G Rbms3 RNA binding motif, single stranded interacting protein 3 affects binding ISO RBMS3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:125,183,315...126,503,586 		JBrowse link
G Rbmx RNA binding motif protein, X-linked affects binding ISO RBMX protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr  X:140,342,544...140,352,121
Ensembl chr  X:140,345,571...140,352,035 		JBrowse link
G Rpl14 ribosomal protein L14 affects binding ISO RPL14 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:129,163,620...129,166,745
Ensembl chr 8:129,163,317...129,167,459 		JBrowse link
G Rpl24 ribosomal protein L24 affects binding ISO RPL24 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr11:58,122,997...58,128,405
Ensembl chr11:58,122,997...58,128,405 		JBrowse link
G Rpl26l1 ribosomal protein L26 like 1 affects binding ISO RPL26L1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:17,024,807...17,029,028 JBrowse link
G Rpl31 ribosomal protein L31 affects binding ISO RPL31 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:49,142,955...49,147,155 		JBrowse link
G Rpl34 ribosomal protein L34 affects binding ISO RPL34 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:221,958,551...221,962,309
Ensembl chr17:79,783,869...79,820,922
Ensembl chr 2:79,783,869...79,820,922 		JBrowse link
G Rpl5 ribosomal protein L5 affects binding ISO RPL5 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr14:1,988,792...1,995,236
Ensembl chr14:1,988,793...1,995,225 		JBrowse link
G Rps10l2 ribosomal protein S10-like 2 affects binding ISO RPS10P5 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr16:25,469,301...25,470,442
Ensembl chr16:25,469,789...25,470,280 		JBrowse link
G Rps20 ribosomal protein S20 affects binding ISO RPS20 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:21,616,687...21,618,068
Ensembl chr 3:42,839,965...43,095,621
Ensembl chr 9:42,839,965...43,095,621
Ensembl chr 5:42,839,965...43,095,621 		JBrowse link
G Scmh1 Scm polycomb group protein homolog 1 affects binding ISO SCMH1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:139,276,352...139,401,118
Ensembl chr 5:139,314,447...139,403,081 		JBrowse link
G Sf3b4 splicing factor 3B subunit 4 affects binding ISO SF3B4 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 2:186,421,667...186,426,419
Ensembl chr 2:186,421,636...186,426,833 		JBrowse link
G Sfpq splicing factor proline and glutamine rich affects binding ISO SFPQ protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926 		JBrowse link
G Slirp SRA stem-loop interacting RNA binding protein affects binding ISO SLIRP protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 6:112,819,684...112,828,715
Ensembl chr 6:112,819,448...112,828,715 		JBrowse link
G Snd1 staphylococcal nuclease and tudor domain containing 1 affects binding ISO SND1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 4:58,060,689...58,459,926
Ensembl chr 4:58,060,640...58,459,925 		JBrowse link
G Spen spen family transcriptional repressor affects binding ISO SPEN protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:159,058,258...159,131,789
Ensembl chr 5:159,058,258...159,165,934 		JBrowse link
G Srsf1 serine and arginine rich splicing factor 1 affects binding ISO SRSF1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:73,335,519...73,342,549
Ensembl chr10:73,336,422...73,342,548 		JBrowse link
G Srsf10 serine and arginine rich splicing factor 10 affects binding ISO SRSF10 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:153,372,307...153,386,520
Ensembl chr 5:153,372,316...153,386,513 		JBrowse link
G Srsf2 serine and arginine rich splicing factor 2 affects binding ISO SRSF2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:102,550,962...102,554,200
Ensembl chr10:102,553,072...102,554,141 		JBrowse link
G Srsf3 serine and arginine rich splicing factor 3 affects binding ISO SRSF3 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr20:7,093,529...7,103,517
Ensembl chr20:7,093,565...7,103,516 		JBrowse link
G Srsf5 serine and arginine rich splicing factor 5 affects binding ISO SRSF5 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 6:106,333,998...106,341,467
Ensembl chr 6:106,336,756...106,341,931 		JBrowse link
G Srsf6 serine and arginine rich splicing factor 6 affects binding ISO SRSF6 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 3:172,009,072...172,014,395
Ensembl chr 3:172,009,061...172,014,392 		JBrowse link
G Srsf7 serine and arginine rich splicing factor 7 affects binding ISO SRSF7 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:20,564,044...20,571,212 		JBrowse link
G Srsf9 serine and arginine rich splicing factor 9 affects binding ISO SRSF9 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr12:46,938,948...46,945,213
Ensembl chr12:46,938,950...46,945,283 		JBrowse link
G Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein affects binding ISO SYNCRIP protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 8:98,282,358...98,315,412
Ensembl chr 8:98,282,358...98,315,386 		JBrowse link
G Taco1 translational activator of cytochrome c oxidase I affects binding ISO TACO1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:91,502,395...91,510,299
Ensembl chr10:91,502,460...91,515,678 		JBrowse link
G Tardbp TAR DNA binding protein affects binding ISO TARDBP protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204 		JBrowse link
G Tia1 TIA1 cytotoxic granule-associated RNA binding protein affects binding ISO TIA1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665 		JBrowse link
G Tial1 Tia1 cytotoxic granule-associated RNA binding protein-like 1 affects binding ISO TIAL1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:192,438,794...192,475,520
Ensembl chr 1:192,441,247...192,475,674 		JBrowse link
G U2af2 U2 small nuclear RNA auxiliary factor 2 affects binding ISO U2AF2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 1:77,789,752...77,807,307
Ensembl chr 1:77,789,752...77,807,413 		JBrowse link
G Ybx1 Y box binding protein 1 affects binding ISO YBX1 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr 5:138,167,444...138,188,155
Ensembl chr 5:138,167,444...138,184,188 		JBrowse link
G Ybx2 Y box binding protein 2 affects binding ISO YBX2 protein binds to cyclic 3',5'-uridine monophosphate CTD PMID:30528433 NCBI chr10:55,158,420...55,164,077
Ensembl chr10:55,158,420...55,164,077 		JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 1:191,013,632...191,017,943
Ensembl chr 1:191,013,463...191,017,971 		JBrowse link
3'-O-(4-Benzoyl)benzoyl ATP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp1 caspase 1 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased cleavage of CASP1 protein] CTD PMID:29545090 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp3 caspase 3 increases activity ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of CASP3 protein CTD PMID:23727220 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:42,588,948...42,595,669
Ensembl chr14:42,588,948...42,595,669 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] CTD PMID:26072274 NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957 		JBrowse link
G Foxp3 forkhead box P3 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in decreased expression of FOXP3 mRNA] CTD PMID:29545090 NCBI chr  X:17,580,380...17,601,181
Ensembl chr  X:17,580,380...17,595,894 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of GATA3 mRNA] CTD PMID:29545090 NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of and results in increased secretion of HMGB1 protein] CTD PMID:29545090 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion 		ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL1B protein; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; Nicotine inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL1B protein]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:21320518 PMID:29642561 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein] CTD PMID:21320518 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
G Il6 interleukin 6 multiple interactions EXP 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] CTD PMID:25348860 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK1 protein]; 2',3'-dialdehyde ATP inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK1 protein]; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein]
2',3'-dialdehyde ATP inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK1 protein]; [1-palmitoyl-2-lysophosphatidylcholine results in increased susceptibility to 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate] which results in increased phosphorylation of MAPK1 protein 		CTD PMID:17437542 PMID:21320518 PMID:25272052 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK3 protein]; 2',3'-dialdehyde ATP inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK3 protein]; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein]
2',3'-dialdehyde ATP inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of MAPK3 protein]; [1-palmitoyl-2-lysophosphatidylcholine results in increased susceptibility to 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate] which results in increased phosphorylation of MAPK3 protein 		CTD PMID:17437542 PMID:21320518 PMID:25272052 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 affects localization ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate affects the localization of NFATC1 protein CTD PMID:26522449 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of NLRP3 protein] CTD PMID:29545090 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G P2rx7 purinergic receptor P2X 7 multiple interactions
increases activity
increases expression
decreases response to substance
affects response to substance 		ISO
EXP 		[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL1B protein; [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein; Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium]; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein]; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein]; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein]; protoberberine analog inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK1 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of MAPK3 protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL1B protein]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased secretion of IL2 protein]; ZINC09315614 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]
[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of SYN1 protein; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; ZINC09315614 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of P2RX7 protein]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased expression of P2RX7 protein]
P2RX7 gene mutant form results in decreased susceptibility to 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
P2RX7 protein affects the susceptibility to 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 		CTD PMID:10860929 PMID:12873706 PMID:17728465 PMID:18242779 PMID:21320518 More... NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027 		JBrowse link
G Panx1 Pannexin 1 decreases activity ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in decreased activity of PANX1 protein CTD PMID:19023039 NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased expression of PARP1 protein CTD PMID:22253048 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:112,731,803...112,771,978
Ensembl chr 7:112,731,803...112,771,609 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of PYCARD protein] CTD PMID:29545090 NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in increased expression of RORC mRNA] CTD PMID:29545090 NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566 		JBrowse link
G Syn1 synapsin I increases phosphorylation
multiple interactions 		EXP 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of SYN1 protein
[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased phosphorylation of SYN1 protein; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased phosphorylation of SYN1 protein] 		CTD PMID:18242779 NCBI chr  X:3,725,745...3,780,940
Ensembl chr  X:3,725,714...3,780,938 		JBrowse link
G Tbx21 T-box transcription factor 21 multiple interactions ISO 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [Ovalbumin results in decreased expression of TBX21 mRNA] CTD PMID:29545090 NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,578,751...82,595,253 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases secretion 		ISO azetidine analog inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of TNF protein]; N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of TNF protein] CTD PMID:26522449 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
3'-phospho-5'-adenylyl sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G P2ry1 purinergic receptor P2Y1 decreases activity ISO Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein CTD PMID:22273509 NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions
increases sulfation 		ISO 2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]
SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate 		CTD PMID:11425650 PMID:16601080 PMID:20545351 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] CTD PMID:15483193 NCBI chr 1:84,582,011...84,639,001 JBrowse link
7-methyl-7,8-dihydroguanosine-5'-diphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Eif4e eukaryotic translation initiation factor 4E affects binding
multiple interactions 		ISO 7-methylguanosine 5'-diphosphate analog binds to EIF4E protein
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein] 		CTD PMID:27592390 NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105 		JBrowse link
7-methyl-GTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Eif4e eukaryotic translation initiation factor 4E multiple interactions ISO 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] CTD PMID:27592390 NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
affects binding 		ISO 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] CTD PMID:25940091 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4 gamma 1 multiple interactions
affects binding 		ISO 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] CTD PMID:25940091 NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367 		JBrowse link
8-(4-chlorophenylthio)-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression 		ISO Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] CTD PMID:16415093 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA CTD PMID:27160211 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA CTD PMID:27160211 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA CTD PMID:27160211 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein CTD PMID:20610540 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Bcl2l11 Bcl2-like 11 increases expression
increases response to substance 		ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein
BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP 		CTD PMID:14996839 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Casp3 caspase 3 increases activity ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein CTD PMID:14996839 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cfl1 cofilin 1 decreases phosphorylation EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein CTD PMID:20610540 NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353 		JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form CTD PMID:15163550 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
increases phosphorylation 		EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein 		CTD PMID:14741741 PMID:20610540 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] CTD PMID:16415093 NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] CTD PMID:16415093 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA CTD PMID:27160211 NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA CTD PMID:27160211 NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Acetylcysteine results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] which results in increased cleavage of PARP1 protein CTD PMID:38042493 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Rhoa ras homolog family member A multiple interactions
decreases activity 		EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein 		CTD PMID:20610540 NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302 		JBrowse link
G Rtkn rhotekin multiple interactions EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] CTD PMID:20610540 NCBI chr 4:117,198,496...117,215,660
Ensembl chr 4:117,198,647...117,215,660 		JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405 		JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049 		JBrowse link
G Scnn1g sodium channel epithelial 1 subunit gamma multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA CTD PMID:27160211 NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA CTD PMID:27160211 NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA CTD PMID:27160211 NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083 		JBrowse link
G Snap25 synaptosome associated protein 25 multiple interactions
affects splicing 		EXP N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] CTD PMID:22684629 NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions EXP
ISO 		8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] CTD PMID:12886029 NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021 		JBrowse link
G Vip vasoactive intestinal peptide increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA CTD PMID:2156696 NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:44,470,462...44,478,558 		JBrowse link
8-(4-chlorophenylthio)-cGMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alox15 arachidonate 15-lipoxygenase increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein CTD PMID:16166323 NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,559,061...55,567,723 		JBrowse link
G Arhgef17 Rho guanine nucleotide exchange factor 17 multiple interactions ISO 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] CTD PMID:23195829 NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:164,642,690...164,702,241 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions 		ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein] 		CTD PMID:20471953 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Fabp4 fatty acid binding protein 4 increases expression
multiple interactions 		ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein] 		CTD PMID:20471953 NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972 		JBrowse link
G Nppa natriuretic peptide A multiple interactions EXP [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] CTD PMID:11799084 NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression 		ISO 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein] CTD PMID:20471953 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Prkg1 protein kinase cGMP-dependent 1 multiple interactions
increases activity
decreases expression 		ISO
EXP 		2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form 		CTD PMID:9366573 PMID:11799084 PMID:23195829 NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:237,823,053...239,103,005 		JBrowse link
G Rhoa ras homolog family member A multiple interactions ISO [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein] CTD PMID:23195829 NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302 		JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha multiple interactions ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405 		JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta multiple interactions ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049 		JBrowse link
G Scnn1g sodium channel epithelial 1 subunit gamma multiple interactions ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097 		JBrowse link
G Srf serum response factor multiple interactions ISO [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein CTD PMID:23195829 NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:21,924,076...21,933,337 		JBrowse link
G Vasp vasodilator-stimulated phosphoprotein increases phosphorylation
decreases phosphorylation 		ISO
EXP 		8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein 		CTD PMID:11799084 PMID:16166323 NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650 		JBrowse link
8-Br-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein CTD PMID:17478430 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] CTD PMID:27743861 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA CTD PMID:22079614 NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] CTD PMID:27743861 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Abcd2 ATP binding cassette subfamily D member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA CTD PMID:22079614 NCBI chr 7:124,142,597...124,191,202
Ensembl chr 7:124,142,595...124,191,202 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA CTD PMID:22079614 NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] CTD PMID:30610963 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Ablim1 actin-binding LIM protein 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA CTD PMID:22079614 NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:266,088,870...266,377,098 		JBrowse link
G Ablim2 actin binding LIM protein family, member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA CTD PMID:22079614 NCBI chr14:79,090,046...79,214,986
Ensembl chr14:79,090,923...79,214,972 		JBrowse link
G Acat2 acetyl-CoA acetyltransferase 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA CTD PMID:22079614 NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095 		JBrowse link
G Ace2 angiotensin converting enzyme 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA CTD PMID:22079614 NCBI chr  X:33,925,458...33,972,851
Ensembl chr  X:33,925,458...33,971,596 		JBrowse link
G Acp3 acid phosphatase 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA CTD PMID:22079614 NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:113,785,032...113,833,033 		JBrowse link
G Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070 		JBrowse link
G Adamts8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA CTD PMID:22079614 NCBI chr 8:37,607,001...37,626,597
Ensembl chr 8:37,607,001...37,626,597 		JBrowse link
G Adcy7 adenylate cyclase 7 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA CTD PMID:22079614 NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743 		JBrowse link
G Adgrd1 adhesion G protein-coupled receptor D1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA CTD PMID:22079614 NCBI chr12:33,124,981...33,239,778
Ensembl chr12:33,125,915...33,272,509 		JBrowse link
G Adgrf5 adhesion G protein-coupled receptor F5 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA CTD PMID:16997883 NCBI chr 9:25,014,861...25,128,045
Ensembl chr 9:25,018,277...25,121,237 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA CTD PMID:22079614 NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124 		JBrowse link
G Adgrg2 adhesion G protein-coupled receptor G2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA CTD PMID:22079614 NCBI chr  X:38,106,067...38,231,286
Ensembl chr  X:38,106,067...38,231,331 		JBrowse link
G Adra2a adrenoceptor alpha 2A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA CTD PMID:22079614 NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871 		JBrowse link
G Agr2 anterior gradient 2, protein disulphide isomerase family member multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA CTD PMID:16997883 NCBI chr 6:58,435,908...58,456,678
Ensembl chr 6:58,435,908...58,456,677 		JBrowse link
G Agt angiotensinogen decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA CTD PMID:22079614 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA CTD PMID:22079614 NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660 		JBrowse link
G Ahr aryl hydrocarbon receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA CTD PMID:22079614 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA CTD PMID:22079614 NCBI chr  X:132,528,107...132,567,237
Ensembl chr  X:132,528,107...132,567,237 		JBrowse link
G Akap7 A-kinase anchoring protein 7 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA CTD PMID:16997883 NCBI chr 1:21,906,503...22,168,663
Ensembl chr 1:21,906,676...22,037,090 		JBrowse link
G Akap9 A-kinase anchoring protein 9 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA CTD PMID:22079614 NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA CTD PMID:22079614 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alb albumin decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA CTD PMID:22079614 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA CTD PMID:22079614 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Angpt1 angiopoietin 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA CTD PMID:16997883 NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696 		JBrowse link
G Angptl1 angiopoietin-like 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA CTD PMID:22079614 NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA CTD PMID:20147733 NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699 		JBrowse link
G Anxa8 annexin A8 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA CTD PMID:16997883 NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,403,353...9,418,310 		JBrowse link
G Aopep aminopeptidase O decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA CTD PMID:22079614 NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,817,001...2,133,104 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA CTD PMID:22079614 NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772 		JBrowse link
G Apbb1ip amyloid beta precursor protein binding family B member 1 interacting protein increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA CTD PMID:22079614 NCBI chr17:89,849,474...89,941,099
Ensembl chr17:89,671,716...89,941,089 		JBrowse link
G Apc APC regulator of WNT signaling pathway decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA CTD PMID:22079614 NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022 		JBrowse link
G Apcdd1 APC down-regulated 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA CTD PMID:22079614 NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356 		JBrowse link
G Ar androgen receptor decreases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] 		CTD PMID:18467523 PMID:22079614 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Areg amphiregulin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA CTD PMID:20147733 PMID:22079614 NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641 		JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA CTD PMID:22079614 NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646 		JBrowse link
G Arhgef4 Rho guanine nucleotide exchange factor 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA CTD PMID:22079614 NCBI chr 9:44,357,716...44,500,959
Ensembl chr 9:44,357,736...44,501,550 		JBrowse link
G Arid5b AT-rich interaction domain 5B decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA CTD PMID:22079614 NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686 		JBrowse link
G Armcx3 armadillo repeat containing, X-linked 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA CTD PMID:22079614 NCBI chr  X:102,230,464...102,234,017
Ensembl chr  X:102,219,848...102,263,297 		JBrowse link
G Armcx4 armadillo repeat containing, X-linked 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA CTD PMID:22079614 NCBI chr  X:102,153,743...102,164,173
Ensembl chr  X:102,153,800...102,164,633 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA CTD PMID:22079614 NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050 		JBrowse link
G Atp4a ATPase H+/K+ transporting subunit alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA CTD PMID:22079614 NCBI chr 1:95,089,122...95,102,277
Ensembl chr 1:95,089,122...95,102,277 		JBrowse link
G Avpi1 arginine vasopressin-induced 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA CTD PMID:22079614 NCBI chr 1:250,879,530...250,885,448
Ensembl chr 1:250,879,530...250,885,704 		JBrowse link
G B4galnt3 beta-1,4-N-acetyl-galactosaminyl transferase 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA CTD PMID:22079614 NCBI chr 4:155,081,261...155,181,255
Ensembl chr 4:155,081,261...155,181,244 		JBrowse link
G Bank1 B-cell scaffold protein with ankyrin repeats 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA CTD PMID:22079614 NCBI chr 2:227,203,998...227,474,008
Ensembl chr 2:227,203,998...227,474,037 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein 		CTD PMID:11802967 PMID:16709600 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcat1 branched chain amino acid transaminase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA CTD PMID:22079614 NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 CTD PMID:11802967 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein CTD PMID:16709600 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bdkrb1 bradykinin receptor B1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA CTD PMID:20147733 NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973 		JBrowse link
G Bdkrb2 bradykinin receptor B2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA CTD PMID:20147733 NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209 		JBrowse link
G Bmp4 bone morphogenetic protein 4 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA CTD PMID:22079614 NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172 		JBrowse link
G Bmp6 bone morphogenetic protein 6 decreases expression
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA 		CTD PMID:20147733 PMID:22079614 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA CTD PMID:20147733 NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256 		JBrowse link
G Btbd9 BTB domain containing 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA CTD PMID:22079614 NCBI chr20:8,287,813...8,645,437
Ensembl chr20:8,290,456...8,641,292 		JBrowse link
G Cables1 Cdk5 and Abl enzyme substrate 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA CTD PMID:22079614 NCBI chr18:3,349,681...3,455,956
Ensembl chr18:3,351,652...3,455,956 		JBrowse link
G Cabp7 calcium binding protein 7 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA CTD PMID:22079614 NCBI chr14:83,822,322...83,832,667
Ensembl chr14:83,822,327...83,832,735 		JBrowse link
G Cadm1 cell adhesion molecule 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA CTD PMID:22079614 NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:56,744,372...57,080,192 		JBrowse link
G Cadm2 cell adhesion molecule 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA CTD PMID:22079614 NCBI chr11:17,994,856...18,971,895
Ensembl chr11:17,994,856...18,971,448 		JBrowse link
G Caln1 calneuron 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA CTD PMID:22079614 NCBI chr12:31,447,964...31,939,847 JBrowse link
G Calr calreticulin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA CTD PMID:22079614 NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236 		JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA CTD PMID:22079614 NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:155,957,878...155,961,058 		JBrowse link
G Capn15 calpain 15 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA CTD PMID:22079614 NCBI chr10:15,477,311...15,503,913
Ensembl chr10:15,477,313...15,503,913 		JBrowse link
G Capn2 calpain 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA CTD PMID:22079614 NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625 		JBrowse link
G Capn6 calpain 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA CTD PMID:22079614 NCBI chr  X:112,177,467...112,202,178
Ensembl chr  X:112,177,467...112,202,178 		JBrowse link
G Card14 caspase recruitment domain family, member 14 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA CTD PMID:22079614 NCBI chr10:105,064,941...105,100,132
Ensembl chr10:105,064,941...105,100,132 		JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA CTD PMID:22079614 NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407 		JBrowse link
G Casp3 caspase 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA CTD PMID:22079614 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp9 caspase 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA CTD PMID:22079614 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cat catalase multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA CTD PMID:16709600 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cbr4 carbonyl reductase 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA CTD PMID:22079614 NCBI chr16:33,625,734...33,695,067
Ensembl chr16:33,617,399...33,656,832 		JBrowse link
G Ccdc170 coiled-coil domain containing 170 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA CTD PMID:22079614 NCBI chr 1:43,351,010...43,458,192
Ensembl chr 1:43,345,378...43,644,463 		JBrowse link
G Ccdc3 coiled-coil domain containing 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA CTD PMID:22079614 NCBI chr17:77,941,148...78,044,820
Ensembl chr17:77,944,977...78,044,470 		JBrowse link
G Ccdc80 coiled-coil domain containing 80 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA CTD PMID:22079614 NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression 		ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein 		CTD PMID:11230753 PMID:16997883 PMID:20940016 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] CTD PMID:10495789 NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884 		JBrowse link
G Ccn3 cellular communication network factor 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA CTD PMID:22079614 NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581 		JBrowse link
G Ccn6 cellular communication network factor 6 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA CTD PMID:22079614 NCBI chr20:44,123,932...44,139,745
Ensembl chr20:44,123,932...44,139,793 		JBrowse link
G Ccna1 cyclin A1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA CTD PMID:22079614 NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300 		JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA CTD PMID:22079614 NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301 		JBrowse link
G Cd244 CD244 molecule increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA CTD PMID:22079614 NCBI chr13:86,583,727...86,606,902
Ensembl chr13:86,584,826...86,616,009 		JBrowse link
G Cd74 CD74 molecule increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA CTD PMID:22079614 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cd9 CD9 molecule increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA CTD PMID:22079614 NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444 		JBrowse link
G Cdh1 cadherin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein CTD PMID:32028606 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh22 cadherin 22 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA CTD PMID:22079614 NCBI chr 3:174,264,869...174,389,940
Ensembl chr 3:174,264,869...174,390,142 		JBrowse link
G Cdh4 cadherin 4 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA CTD PMID:22079614 NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020 		JBrowse link
G Cdh6 cadherin 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA CTD PMID:22079614 NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA CTD PMID:22079614 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA CTD PMID:22079614 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdon cell adhesion associated, oncogene regulated increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA CTD PMID:20147733 NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345 		JBrowse link
G Cdx1 caudal type homeo box 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA CTD PMID:22079614 NCBI chr18:56,742,970...56,761,299
Ensembl chr18:56,742,984...56,761,299 		JBrowse link
G Ceacam6 CEA cell adhesion molecule 6 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA CTD PMID:16997883 NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:89,544,400...89,562,552 		JBrowse link
G Cebpg CCAAT/enhancer binding protein gamma increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA CTD PMID:22079614 NCBI chr 1:96,820,981...96,829,736
Ensembl chr 1:96,810,214...96,830,283 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form CTD PMID:16709600 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434 		JBrowse link
G Cga glycoprotein hormones, alpha polypeptide increases expression EXP
ISO 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA CTD PMID:8404651 PMID:21467749 PMID:22079614 NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:54,235,019...54,295,464 		JBrowse link
G Cgn cingulin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA CTD PMID:22079614 NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:184,997,425...185,023,635 		JBrowse link
G Chn1 chimerin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA CTD PMID:22079614 NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:78,917,329...79,084,197 		JBrowse link
G Chp1 calcineurin-like EF-hand protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA CTD PMID:22079614 NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:126,989,579...127,042,443 		JBrowse link
G Cidea cell death-inducing DFFA-like effector a increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA CTD PMID:22079614 NCBI chr18:63,164,817...63,190,384
Ensembl chr18:63,164,099...63,190,382 		JBrowse link
G Cidec cell death-inducing DFFA-like effector c increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein CTD PMID:21097823 NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806 		JBrowse link
G Ckmt2 creatine kinase, mitochondrial 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA CTD PMID:22079614 NCBI chr 2:24,815,008...24,845,511
Ensembl chr 2:24,815,008...24,845,511 		JBrowse link
G Cldn1 claudin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA CTD PMID:22079614 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Cldn5 claudin 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA CTD PMID:20711499 NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322 		JBrowse link
G Clgn calmegin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA CTD PMID:20147733 PMID:22079614 NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325 		JBrowse link
G Clic3 chloride intracellular channel 3 multiple interactions
increases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA 		CTD PMID:16997883 PMID:22079614 NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723 		JBrowse link
G Cmklr1 chemerin chemokine-like receptor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA CTD PMID:20147733 NCBI chr12:48,634,929...48,687,833
Ensembl chr12:48,634,003...48,691,458 		JBrowse link
G Cnih3 cornichon family AMPA receptor auxiliary protein 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA CTD PMID:22079614 NCBI chr13:95,548,440...95,739,500
Ensembl chr13:95,598,998...95,772,064 		JBrowse link
G Cnr1 cannabinoid receptor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA CTD PMID:22079614 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Col15a1 collagen type XV alpha 1 chain multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA CTD PMID:16997883 NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170 		JBrowse link
G Col4a4 collagen type IV alpha 4 chain decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA CTD PMID:22079614 NCBI chr 9:91,281,324...91,323,577
Ensembl chr 9:91,203,670...91,323,577 		JBrowse link
G Col4a6 collagen type IV alpha 6 chain multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA CTD PMID:16997883 NCBI chr  X:109,554,945...109,905,987
Ensembl chr  X:109,552,651...109,905,944 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA CTD PMID:22079614 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Col7a1 collagen type VII alpha 1 chain multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA CTD PMID:16997883 NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439 		JBrowse link
G Colec12 collectin sub-family member 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA CTD PMID:22079614 NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297 		JBrowse link
G Coro2a coronin 2A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA CTD PMID:22079614 NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602 		JBrowse link
G Cpm carboxypeptidase M decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA CTD PMID:22079614 NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:55,111,599...55,172,114 		JBrowse link
G Cpo carboxypeptidase O increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA CTD PMID:22079614 NCBI chr 9:72,813,802...72,832,056 JBrowse link
G Cradd CASP2 and RIPK1 domain containing adaptor with death domain increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA CTD PMID:22079614 NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein CTD PMID:18467523 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] CTD PMID:2153673 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Crhbp corticotropin releasing hormone binding protein decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA CTD PMID:22079614 NCBI chr 2:28,427,139...28,439,446
Ensembl chr 2:28,427,139...28,439,446 		JBrowse link
G Cst6 cystatin E/M multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA CTD PMID:16997883 NCBI chr 1:212,084,676...212,086,384
Ensembl chr 1:212,084,676...212,086,384 		JBrowse link
G Ctnna2 catenin alpha 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA CTD PMID:22079614 NCBI chr 4:110,852,265...112,001,351
Ensembl chr 4:110,852,265...112,001,365 		JBrowse link
G Cttnbp2 cortactin binding protein 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA CTD PMID:22079614 NCBI chr 4:47,766,867...47,930,598
Ensembl chr 4:47,766,870...47,930,540 		JBrowse link
G Cux2 cut-like homeobox 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA CTD PMID:22079614 NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA CTD PMID:22079614 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA CTD PMID:22079614 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA 		CTD PMID:20711499 PMID:22079614 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cycs cytochrome c, somatic decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA CTD PMID:22079614 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions
increases expression
increases activity 		ISO
EXP 		2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]
bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein 		CTD PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 More... NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 multiple interactions
increases expression 		ISO bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA]; Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA] CTD PMID:22079614 PMID:22172629 PMID:22546480 PMID:34896276 NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763 		JBrowse link
G Cyp11b3 cytochrome P450, family 11, subfamily b, polypeptide 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA CTD PMID:22079614 PMID:34896276 NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions
increases expression 		ISO [4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] 		CTD PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 More... NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions
increases expression
increases activity 		EXP
ISO 		[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]
[NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein 		CTD PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 More... NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein 		CTD PMID:7588239 PMID:22079614 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA CTD PMID:22079614 NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA CTD PMID:22079614 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA CTD PMID:22079614 NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA CTD PMID:22079614 NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154 		JBrowse link
G Cyp51 cytochrome P450, family 51 increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] 		CTD PMID:18467523 PMID:22079614 NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA CTD PMID:22079614 NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689 		JBrowse link
G Cyth1 cytohesin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA CTD PMID:22079614 NCBI chr10:103,901,376...103,984,496
Ensembl chr10:103,864,804...103,984,383 		JBrowse link
G Dach2 dachshund family transcription factor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA CTD PMID:22079614 NCBI chr  X:82,644,374...83,210,181
Ensembl chr  X:82,644,128...83,210,000 		JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA CTD PMID:22079614 NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053 		JBrowse link
G Dcaf12l1 DDB1 and CUL4 associated factor 12-like 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA CTD PMID:22079614 NCBI chr  X:128,572,969...128,576,588
Ensembl chr  X:128,572,811...128,577,222 		JBrowse link
G Dcbld2 discoidin, CUB and LCCL domain containing 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA CTD PMID:22079614 NCBI chr11:55,594,691...55,649,113
Ensembl chr11:55,594,691...55,649,085 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA CTD PMID:22079614 NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566 		JBrowse link
G Dgkb diacylglycerol kinase, beta increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA CTD PMID:22079614 NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:60,368,519...61,124,420 		JBrowse link
G Dhcr24 24-dehydrocholesterol reductase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA CTD PMID:22079614 NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936 		JBrowse link
G Dhcr7 7-dehydrocholesterol reductase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA CTD PMID:22079614 NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA CTD PMID:22079614 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions ISO 7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] CTD PMID:23275455 NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653 		JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions
increases activity 		ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein
Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]] 		CTD PMID:11425850 PMID:18420745 NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594 		JBrowse link
G Dio3 iodothyronine deiodinase 3 multiple interactions EXP Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] CTD PMID:18420745 NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985 		JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA CTD PMID:22079614 NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650 		JBrowse link
G Dnah5 dynein, axonemal, heavy chain 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA CTD PMID:22079614 NCBI chr 2:80,668,182...80,985,918
Ensembl chr 2:80,668,208...80,985,914 		JBrowse link
G Dnajb3 DnaJ heat shock protein family (Hsp40) member B3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA CTD PMID:22079614 NCBI chr 9:96,243,345...96,244,358
Ensembl chr 9:96,243,071...96,244,408 		JBrowse link
G Dnajb7 DnaJ heat shock protein family (Hsp40) member B7 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA CTD PMID:22079614 NCBI chr 7:114,812,886...114,814,200
Ensembl chr 7:114,810,853...114,814,405 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA CTD PMID:22079614 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA CTD PMID:22079614 NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568 		JBrowse link
G Dock11 dedicator of cytokinesis 11 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA CTD PMID:22079614 NCBI chr  X:119,997,523...120,180,643
Ensembl chr  X:119,997,552...120,180,634 		JBrowse link
G Dok5 docking protein 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA CTD PMID:22079614 NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:179,934,552...180,071,333 		JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA CTD PMID:22079614 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp16 dual specificity phosphatase 16 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA CTD PMID:22079614 NCBI chr 4:169,278,118...169,361,508
Ensembl chr 4:169,278,118...169,361,508 		JBrowse link
G Dusp4 dual specificity phosphatase 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA CTD PMID:20147733 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp6 dual specificity phosphatase 6 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA CTD PMID:22079614 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Ebp EBP, cholestenol delta-isomerase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA CTD PMID:22079614 NCBI chr  X:16,971,372...16,977,782
Ensembl chr  X:16,971,405...16,977,781 		JBrowse link
G Echs1 enoyl-CoA hydratase, short chain 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA CTD PMID:22079614 NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] CTD PMID:18467523 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfr epidermal growth factor receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA CTD PMID:22079614 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egr1 early growth response 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA CTD PMID:22079614 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Egr2 early growth response 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748 		JBrowse link
G Elp1 elongator acetyltransferase complex subunit 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA CTD PMID:22079614 NCBI chr 5:76,248,545...76,300,985
Ensembl chr 5:76,248,550...76,300,985 		JBrowse link
G Emp2 epithelial membrane protein 2 multiple interactions
decreases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA 		CTD PMID:16997883 PMID:22079614 NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532 		JBrowse link
G Enox1 ecto-NOX disulfide-thiol exchanger 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA CTD PMID:20147733 NCBI chr15:58,924,519...59,488,919
Ensembl chr15:59,215,018...59,488,918 		JBrowse link
G Ep300 E1A binding protein p300 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA CTD PMID:22079614 NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574 		JBrowse link
G Epg5 ectopic P-granules 5 autophagy tethering factor decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA CTD PMID:20147733 NCBI chr18:73,679,106...73,776,694
Ensembl chr18:73,679,116...73,776,677 		JBrowse link
G Ephx1 epoxide hydrolase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA CTD PMID:22079614 NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA CTD PMID:22079614 NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056 		JBrowse link
G Erf Ets2 repressor factor decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA CTD PMID:22079614 NCBI chr 1:89,957,760...89,966,213
Ensembl chr 1:89,957,760...89,966,213 		JBrowse link
G Esr2 estrogen receptor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA CTD PMID:22079614 NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709 		JBrowse link
G Esrra estrogen related receptor, alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA CTD PMID:23166782 NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811 		JBrowse link
G Esrrg estrogen-related receptor gamma decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA CTD PMID:22079614 NCBI chr13:101,699,043...102,316,877
Ensembl chr13:101,889,706...102,316,877 		JBrowse link
G Etnppl ethanolamine-phosphate phospho-lyase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA CTD PMID:22079614 NCBI chr 2:221,847,210...221,868,827
Ensembl chr 2:221,847,250...221,866,357 		JBrowse link
G Etv1 ETS variant transcription factor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA CTD PMID:20147733 NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959 		JBrowse link
G Etv5 ETS variant transcription factor 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA CTD PMID:22079614 NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit decreases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] 		CTD PMID:21903722 NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA CTD PMID:20147733 NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473 		JBrowse link
G Fabp1 fatty acid binding protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA CTD PMID:22079614 NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113 		JBrowse link
G Fads1 fatty acid desaturase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA CTD PMID:22079614 NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615 		JBrowse link
G Faslg Fas ligand multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein CTD PMID:16709600 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Fbln1 fibulin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA CTD PMID:15774544 NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965 		JBrowse link
G Fbxo32 F-box protein 32 multiple interactions ISO [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] CTD PMID:23275455 NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491 		JBrowse link
G Fdft1 farnesyl diphosphate farnesyl transferase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA CTD PMID:22079614 NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168 		JBrowse link
G Fdx1 ferredoxin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA CTD PMID:22079614 NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:61,164,839...61,183,583 		JBrowse link
G Fdxr ferredoxin reductase increases expression
decreases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FDXR protein
Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein]; mono-(2-ethylhexyl)phthalate promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FDXR protein] 		CTD PMID:24740604 PMID:34768887 NCBI chr10:101,006,845...101,015,582
Ensembl chr10:101,006,849...101,015,542 		JBrowse link
G Fer1l6 fer-1-like family member 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA CTD PMID:20147733 NCBI chr 7:91,951,174...92,106,617
Ensembl chr 7:91,939,589...92,106,397 		JBrowse link
G Fgf10 fibroblast growth factor 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF10 mRNA CTD PMID:20147733 NCBI chr 2:52,533,939...52,610,980
Ensembl chr 2:52,533,939...52,610,980 		JBrowse link
G Fgf13 fibroblast growth factor 13 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FGF13 mRNA CTD PMID:22079614 NCBI chr  X:142,312,381...142,838,581
Ensembl chr  X:142,312,391...142,423,536 		JBrowse link
G Fgf9 fibroblast growth factor 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA CTD PMID:22079614 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Fhl2 four and a half LIM domains 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FHL2 mRNA CTD PMID:22079614 NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:52,880,998...52,923,326 		JBrowse link
G Flot1 flotillin 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA CTD PMID:16997883 NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,922,655...2,932,771 		JBrowse link
G Flot2 flotillin 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FLOT2 mRNA CTD PMID:22079614 NCBI chr10:63,424,084...63,445,811
Ensembl chr10:63,423,806...63,445,810 		JBrowse link
G Fn1 fibronectin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FN1 mRNA CTD PMID:22079614 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein] CTD PMID:16709600 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA] CTD PMID:16709600 NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845 		JBrowse link
G Foxr1 forkhead box R1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FOXR1 mRNA CTD PMID:22079614 NCBI chr 8:53,657,388...53,669,424
Ensembl chr 8:53,657,256...53,669,629 		JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FRAS1 mRNA CTD PMID:22079614 NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664 		JBrowse link
G Fshb follicle stimulating hormone subunit beta increases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein
Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA] 		CTD PMID:8404651 PMID:10746652 PMID:21467749 NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072 		JBrowse link
G Fzd10 frizzled class receptor 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD10 mRNA CTD PMID:22079614 NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646 		JBrowse link
G Fzd4 frizzled class receptor 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD4 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 1:152,692,507...152,701,372
Ensembl chr 1:152,692,507...152,701,372 		JBrowse link
G Fzd7 frizzled class receptor 7 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FZD7 mRNA CTD PMID:22079614 NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585 		JBrowse link
G Gabbr2 gamma-aminobutyric acid type B receptor subunit 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GABBR2 mRNA CTD PMID:22079614 NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:65,743,073...66,083,695 		JBrowse link
G Gabra4 gamma-aminobutyric acid type A receptor subunit alpha 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRA4 mRNA CTD PMID:22079614 NCBI chr14:36,944,747...37,021,652
Ensembl chr14:36,944,388...37,021,648 		JBrowse link
G Gabrg1 gamma-aminobutyric acid type A receptor subunit gamma 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRG1 mRNA CTD PMID:22079614 NCBI chr14:37,750,292...37,821,651
Ensembl chr14:37,750,292...37,989,945 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein CTD PMID:16709600 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Galnt12 polypeptide N-acetylgalactosaminyltransferase 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALNT12 mRNA CTD PMID:20147733 NCBI chr 5:66,180,171...66,208,931
Ensembl chr 5:66,180,164...66,208,938 		JBrowse link
G Galr1 galanin receptor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALR1 mRNA CTD PMID:22079614 NCBI chr18:78,046,803...78,062,359
Ensembl chr18:78,046,805...78,062,359 		JBrowse link
G Gap43 growth associated protein 43 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GAP43 mRNA CTD PMID:20147733 NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797 		JBrowse link
G Gck glucokinase decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GCK mRNA CTD PMID:22079614 NCBI chr14:84,999,019...85,041,098
Ensembl chr14:84,999,020...85,040,949 		JBrowse link
G Gcsam germinal center-associated, signaling and motility increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GCSAM mRNA CTD PMID:22079614 NCBI chr11:68,658,350...68,669,598
Ensembl chr11:68,660,438...68,669,584 		JBrowse link
G Gdf10 growth differentiation factor 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF10 mRNA CTD PMID:22079614 NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF15 mRNA CTD PMID:22079614 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gfap glial fibrillary acidic protein increases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFAP mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] 		CTD PMID:15994020 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Gfpt2 glutamine-fructose-6-phosphate transaminase 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFPT2 mRNA CTD PMID:20147733 NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419 		JBrowse link
G Gimap8 GTPase, IMAP family member 8 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GIMAP8 mRNA CTD PMID:22079614 NCBI chr 4:78,931,003...78,942,491
Ensembl chr 4:78,931,029...78,942,488 		JBrowse link
G Gja1 gap junction protein, alpha 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJA1 mRNA CTD PMID:22079614 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Gjb2 gap junction protein, beta 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJB2 mRNA CTD PMID:22079614 NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877 		JBrowse link
G Gk glycerol kinase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GK mRNA CTD PMID:22079614 NCBI chr  X:54,106,708...54,189,940
Ensembl chr  X:54,112,214...54,196,701 		JBrowse link
G Glipr1 GLI pathogenesis-related 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLIPR1 mRNA CTD PMID:20147733 NCBI chr 7:49,373,579...49,399,190
Ensembl chr 7:49,373,581...49,384,640 		JBrowse link
G Glrx glutaredoxin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLRX mRNA CTD PMID:22079614 NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:7,073,759...7,083,543 		JBrowse link
G Gnai2 G protein subunit alpha i2 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein] CTD PMID:19252090 NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:117,167,045...117,187,622 		JBrowse link
G Gnai3 G protein subunit alpha i3 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] CTD PMID:19252090 NCBI chr 2:198,430,920...198,468,874 JBrowse link
G Gng2 G protein subunit gamma 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GNG2 mRNA CTD PMID:22079614 NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,365,135...4,466,059 		JBrowse link
G Gpr22 G protein-coupled receptor 22 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR22 mRNA CTD PMID:22079614 NCBI chr 6:54,037,998...54,044,994
Ensembl chr 6:54,037,552...54,045,020 		JBrowse link
G Gpr37 G protein-coupled receptor 37 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR37 mRNA CTD PMID:22079614 NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494 		JBrowse link
G Gpx1 glutathione peroxidase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GPX1 mRNA CTD PMID:22079614 NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581 		JBrowse link
G Grb10 growth factor receptor bound protein 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GRB10 mRNA CTD PMID:22079614 NCBI chr14:90,708,653...90,816,399
Ensembl chr14:90,708,653...90,816,387 		JBrowse link
G Grb14 growth factor receptor bound protein 14 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRB14 mRNA CTD PMID:22079614 NCBI chr 3:69,976,331...70,091,921
Ensembl chr 3:69,976,339...70,091,921 		JBrowse link
G Grem2 gremlin 2, DAN family BMP antagonist increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GREM2 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr13:89,310,897...89,403,856
Ensembl chr13:89,310,662...89,404,312 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA] CTD PMID:23275455 NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309 		JBrowse link
G Grin3a glutamate ionotropic receptor NMDA type subunit 3A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRIN3A mRNA CTD PMID:22079614 NCBI chr 5:68,802,333...69,001,880
Ensembl chr 5:68,804,970...69,001,558 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTA2 mRNA CTD PMID:22079614 NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTM2 mRNA CTD PMID:22079614 NCBI chr 2:198,312,179...198,316,962 JBrowse link
G Gstm4 glutathione S-transferase mu 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GSTM4 mRNA CTD PMID:20147733 NCBI chr 2:198,356,114...198,373,487
Ensembl chr 2:198,358,744...198,373,638 		JBrowse link
G Has2 hyaluronan synthase 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HAS2 mRNA CTD PMID:20147733 NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535 		JBrowse link
G Hbg1 hemoglobin subunit gamma 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HBG1 mRNA CTD PMID:22079614 NCBI chr 1:167,683,760...167,685,315
Ensembl chr 1:167,683,760...167,706,139 		JBrowse link
G Hdac3 histone deacetylase 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC3 mRNA CTD PMID:22079614 NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025 		JBrowse link
G Hdac5 histone deacetylase 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC5 mRNA CTD PMID:22079614 NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,652,656...87,694,244 		JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HEY2 mRNA CTD PMID:22079614 NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:28,641,057...28,651,187 		JBrowse link
G Hlf HLF transcription factor, PAR bZIP family member decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HLF mRNA CTD PMID:22079614 NCBI chr10:75,651,320...75,708,979
Ensembl chr10:75,654,534...75,708,619 		JBrowse link
G Hmga1 high mobility group AT-hook 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGA1 mRNA CTD PMID:22079614 NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGCS1 mRNA CTD PMID:22079614 NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA] 		CTD PMID:15179140 PMID:15994020 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hnf4g hepatocyte nuclear factor 4, gamma increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HNF4G mRNA CTD PMID:22079614 NCBI chr 2:99,792,942...99,943,811
Ensembl chr 2:99,792,942...99,943,811 		JBrowse link
G Hoxb9 homeo box B9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HOXB9 mRNA CTD PMID:22079614 NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872 		JBrowse link
G Hpca hippocalcin decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HPCA mRNA CTD PMID:22079614 NCBI chr 5:146,739,978...146,750,961
Ensembl chr 5:146,739,978...146,749,983 		JBrowse link
G Hs3st1 heparan sulfate-glucosamine 3-sulfotransferase 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HS3ST1 mRNA CTD PMID:22079614 NCBI chr14:75,398,101...75,429,628
Ensembl chr14:75,398,026...75,436,848 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA] CTD PMID:23275455 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 decreases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD11B2 mRNA
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein 		CTD PMID:22079614 PMID:23275455 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [bisphenol A results in decreased expression of HSD17B1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B1 mRNA 		CTD PMID:18815356 PMID:21273127 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD17B14 mRNA CTD PMID:22079614 NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:105,165,695...105,176,510 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions
increases expression 		ISO bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA]
[NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 protein 		CTD PMID:18815356 PMID:21273127 PMID:21610156 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B3 mRNA CTD PMID:22079614 NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO [4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD17B4 protein CTD PMID:18336853 NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B7 mRNA CTD PMID:22079614 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions
decreases expression
increases expression 		ISO 2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD3B1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 protein 		CTD PMID:18815356 PMID:21726595 PMID:22079614 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA
[4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of HSD3B2 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA] 		CTD PMID:18336853 PMID:22079614 PMID:22546480 PMID:34896276 NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSP90AA1 mRNA CTD PMID:22079614 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA1A mRNA CTD PMID:22079614 NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPA5 mRNA CTD PMID:22079614 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA8 mRNA CTD PMID:22079614 NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPH1 mRNA CTD PMID:22079614 NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] CTD PMID:10495789 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Icam2 intercellular adhesion molecule 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ICAM2 mRNA CTD PMID:22079614 NCBI chr10:91,808,449...91,819,319
Ensembl chr10:91,808,316...91,815,072 		JBrowse link
G Id1 inhibitor of DNA binding 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ID1 mRNA CTD PMID:22079614 NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IDI1 mRNA CTD PMID:22079614 NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524 		JBrowse link
G Ier3 immediate early response 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IER3 mRNA CTD PMID:20147733 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Igf1 insulin-like growth factor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF1 mRNA CTD PMID:20147733 NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764 		JBrowse link
G Igf2bp2 insulin-like growth factor 2 mRNA binding protein 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF2BP2 mRNA CTD PMID:22079614 NCBI chr11:92,378,908...92,478,893
Ensembl chr11:92,378,908...92,478,867 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions
increases expression
decreases expression
increases secretion 		ISO 1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; Dexamethasone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 protein
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of IGFBP1 protein 		CTD PMID:16709600 PMID:17065600 PMID:18815356 PMID:20147733 PMID:21273127 More... NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP5 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390 		JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IKZF1 mRNA CTD PMID:22079614 NCBI chr14:90,468,696...90,556,522
Ensembl chr14:90,469,172...90,557,574 		JBrowse link
G Il18 interleukin 18 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL18 mRNA CTD PMID:22079614 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL1A mRNA 		CTD PMID:11230753 PMID:22079614 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] CTD PMID:11112151 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il27ra interleukin 27 receptor subunit alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL27RA mRNA CTD PMID:22079614 NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760 		JBrowse link
G Il4 interleukin 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4 mRNA CTD PMID:22079614 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il4r interleukin 4 receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4R mRNA CTD PMID:20147733 NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP 		[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of IL6 mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] 		CTD PMID:16997883 PMID:21803157 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Il7r interleukin 7 receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL7R mRNA CTD PMID:22079614 NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027 		JBrowse link
G Inhba inhibin subunit beta A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INHBA mRNA CTD PMID:20147733 PMID:22079614 NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508 		JBrowse link
G Insig1 insulin induced gene 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INSIG1 mRNA CTD PMID:22079614 NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778 		JBrowse link
G Insm2 INSM transcriptional repressor 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INSM2 mRNA CTD PMID:22079614 NCBI chr 6:78,708,983...78,711,575
Ensembl chr 6:78,705,641...78,717,027 		JBrowse link
G Iqgap2 IQ motif containing GTPase activating protein 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IQGAP2 mRNA CTD PMID:22079614 NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:28,629,558...28,904,649 		JBrowse link
G Irs1 insulin receptor substrate 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IRS1 mRNA CTD PMID:22079614 NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538 		JBrowse link
G Ism1 isthmin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ISM1 mRNA CTD PMID:20147733 NCBI chr 3:147,476,983...147,555,900
Ensembl chr 3:147,475,533...147,555,908 		JBrowse link
G Itga2 integrin subunit alpha 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ITGA2 mRNA CTD PMID:20147733 NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509 		JBrowse link
G Itpkb inositol-trisphosphate 3-kinase B increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ITPKB mRNA CTD PMID:22079614 NCBI chr13:94,601,072...94,696,180
Ensembl chr13:94,601,167...94,696,179 		JBrowse link
G Jag1 jagged canonical Notch ligand 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of JAG1 mRNA CTD PMID:22079614 NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872 		JBrowse link
G Jarid2 jumonji and AT-rich interaction domain containing 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of JARID2 mRNA CTD PMID:20147733 NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased phosphorylation of JUN protein CTD PMID:28697429 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of JUND mRNA CTD PMID:22079614 NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148 		JBrowse link
G Kcnc2 potassium voltage-gated channel subfamily C member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCNC2 mRNA CTD PMID:22079614 NCBI chr 7:49,586,274...49,770,212
Ensembl chr 7:49,586,136...49,770,212 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCND2 mRNA CTD PMID:22079614 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kcne4 potassium voltage-gated channel subfamily E regulatory subunit 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCNE4 mRNA CTD PMID:22079614 NCBI chr 9:87,674,264...87,699,088
Ensembl chr 9:87,650,462...87,704,131 		JBrowse link
G Kcnh6 potassium voltage-gated channel subfamily H member 6 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCNH6 mRNA CTD PMID:22079614 NCBI chr10:91,449,025...91,471,012
Ensembl chr10:91,449,651...91,470,506 		JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCNQ1 mRNA CTD PMID:22079614 NCBI chr 1:207,721,134...208,054,073
Ensembl chr 1:207,721,131...208,054,072 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 multiple interactions
increases expression
decreases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of KCTD12 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCTD12 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCTD12 mRNA 		CTD PMID:16997883 PMID:20147733 PMID:22079614 NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539 		JBrowse link
G Kif5c kinesin family member 5C increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KIF5C mRNA CTD PMID:22079614 NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:54,441,310...54,594,813 		JBrowse link
G Kirrel3 kirre like nephrin family adhesion molecule 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KIRREL3 mRNA CTD PMID:22079614 NCBI chr 8:41,123,692...41,663,528
Ensembl chr 8:41,123,878...41,664,147 		JBrowse link
G Klhl5 kelch-like family member 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KLHL5 mRNA CTD PMID:22079614 NCBI chr14:43,497,915...43,565,833
Ensembl chr14:43,497,918...43,537,894 		JBrowse link
G Klrc1 killer cell lectin like receptor C1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC1 mRNA CTD PMID:22079614 NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:164,828,163...164,838,464 		JBrowse link
G Klrc2 killer cell lectin like receptor C2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC2 mRNA CTD PMID:22079614 NCBI chr 4:164,808,722...164,819,865
Ensembl chr 4:164,808,722...164,819,865 		JBrowse link
G Klrc3 killer cell lectin like receptor C3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC3 mRNA CTD PMID:22079614 NCBI chr 4:164,791,102...164,798,758
Ensembl chr 4:164,791,128...164,798,758 		JBrowse link
G Krt34 keratin 34 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KRT34 mRNA CTD PMID:20147733 NCBI chr10:85,470,391...85,474,501
Ensembl chr10:85,470,391...85,474,501 		JBrowse link
G Krtap1-1 keratin associated protein 1-1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KRTAP1-5 mRNA CTD PMID:20147733 NCBI chr10:85,041,910...85,042,476
Ensembl chr10:85,041,910...85,042,476 		JBrowse link
G L3mbtl3 L3MBTL histone methyl-lysine binding protein 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of L3MBTL3 mRNA CTD PMID:22079614 NCBI chr 1:20,807,679...20,908,609
Ensembl chr 1:20,808,973...20,908,608 		JBrowse link
G Lama3 laminin subunit alpha 3 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMA3 mRNA CTD PMID:16997883 NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449 		JBrowse link
G Lamb3 laminin subunit beta 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LAMB3 mRNA CTD PMID:22079614 NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081 		JBrowse link
G Lamp3 lysosomal-associated membrane protein 3 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMP3 mRNA CTD PMID:16997883 NCBI chr11:94,657,817...94,726,451
Ensembl chr11:94,661,399...94,726,195 		JBrowse link
G Lat2 linker for activation of T cells family, member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LAT2 mRNA CTD PMID:22079614 NCBI chr12:27,740,647...27,754,760
Ensembl chr12:27,740,654...27,755,843 		JBrowse link
G Ldlr low density lipoprotein receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LDLR mRNA CTD PMID:22079614 NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675 		JBrowse link
G Lef1 lymphoid enhancer binding factor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LEF1 mRNA CTD PMID:22079614 NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929 		JBrowse link
G Lep leptin multiple interactions
decreases response to substance 		ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]
LEP protein results in decreased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate 		CTD PMID:19849856 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lepr leptin receptor multiple interactions ISO LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]] CTD PMID:19849856 NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215 		JBrowse link
G Lgals1 galectin 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LGALS1 mRNA CTD PMID:22079614 NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800 		JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LGR4 mRNA CTD PMID:20147733 NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:116,901,968...117,004,153 		JBrowse link
G Lhb luteinizing hormone subunit beta increases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA] 		CTD PMID:2153673 PMID:8404651 PMID:21467749 NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor decreases expression
increases expression
multiple interactions 		ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LHCGR mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA
T-2 Toxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA]
Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA] 		CTD PMID:22079614 PMID:23583632 PMID:30951242 NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061 		JBrowse link
G Lif LIF, interleukin 6 family cytokine multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LIF mRNA
[NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone 		CTD PMID:16997883 PMID:21610156 NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053 		JBrowse link
G Limch1 LIM and calponin homology domains 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LIMCH1 mRNA CTD PMID:16997883 NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,466,433...41,778,837 		JBrowse link
G Lingo1 leucine rich repeat and Ig domain containing 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LINGO1 mRNA CTD PMID:22079614 NCBI chr 8:65,907,275...66,089,485
Ensembl chr 8:65,897,844...66,091,740 		JBrowse link
G Lipc lipase C, hepatic type increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LIPC mRNA CTD PMID:22079614 NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285 		JBrowse link
G Lmnb1 lamin B1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LMNB1 mRNA CTD PMID:22079614 NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283 		JBrowse link
G Lmo3 LIM domain only 3 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA CTD PMID:16997883 NCBI chr 4:172,965,944...173,028,980
Ensembl chr 4:172,965,951...173,025,156 		JBrowse link
G Loxl1 lysyl oxidase-like 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LOXL1 mRNA CTD PMID:16997883 NCBI chr 8:67,587,636...67,612,224
Ensembl chr 8:67,587,636...67,612,224 		JBrowse link
G Lpcat1 lysophosphatidylcholine acyltransferase 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA CTD PMID:16997883 NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:31,594,622...31,644,946 		JBrowse link
G Lpl lipoprotein lipase increases expression
decreases activity 		EXP
ISO 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LPL mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased activity of LPL protein 		CTD PMID:9032464 PMID:9414485 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Lrrc17 leucine rich repeat containing 17 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LRRC17 mRNA CTD PMID:22079614 NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048 		JBrowse link
G Lss lanosterol synthase decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LSS mRNA CTD PMID:22079614 NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253 		JBrowse link
G Lum lumican increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LUM mRNA CTD PMID:22079614 NCBI chr 7:34,245,323...34,252,510
Ensembl chr 7:34,245,360...34,252,508 		JBrowse link
G Lxn latexin multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LXN mRNA CTD PMID:16997883 NCBI chr 2:154,037,604...154,043,473
Ensembl chr 2:154,037,292...154,043,488 		JBrowse link
G Lypd1 Ly6/Plaur domain containing 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LYPD1 mRNA CTD PMID:20147733 NCBI chr13:39,874,937...39,922,385
Ensembl chr13:39,879,096...39,922,338 		JBrowse link
G Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of XLKD1 mRNA CTD PMID:22079614 NCBI chr 1:174,393,387...174,410,977 JBrowse link
G Mamdc2 MAM domain containing 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MAMDC2 mRNA CTD PMID:22079614 NCBI chr 1:230,290,482...230,443,014
Ensembl chr 1:230,290,499...230,442,711 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MAN1A1 mRNA CTD PMID:22079614 NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,745,165...33,928,584 		JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAP3K8 mRNA CTD PMID:22079614 NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP 		3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK1 protein] 		CTD PMID:8526880 PMID:12657697 PMID:18467523 PMID:19252090 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPK10 mRNA CTD PMID:22079614 NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases expression 		ISO
EXP 		3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPK3 mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein] 		CTD PMID:8526880 PMID:12657697 PMID:18467523 PMID:19252090 PMID:22079614 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapt microtubule-associated protein tau decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPT mRNA CTD PMID:22079614 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Mc2r melanocortin 2 receptor increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MC2R mRNA
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter] 		CTD PMID:21610156 PMID:22079614 NCBI chr18:64,279,878...64,291,775
Ensembl chr18:64,277,360...64,291,881 		JBrowse link
G Mcf2 MCF.2 cell line derived transforming sequence decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MCF2 mRNA CTD PMID:22079614 NCBI chr  X:143,444,510...143,550,839
Ensembl chr  X:143,444,038...143,567,714 		JBrowse link
G Mcf2l MCF.2 cell line derived transforming sequence-like decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MCF2L mRNA CTD PMID:22079614 NCBI chr16:83,209,277...83,355,683
Ensembl chr16:83,209,280...83,354,956 		JBrowse link
G Mdh1 malate dehydrogenase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MDH1 mRNA CTD PMID:22079614 NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232 		JBrowse link
G Medag mesenteric estrogen-dependent adipogenesis increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MEDAG mRNA CTD PMID:20147733 NCBI chr12:10,649,526...10,670,913
Ensembl chr12:10,649,526...10,692,756 		JBrowse link
G Mertk MER proto-oncogene, tyrosine kinase decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MERTK mRNA CTD PMID:22079614 NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of METRNL mRNA CTD PMID:22079614 NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MGST1 mRNA CTD PMID:22079614 NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875 		JBrowse link
G Mia2 MIA SH3 domain ER export factor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MIA2 mRNA CTD PMID:22079614 NCBI chr 6:82,522,398...82,620,136
Ensembl chr 6:82,522,422...82,620,178 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MICB mRNA CTD PMID:22079614 NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872 		JBrowse link
G Milr1 mast cell immunoglobulin-like receptor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MILR1 mRNA CTD PMID:20147733 NCBI chr10:92,184,002...92,205,001
Ensembl chr10:92,187,479...92,205,003 		JBrowse link
G Mme membrane metallo-endopeptidase decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MME mRNA CTD PMID:22079614 NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463 		JBrowse link
G Mmp10 matrix metallopeptidase 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MMP10 mRNA CTD PMID:22079614 NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613 		JBrowse link
G Mmp16 matrix metallopeptidase 16 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MMP16 mRNA CTD PMID:20147733 NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252 		JBrowse link
G Mob4 MOB family member 4, phocein increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MOB4 mRNA CTD PMID:22079614 NCBI chr 9:64,111,170...64,135,740
Ensembl chr 9:64,111,718...64,135,779 		JBrowse link
G Mocos molybdenum cofactor sulfurase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MOCOS mRNA CTD PMID:22079614 NCBI chr18:16,206,402...16,251,928
Ensembl chr18:16,206,402...16,251,928 		JBrowse link
G Moxd1 monooxygenase, DBH-like 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MOXD1 mRNA CTD PMID:22079614 NCBI chr 1:22,894,543...22,984,599
Ensembl chr 1:22,894,543...22,984,223 		JBrowse link
G Mpp3 MAGUK p55 scaffold protein 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MPP3 mRNA CTD PMID:22079614 NCBI chr10:87,445,905...87,475,461
Ensembl chr10:87,445,905...87,474,811 		JBrowse link
G Mrap melanocortin 2 receptor accessory protein decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MRAP mRNA CTD PMID:22079614 NCBI chr11:43,477,382...43,489,118
Ensembl chr11:43,478,001...43,489,118 		JBrowse link
G Mras muscle RAS oncogene homolog increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MRAS mRNA CTD PMID:22079614 NCBI chr 8:108,823,374...108,886,104
Ensembl chr 8:108,823,374...108,875,911 		JBrowse link
G Msmo1 methylsterol monooxygenase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MSMO1 mRNA CTD PMID:22079614 NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MSRB3 mRNA CTD PMID:22079614 NCBI chr 7:58,188,827...58,311,459
Ensembl chr 7:57,968,124...58,311,116 		JBrowse link
G Mtmr4 myotubularin related protein 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MTMR4 mRNA CTD PMID:20147733 NCBI chr10:72,890,665...72,913,598
Ensembl chr10:72,889,827...72,913,598 		JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MTSS1 mRNA CTD PMID:22079614 NCBI chr 7:92,378,228...92,517,444
Ensembl chr 7:92,378,238...92,517,303 		JBrowse link
G Muc1 mucin 1, cell surface associated multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MUC1 mRNA CTD PMID:16997883 NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491 		JBrowse link
G Mug2 murinoglobulin 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PZP mRNA CTD PMID:22079614 NCBI chr 4:156,836,140...156,908,972 JBrowse link
G Mvd mevalonate diphosphate decarboxylase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MVD mRNA CTD PMID:22079614 NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366 		JBrowse link
G Mvk mevalonate kinase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MVK mRNA CTD PMID:22079614 NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503 		JBrowse link
G Myb MYB proto-oncogene, transcription factor decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYB mRNA CTD PMID:22079614 NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYC mRNA CTD PMID:22079614 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Myh7b myosin heavy chain 7B decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYH7B mRNA CTD PMID:22079614 NCBI chr 3:164,537,211...164,582,441
Ensembl chr 3:164,558,340...164,582,094 		JBrowse link
G Mylip myosin regulatory light chain interacting protein decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYLIP mRNA CTD PMID:22079614 NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471 		JBrowse link
G Myof myoferlin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYOF mRNA CTD PMID:22079614 NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768 		JBrowse link
G Mypn myopalladin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYPN mRNA CTD PMID:22079614 NCBI chr20:25,435,554...25,521,149
Ensembl chr20:25,435,554...25,521,149 		JBrowse link
G N4bp2l1 NEDD4 binding protein 2-like 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of N4BP2L1 mRNA CTD PMID:22079614 NCBI chr12:4,938,199...4,965,003
Ensembl chr12:4,927,142...4,963,045 		JBrowse link
G Nalf1 NALCN channel auxiliary factor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NALF1 mRNA CTD PMID:22079614 NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150 		JBrowse link
G Nanos1 nanos C2HC-type zinc finger 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NANOS1 mRNA CTD PMID:22079614 NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417 		JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NAP1L2 mRNA CTD PMID:22079614 NCBI chr  X:72,239,849...72,242,247
Ensembl chr  X:72,238,310...72,242,464 		JBrowse link
G Nav3 neuron navigator 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NAV3 mRNA CTD PMID:22079614 NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893 		JBrowse link
G Ncf2 neutrophil cytosolic factor 2 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of NCF2 mRNA CTD PMID:16997883 NCBI chr13:67,505,492...67,536,015
Ensembl chr13:67,505,375...67,536,149 		JBrowse link
G Nectin3 nectin cell adhesion molecule 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NECTIN3 mRNA CTD PMID:22079614 NCBI chr11:67,825,296...67,931,999
Ensembl chr11:67,827,137...67,871,383 		JBrowse link
G Nek6 NIMA-related kinase 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NEK6 mRNA CTD PMID:22079614 NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:42,693,971...42,767,773 		JBrowse link
G Ngef neuronal guanine nucleotide exchange factor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NGEF mRNA CTD PMID:22079614 NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251 		JBrowse link
G Ngf nerve growth factor decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NGF mRNA CTD PMID:22079614 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NIBAN1 mRNA CTD PMID:22079614 NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724 		JBrowse link
G Nid2 nidogen 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NID2 mRNA CTD PMID:20147733 NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,506,756...4,562,949 		JBrowse link
G Nkx2-1 NK2 homeobox 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of NKX2-1 mRNA CTD PMID:16997883 NCBI chr 6:79,731,677...79,735,952
Ensembl chr 6:79,731,677...79,736,441 		JBrowse link
G Nmu neuromedin U increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NMU mRNA CTD PMID:23423171 NCBI chr14:32,198,789...32,226,397
Ensembl chr14:32,198,943...32,226,632 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA] CTD PMID:15994020 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Notch3 notch receptor 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NOTCH3 mRNA CTD PMID:20147733 NCBI chr 7:11,783,550...11,834,585
Ensembl chr 7:11,784,272...11,834,778 		JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1D1 mRNA CTD PMID:22079614 NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812 		JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1D2 mRNA CTD PMID:22079614 NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1H2 mRNA CTD PMID:22079614 NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein] CTD PMID:27743861 NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR1I2 mRNA CTD PMID:22079614 NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR1I3 mRNA CTD PMID:22079614 NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of ZNF486 mRNA]; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA] CTD PMID:23275455 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR3C2 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] 		CTD PMID:22079614 PMID:23275455 NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 mRNA 		CTD PMID:21726595 PMID:22079614 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A2 mRNA CTD PMID:22079614 NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769 		JBrowse link
G Nr4a3 nuclear receptor subfamily 4, group A, member 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A3 mRNA CTD PMID:22079614 NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285 		JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO [20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Estradiol; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Testosterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA; [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone CTD PMID:21610156 NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:42,875,221...42,896,046 		JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NRCAM mRNA CTD PMID:22079614 NCBI chr 6:67,129,723...67,425,510
Ensembl chr 6:67,129,801...67,430,539 		JBrowse link
G Nrp1 neuropilin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NRP1 mRNA CTD PMID:22079614 NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702 		JBrowse link
G Ntf4 neurotrophin 4 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NTF5 mRNA CTD PMID:22079614 NCBI chr 1:105,030,035...105,032,866
Ensembl chr 1:105,029,764...105,034,038 		JBrowse link
G Nxn nucleoredoxin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NXN mRNA CTD PMID:22079614 NCBI chr10:61,607,557...61,745,807
Ensembl chr10:61,607,568...61,745,807 		JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OGT mRNA CTD PMID:22079614 NCBI chr  X:70,811,317...70,856,123
Ensembl chr  X:70,811,319...70,856,123 		JBrowse link
G Omg oligodendrocyte-myelin glycoprotein increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OMG mRNA CTD PMID:22079614 NCBI chr10:64,959,316...64,962,050
Ensembl chr10:64,936,145...64,962,050 		JBrowse link
G Osbp2 oxysterol binding protein 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of OSBP2 mRNA CTD PMID:22079614 NCBI chr14:82,808,693...82,970,386
Ensembl chr14:82,808,693...82,970,532 		JBrowse link
G Ostf1 osteoclast stimulating factor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of OSTF1 mRNA CTD PMID:22079614 NCBI chr 1:225,428,661...225,475,851
Ensembl chr 1:225,428,661...225,541,027 		JBrowse link
G Oxgr1 oxoglutarate receptor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OXGR1 mRNA CTD PMID:22079614 NCBI chr15:103,551,338...103,573,611
Ensembl chr15:103,552,861...103,553,874 		JBrowse link
G P4ha3 prolyl 4-hydroxylase subunit alpha 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of P4HA3 mRNA CTD PMID:20147733 NCBI chr 1:164,040,852...164,075,922
Ensembl chr 1:164,040,864...164,076,435 		JBrowse link
G Pakap paralemmin A kinase anchor protein increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PALM2AKAP2 mRNA CTD PMID:22079614 NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:76,977,112...77,443,656 		JBrowse link
G Palmd palmdelphin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PALMD mRNA CTD PMID:20147733 NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:207,574,249...207,626,239 		JBrowse link
G Pappa pappalysin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAPPA mRNA CTD PMID:20147733 NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361 		JBrowse link
G Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAPSS2 mRNA CTD PMID:22079614 NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:239,867,574...239,952,616 		JBrowse link
G Paqr5 progestin and adipoQ receptor family member 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAQR5 mRNA CTD PMID:20147733 NCBI chr 8:71,327,397...71,409,201
Ensembl chr 8:71,327,397...71,409,201 		JBrowse link
G Patj PATJ, crumbs cell polarity complex component increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PATJ mRNA CTD PMID:22079614 NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:118,177,565...118,480,301 		JBrowse link
G Pbx4 PBX homeobox 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PBX4 mRNA CTD PMID:22079614 NCBI chr16:19,588,998...19,624,016
Ensembl chr16:19,588,999...19,623,921 		JBrowse link
G Pcdh20 protocadherin 20 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PCDH20 mRNA CTD PMID:22079614 NCBI chr15:70,834,042...70,840,298
Ensembl chr15:70,834,042...70,840,298 		JBrowse link
G Pcdhb5 protocadherin beta 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PCDHB4 mRNA CTD PMID:20147733 NCBI chr18:29,302,466...29,305,048 JBrowse link
G Pcsk1 proprotein convertase subtilisin/kexin type 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PCSK1 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 2:6,130,045...6,176,974
Ensembl chr 2:6,129,592...6,176,974 		JBrowse link
G Pde1a phosphodiesterase 1A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDE1A mRNA CTD PMID:20147733 NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212 		JBrowse link
G Pde2a phosphodiesterase 2A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDE2A mRNA CTD PMID:22079614 NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:165,235,623...165,327,466 		JBrowse link
G Pde3a phosphodiesterase 3A increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDE3A mRNA CTD PMID:12466227 NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270 		JBrowse link
G Pdgfd platelet derived growth factor D decreases expression
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDGFD mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDGFD mRNA 		CTD PMID:20147733 PMID:22079614 NCBI chr 8:11,773,335...12,007,277
Ensembl chr 8:11,773,475...12,007,271 		JBrowse link
G Pdlim4 PDZ and LIM domain 4 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of PDLIM4 mRNA CTD PMID:16997883 NCBI chr10:38,699,444...38,713,696
Ensembl chr10:38,699,444...38,713,659 		JBrowse link
G Pdzrn3 PDZ domain containing RING finger 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDZRN3 mRNA CTD PMID:22079614 NCBI chr 4:135,327,082...135,553,294
Ensembl chr 4:135,327,082...135,553,294 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PECAM1 mRNA CTD PMID:16997883 NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839 		JBrowse link
G Peg10 paternally expressed 10 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PEG10 mRNA CTD PMID:20147733 NCBI chr 4:33,809,026...33,822,224
Ensembl chr 4:33,817,190...33,819,166
Ensembl chr 4:33,817,190...33,819,166 		JBrowse link
G Pgm5 phosphoglucomutase 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PGM5 mRNA CTD PMID:22079614 NCBI chr 1:231,752,052...231,939,812
Ensembl chr 1:231,752,052...231,939,812 		JBrowse link
G Pgr progesterone receptor multiple interactions
decreases expression 		ISO [8-Bromo Cyclic Adenosine Monophosphate co-treated with Progesterone co-treated with Estradiol] affects the expression of and affects the phosphorylation of PGR protein
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PGR protein 		CTD PMID:23275455 NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271 		JBrowse link
G Phactr3 phosphatase and actin regulator 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PHACTR3 mRNA CTD PMID:22079614 NCBI chr 3:185,582,134...185,801,404
Ensembl chr 3:185,582,796...185,801,822 		JBrowse link
G Phaf1 phagophore assembly factor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PHAF1 mRNA CTD PMID:22079614 NCBI chr19:50,011,350...50,050,880
Ensembl chr19:50,011,369...50,053,987 		JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PID1 mRNA CTD PMID:20147733 NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PIK3R3 mRNA CTD PMID:22079614 NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:134,934,857...135,007,762 		JBrowse link
G Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PITPNC1 mRNA CTD PMID:20147733 NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,663,260...92,928,344 		JBrowse link
G Pla2r1 phospholipase A2 receptor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PLA2R1 mRNA CTD PMID:22079614 NCBI chr 3:65,292,629...65,422,462
Ensembl chr 3:65,292,629...65,422,335 		JBrowse link
G Plat plasminogen activator, tissue type increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PLAT mRNA CTD PMID:20147733 NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696 		JBrowse link
G Plcb1 phospholipase C beta 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PLCB1 mRNA CTD PMID:20147733 NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646 		JBrowse link
G Pld1 phospholipase D1 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of PLD1 protein; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA] CTD PMID:17065600 NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245 		JBrowse link
G Pmepa1 prostate transmembrane protein, androgen induced 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PMEPA1 mRNA CTD PMID:22079614 NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:182,430,193...182,478,649 		JBrowse link
G Pon3 paraoxonase 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PON3 mRNA CTD PMID:22079614 NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:34,315,889...34,350,244 		JBrowse link
G Pou3f1 POU class 3 homeobox 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of POU3F1 mRNA CTD PMID:22079614 NCBI chr 5:142,195,090...142,198,070
Ensembl chr 5:142,194,066...142,202,704 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPARA mRNA CTD PMID:22079614 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPARG mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 		CTD PMID:15994020 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppfibp1 PPFIA binding protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PPFIBP1 mRNA CTD PMID:22079614 NCBI chr 4:181,538,249...181,682,079
Ensembl chr 4:181,539,450...181,682,076 		JBrowse link
G Ppm1h protein phosphatase, Mg2+/Mn2+ dependent, 1H decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPM1H mRNA CTD PMID:22079614 NCBI chr 7:60,224,087...60,484,947
Ensembl chr 7:60,223,745...60,488,140 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PPP1R3C mRNA CTD PMID:20147733 NCBI chr 1:243,873,524...243,878,527
Ensembl chr 1:243,871,704...243,878,835 		JBrowse link
G Prkacb protein kinase cAMP-activated catalytic subunit beta multiple interactions ISO [PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:238,300,127...238,386,315 		JBrowse link
G Prkar1a protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions ISO [PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr10:95,120,537...95,139,028
Ensembl chr10:95,120,487...95,139,025 		JBrowse link
G Prkar2b protein kinase cAMP-dependent type II regulatory subunit beta increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRKAR2B mRNA
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of PRKAR2B protein 		CTD PMID:18467523 PMID:22079614 NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:54,291,151...54,381,411 		JBrowse link
G Prkca protein kinase C, alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRKCA mRNA CTD PMID:22079614 NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572 		JBrowse link
G Prl prolactin multiple interactions
increases expression
decreases expression
increases secretion 		ISO
EXP 		1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Dexamethasone] results in increased expression of PRL mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Tobacco Smoke Pollution inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL protein
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL protein
8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of PRL protein 		CTD PMID:15774544 PMID:16709600 PMID:17065600 PMID:18815356 PMID:20147733 More... NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217 		JBrowse link
G Prmt7 protein arginine methyltransferase 7 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRMT7 mRNA CTD PMID:22079614 NCBI chr19:51,020,596...51,071,401
Ensembl chr19:51,020,512...51,072,424 		JBrowse link
G Prss23 serine protease 23 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRSS23 mRNA CTD PMID:22079614 NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871 		JBrowse link
G Psat1 phosphoserine aminotransferase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PSAT1 mRNA CTD PMID:22079614 NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693 		JBrowse link
G Ptgdr2 prostaglandin D2 receptor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTGDR2 mRNA CTD PMID:22079614 NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:216,995,629...217,022,393 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTGS1 mRNA CTD PMID:22079614 NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA CTD PMID:11112151 PMID:12821125 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Pth parathyroid hormone increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTH mRNA CTD PMID:22079614 NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:176,943,102...176,946,034 		JBrowse link
G Pthlh parathyroid hormone-like hormone increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTHLH mRNA CTD PMID:20147733 NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454 		JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [HU 211 results in increased phosphorylation of PTK2 protein] CTD PMID:12163181 NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091 		JBrowse link
G Ptp4a1 protein tyrosine phosphatase 4A1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTP4A1 mRNA CTD PMID:22079614 NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176 		JBrowse link
G Ptpre protein tyrosine phosphatase, receptor type, E increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTPRE mRNA CTD PMID:22079614 NCBI chr 1:199,774,195...199,924,646
Ensembl chr 1:199,774,198...199,922,242 		JBrowse link
G Ptprf protein tyrosine phosphatase, receptor type, F decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTPRF mRNA CTD PMID:22079614 NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426 		JBrowse link
G Ptprz1 protein tyrosine phosphatase, receptor type Z1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTPRZ1 mRNA CTD PMID:22079614 NCBI chr 4:52,363,006...52,560,905
Ensembl chr 4:52,363,295...52,560,903 		JBrowse link
G Pts 6-pyruvoyl-tetrahydropterin synthase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTS mRNA CTD PMID:22079614 NCBI chr 8:59,767,234...59,774,265
Ensembl chr 8:59,765,185...59,774,265 		JBrowse link
G Pxylp1 2-phosphoxylose phosphatase 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PXYLP1 mRNA CTD PMID:22079614 NCBI chr 8:106,299,303...106,364,603
Ensembl chr 8:106,299,304...106,364,603 		JBrowse link
G Pygl glycogen phosphorylase L decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PYGL mRNA CTD PMID:22079614 NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269 		JBrowse link
G Rab25 RAB25, member RAS oncogene family decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RAB25 mRNA CTD PMID:22079614 NCBI chr 2:176,298,124...176,304,221
Ensembl chr 2:176,298,124...176,304,221 		JBrowse link
G Rab27b RAB27B, member RAS oncogene family increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RAB27B mRNA CTD PMID:20147733 NCBI chr18:65,870,230...66,069,597
Ensembl chr18:65,876,342...66,067,700 		JBrowse link
G Rabgap1 RAB GTPase activating protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RABGAP1 mRNA CTD PMID:22079614 NCBI chr 3:41,617,784...41,735,795
Ensembl chr 3:41,617,793...41,735,791 		JBrowse link
G Ran RAN, member RAS oncogene family increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RAN mRNA CTD PMID:22079614 NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family increases activity EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of RAP1A protein CTD PMID:10908723 NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808 		JBrowse link
G Rap1b RAP1B, member of RAS oncogene family increases activity EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of RAP1B protein CTD PMID:10908723 NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217 		JBrowse link
G Rarg retinoic acid receptor, gamma increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RARG mRNA CTD PMID:22079614 NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:135,246,427...135,268,889 		JBrowse link
G Rarres2 retinoic acid receptor responder 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RARRES2 mRNA CTD PMID:22079614 NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RASD1 mRNA CTD PMID:20147733 NCBI chr10:45,265,975...45,275,279
Ensembl chr10:45,265,979...45,267,710 		JBrowse link
G Rasip1 Ras interacting protein 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RASIP1 mRNA CTD PMID:22079614 NCBI chr 1:105,233,599...105,246,028
Ensembl chr 1:105,233,599...105,246,028 		JBrowse link
G Rassf5 Ras association domain family member 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RASSF5 mRNA CTD PMID:22079614 NCBI chr13:45,189,768...45,255,277
Ensembl chr13:45,189,804...45,255,277 		JBrowse link
G Rassf6 Ras association domain family member 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RASSF6 mRNA CTD PMID:22079614 NCBI chr14:17,717,505...17,757,507
Ensembl chr14:17,717,567...17,760,378 		JBrowse link
G Rbms3 RNA binding motif, single stranded interacting protein 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RBMS3 mRNA CTD PMID:22079614 NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:125,183,315...126,503,586 		JBrowse link
G Rbp1 retinol binding protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RBP1 mRNA CTD PMID:22079614 NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:107,887,417...107,983,847 		JBrowse link
G Reps2 RALBP1 associated Eps domain containing 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of REPS2 mRNA CTD PMID:22079614 NCBI chr  X:35,681,260...35,954,103
Ensembl chr  X:35,681,263...35,954,103 		JBrowse link
G Rfx6 regulatory factor X, 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RFX6 mRNA CTD PMID:22079614 NCBI chr20:31,562,490...31,615,967
Ensembl chr20:31,562,490...31,615,967 		JBrowse link
G Rgs16 regulator of G-protein signaling 16 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RGS16 mRNA CTD PMID:22079614 NCBI chr13:68,421,480...68,443,312
Ensembl chr13:68,438,120...68,443,313 		JBrowse link
G Rhbg Rh family B glycoprotein decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHBG mRNA CTD PMID:22079614 NCBI chr 2:176,002,886...176,015,201
Ensembl chr 2:176,002,887...176,015,609 		JBrowse link
G Rhob ras homolog family member B increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RHOB mRNA CTD PMID:22079614 NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772 		JBrowse link
G Rhobtb1 Rho-related BTB domain containing 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHOBTB1 mRNA CTD PMID:22079614 NCBI chr20:19,326,197...19,455,182
Ensembl chr20:19,326,212...19,402,057 		JBrowse link
G Rhou ras homolog family member U decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHOU mRNA CTD PMID:22079614 NCBI chr19:68,538,960...68,548,733
Ensembl chr19:68,538,960...68,548,733 		JBrowse link
G Rilp Rab interacting lysosomal protein increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RILP mRNA CTD PMID:22079614 NCBI chr10:60,853,316...60,857,096
Ensembl chr10:60,853,547...60,857,092 		JBrowse link
G Rin3 Ras and Rab interactor 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIN3 mRNA CTD PMID:22079614 NCBI chr 6:127,196,648...127,305,821
Ensembl chr 6:127,196,632...127,305,821 		JBrowse link
G Ripk3 receptor-interacting serine-threonine kinase 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIPK3 mRNA CTD PMID:22079614 NCBI chr15:33,253,071...33,262,025
Ensembl chr15:33,253,071...33,262,025 		JBrowse link
G Ripor2 RHO family interacting cell polarization regulator 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIPOR2 mRNA CTD PMID:20147733 NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,751,771...40,975,337 		JBrowse link
G Rnf144b ring finger protein 144B increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RNF144B mRNA CTD PMID:22079614 NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037 		JBrowse link
G Robo2 roundabout guidance receptor 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ROBO2 mRNA CTD PMID:22079614 NCBI chr11:26,015,919...27,583,750
Ensembl chr11:26,015,919...26,876,185 		JBrowse link
G Ror1 receptor tyrosine kinase-like orphan receptor 1 multiple interactions
decreases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ROR1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ROR1 mRNA 		CTD PMID:16997883 PMID:22079614 NCBI chr 5:119,859,744...120,203,573
Ensembl chr 5:119,859,970...120,205,801 		JBrowse link
G Rora RAR-related orphan receptor A decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RORA mRNA CTD PMID:22079614 NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730 		JBrowse link
G Rorb RAR-related orphan receptor B decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RORB mRNA CTD PMID:22079614 NCBI chr 1:225,790,216...225,970,973
Ensembl chr 1:225,790,216...225,970,973 		JBrowse link
G Rph3al rabphilin 3A-like (without C2 domains) increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RPH3AL mRNA CTD PMID:22079614 NCBI chr10:61,188,288...61,331,591
Ensembl chr10:61,188,293...61,300,145 		JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RRM2 mRNA CTD PMID:22079614 NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370 		JBrowse link
G Rspo1 R-spondin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RSPO1 mRNA CTD PMID:22079614 NCBI chr 5:142,536,162...142,557,611
Ensembl chr 5:142,536,344...142,557,776 		JBrowse link
G Runx1t1 RUNX1 partner transcriptional co-repressor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RUNX1T1 mRNA CTD PMID:22079614 NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:31,984,855...32,132,855 		JBrowse link
G Rxrb retinoid X receptor beta decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RXRB mRNA CTD PMID:22079614 NCBI chr20:4,818,707...4,824,968
Ensembl chr20:4,818,709...4,825,359 		JBrowse link
G Rxrg retinoid X receptor gamma decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RXRG mRNA CTD PMID:22079614 NCBI chr13:82,276,330...82,318,097
Ensembl chr13:82,276,291...82,318,095 		JBrowse link
G Ryr3 ryanodine receptor 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RYR3 mRNA CTD PMID:22079614 NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677 		JBrowse link
G Samd3 sterile alpha motif domain containing 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SAMD3 mRNA CTD PMID:22079614 NCBI chr 1:20,920,129...20,967,595
Ensembl chr 1:20,920,129...20,967,595 		JBrowse link
G Sc5d sterol-C5-desaturase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SC5D mRNA CTD PMID:22079614 NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:51,529,346...51,538,277 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCARB1 mRNA CTD PMID:22079614 NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980 		JBrowse link
G Scg2 secretogranin II increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCG2 mRNA CTD PMID:22079614 NCBI chr 9:88,251,531...88,257,208
Ensembl chr 9:88,251,354...88,269,598 		JBrowse link
G Scgb1c1 secretoglobin, family 1C, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCGB1C1 mRNA CTD PMID:22079614 NCBI chr 1:205,352,216...205,354,656
Ensembl chr 1:205,353,437...205,354,656 		JBrowse link
G Scrg1 stimulator of chondrogenesis 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCRG1 mRNA CTD PMID:22079614 NCBI chr16:37,770,739...37,799,010
Ensembl chr16:37,770,739...37,799,010 		JBrowse link
G Serpina11 serpin family A member 11 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SERPINA11 mRNA CTD PMID:22079614 NCBI chr 6:128,668,030...128,677,476
Ensembl chr 6:128,668,034...128,677,454 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of SERPINE1 mRNA CTD PMID:16997883 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Serpini1 serpin family I member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SERPINI1 mRNA CTD PMID:22079614 NCBI chr 2:162,645,209...162,731,737
Ensembl chr 2:162,645,350...162,731,740 		JBrowse link
G Sesn3 sestrin 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SESN3 mRNA CTD PMID:20147733 NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:19,415,347...19,466,904 		JBrowse link
G Sf1 splicing factor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SF1 mRNA CTD PMID:22079614 NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590 		JBrowse link
G Sfrp1 secreted frizzled-related protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SFRP1 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr16:75,278,325...75,316,736
Ensembl chr16:75,278,325...75,316,736 		JBrowse link
G Sftpb surfactant protein B multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPB mRNA CTD PMID:16997883 NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646 		JBrowse link
G Sftpc surfactant protein C multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPC mRNA CTD PMID:16997883 NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475 		JBrowse link
G Sgcd sarcoglycan, delta increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGCD mRNA CTD PMID:20147733 NCBI chr10:31,847,713...32,829,554
Ensembl chr10:31,781,748...32,419,064 		JBrowse link
G Sgk1 serum/glucocorticoid regulated kinase 1 increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA
Estradiol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA]; Genistein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA] 		CTD PMID:21056929 NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231 		JBrowse link
G Sgms1 sphingomyelin synthase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGMS1 mRNA CTD PMID:22079614 NCBI chr 1:239,409,991...239,681,195
Ensembl chr 1:239,409,991...239,505,774 		JBrowse link
G Sh3bp5 SH3-domain binding protein 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SH3BP5 mRNA CTD PMID:22079614 NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,589,877...6,655,211 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SIRT1 protein CTD PMID:16709600 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Sirt3 sirtuin 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SIRT3 mRNA CTD PMID:23166782 NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076 		JBrowse link
G Slc16a6 solute carrier family 16, member 6 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC16A6 mRNA CTD PMID:20147733 NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,923,888...94,947,965 		JBrowse link
G Slc17a5 solute carrier family 17 member 5 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC17A5 mRNA CTD PMID:22079614 NCBI chr 8:88,274,497...88,309,734
Ensembl chr 8:88,274,721...88,309,664 		JBrowse link
G Slc25a36 solute carrier family 25 member 36 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC25A36 mRNA CTD PMID:16997883 NCBI chr 8:106,539,355...106,573,240 JBrowse link
G Slc26a4 solute carrier family 26 member 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC26A4 protein CTD PMID:22811483 NCBI chr 6:53,835,102...53,873,968
Ensembl chr 6:53,835,110...53,873,216 		JBrowse link
G Slc26a7 solute carrier family 26 member 7 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC26A7 mRNA CTD PMID:22079614 NCBI chr 5:32,681,653...32,819,110
Ensembl chr 5:32,684,288...32,818,905 		JBrowse link
G Slc27a2 solute carrier family 27 member 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC27A2 mRNA CTD PMID:22079614 NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581 		JBrowse link
G Slc27a4 solute carrier family 27 member 4 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC27A4 mRNA CTD PMID:22079614 NCBI chr 3:33,472,903...33,485,824
Ensembl chr 3:33,472,903...33,485,824 		JBrowse link
G Slc2a12 solute carrier family 2 member 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC2A12 mRNA CTD PMID:20147733 NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:24,589,707...24,694,290 		JBrowse link
G Slc39a8 solute carrier family 39 member 8 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC39A8 mRNA CTD PMID:16997883 NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667 		JBrowse link
G Slc3a2 solute carrier family 3 member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC3A2 mRNA CTD PMID:22079614 NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064 		JBrowse link
G Slc51a solute carrier family 51 member A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC51A mRNA CTD PMID:22079614 NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539 		JBrowse link
G Slc5a12 solute carrier family 5 member 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC5A12 mRNA CTD PMID:22079614 NCBI chr 3:117,633,885...117,683,966
Ensembl chr 3:117,633,887...117,682,963 		JBrowse link
G Slc5a7 solute carrier family 5 member 7 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC5A7 mRNA CTD PMID:22079614 NCBI chr 9:7,922,693...7,953,509
Ensembl chr 9:7,922,697...7,953,509 		JBrowse link
G Slc6a14 solute carrier family 6 member 14 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC6A14 mRNA CTD PMID:16997883 NCBI chr  X:117,109,063...117,169,522
Ensembl chr  X:117,108,947...117,169,828 		JBrowse link
G Slc6a9 solute carrier family 6 member 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC6A9 mRNA CTD PMID:20147733 NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172 		JBrowse link
G Slc7a1 solute carrier family 7 member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC7A1 mRNA CTD PMID:22079614 NCBI chr12:11,664,488...11,740,030
Ensembl chr12:11,664,399...11,740,030 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC7A11 mRNA CTD PMID:22079614 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Slc9a1 solute carrier family 9 member A1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC9A1 mRNA CTD PMID:22079614 NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517 		JBrowse link
G Slco4c1 solute carrier organic anion transporter family, member 4C1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLCO4C1 mRNA CTD PMID:16997883 NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462 		JBrowse link
G Smoc1 SPARC related modular calcium binding 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SMOC1 mRNA CTD PMID:20147733 NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:106,432,603...106,593,956 		JBrowse link
G Smox spermine oxidase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SMOX mRNA CTD PMID:20147733 NCBI chr 3:139,184,793...139,220,174
Ensembl chr 3:139,184,798...139,220,170
Ensembl chr  X:139,184,798...139,220,170 		JBrowse link
G Snca synuclein alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SNCA mRNA CTD PMID:22079614 NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315 		JBrowse link
G Soat1 sterol O-acyltransferase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOAT1 mRNA CTD PMID:22079614 NCBI chr13:71,105,178...71,147,776
Ensembl chr13:71,105,178...71,147,672 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOCS3 mRNA CTD PMID:22079614 NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
increases expression 		ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOD1 mRNA 		CTD PMID:16709600 PMID:22079614 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA] CTD PMID:16709600 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox5 SRY-box transcription factor 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOX5 mRNA CTD PMID:22079614 NCBI chr 4:178,512,272...179,467,686
Ensembl chr 4:178,512,272...178,938,495 		JBrowse link
G Spata9 spermatogenesis associated 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPATA9 mRNA CTD PMID:22079614 NCBI chr 2:7,197,372...7,235,408
Ensembl chr 2:7,197,433...7,235,400 		JBrowse link
G Spink5 serine peptidase inhibitor, Kazal type 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPINK5 mRNA CTD PMID:22079614 NCBI chr18:36,515,347...36,584,038
Ensembl chr18:36,515,347...36,583,799 		JBrowse link
G Spock2 SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPOCK2 mRNA CTD PMID:22079614 NCBI chr20:28,580,262...28,607,198
Ensembl chr20:28,580,226...28,608,409 		JBrowse link
G Spon1 spondin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPON1 mRNA CTD PMID:20147733 NCBI chr 1:177,363,526...177,662,689
Ensembl chr 1:177,363,197...177,662,676 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions
decreases expression 		EXP
ISO 		8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SPP1 mRNA 		CTD PMID:20453393 PMID:22079614 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Sprr1a small proline-rich protein 1A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR1A mRNA CTD PMID:22079614 NCBI chr 2:180,750,709...180,752,625
Ensembl chr 2:180,750,709...180,752,991 		JBrowse link
G Sprr1b small proline-rich protein 1B increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR1B mRNA CTD PMID:22079614 NCBI chr 2:180,704,457...180,706,355
Ensembl chr 2:180,704,457...180,706,355 		JBrowse link
G Sprr3 small proline-rich protein 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR3 mRNA CTD PMID:22079614 NCBI chr 2:180,723,038...180,725,695
Ensembl chr 2:180,723,061...180,725,505 		JBrowse link
G Spry2 sprouty RTK signaling antagonist 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRY2 mRNA CTD PMID:22079614 NCBI chr15:89,106,809...89,111,926
Ensembl chr15:89,103,731...89,115,074 		JBrowse link
G Sqle squalene epoxidase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SQLE mRNA CTD PMID:22079614 NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050 		JBrowse link
G Srd5a1 steroid 5 alpha-reductase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SRD5A1 mRNA CTD PMID:24014645 NCBI chr 1:35,514,914...35,548,898
Ensembl chr 1:35,514,846...35,548,903 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SREBF1 mRNA CTD PMID:22079614 NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164 		JBrowse link
G St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ST3GAL1 mRNA CTD PMID:22079614 NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242 		JBrowse link
G St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ST3GAL6 mRNA CTD PMID:22079614 NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720 		JBrowse link
G Star steroidogenic acute regulatory protein increases expression
multiple interactions 		EXP
ISO 		8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; T-2 Toxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]
2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR protein]; Anisomycin promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; mono-(2-ethylhexyl)phthalate inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein 		CTD PMID:15713539 PMID:16254025 PMID:18815356 PMID:19849856 PMID:20732403 More... NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Stard3 StAR-related lipid transfer domain containing 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STARD3 mRNA CTD PMID:22079614 NCBI chr10:83,853,622...83,876,162
Ensembl chr10:83,862,707...83,876,131 		JBrowse link
G Stc1 stanniocalcin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STC1 mRNA CTD PMID:20147733 NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082 		JBrowse link
G Stc2 stanniocalcin 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STC2 mRNA CTD PMID:22079614 NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447 		JBrowse link
G Stk17b serine/threonine kinase 17b decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STK17B mRNA CTD PMID:22079614 NCBI chr 9:62,801,912...62,832,511
Ensembl chr 9:62,803,005...62,832,511 		JBrowse link
G Stra6 signaling receptor and transporter of retinol STRA6 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STRA6 mRNA CTD PMID:22079614 NCBI chr 8:67,444,757...67,464,719
Ensembl chr 8:67,444,742...67,464,720 		JBrowse link
G Stx2 syntaxin 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STX2 mRNA CTD PMID:22079614 NCBI chr12:33,315,447...33,350,788
Ensembl chr12:33,315,750...33,350,788 		JBrowse link
G Stx3 syntaxin 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STX3 mRNA CTD PMID:22079614 NCBI chr 1:217,940,697...218,114,865
Ensembl chr 1:217,909,169...218,110,466 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SULT2A1 mRNA CTD PMID:22079614 NCBI chr 1:84,582,011...84,639,001 JBrowse link
G Sult4a1 sulfotransferase family 4A, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SULT4A1 mRNA CTD PMID:22079614 NCBI chr 7:117,096,064...117,120,714
Ensembl chr 7:117,096,064...117,120,083 		JBrowse link
G Sv2c synaptic vesicle glycoprotein 2c increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SV2C mRNA CTD PMID:22079614 NCBI chr 2:28,967,631...29,163,168
Ensembl chr 2:28,964,582...29,163,168 		JBrowse link
G Svil supervillin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SVIL mRNA CTD PMID:20147733 NCBI chr17:57,343,910...57,539,508
Ensembl chr17:57,343,910...57,462,660 		JBrowse link
G Syne1 spectrin repeat containing nuclear envelope protein 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SYNE1 mRNA CTD PMID:22079614 NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721 		JBrowse link
G Syt12 synaptotagmin 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SYT12 mRNA CTD PMID:22079614 NCBI chr 1:211,158,745...211,189,780
Ensembl chr 1:211,159,800...211,189,037 		JBrowse link
G Syt9 synaptotagmin 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SYT9 mRNA CTD PMID:22079614 NCBI chr 1:170,687,666...170,868,146
Ensembl chr 1:170,687,606...170,881,375 		JBrowse link
G Tac1 tachykinin, precursor 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TAC1 mRNA CTD PMID:22079614 NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546 		JBrowse link
G Tacc2 transforming, acidic coiled-coil containing protein 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TACC2 mRNA CTD PMID:22079614 NCBI chr 1:194,546,428...194,758,152
Ensembl chr 1:194,569,650...194,758,152 		JBrowse link
G Tafa5 TAFA chemokine like family member 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TAFA5 mRNA CTD PMID:22079614 NCBI chr 7:120,493,447...120,714,720
Ensembl chr 7:120,493,060...120,714,718 		JBrowse link
G Tbc1d2 TBC1 domain family, member 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TBC1D2 mRNA CTD PMID:20147733 NCBI chr 5:65,679,670...65,727,978
Ensembl chr 5:65,679,680...65,726,996 		JBrowse link
G Tcf21 transcription factor 21 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TCF21 mRNA CTD PMID:20147733 NCBI chr 1:24,520,499...24,523,358
Ensembl chr 1:24,520,481...24,523,348 		JBrowse link
G Tef TEF transcription factor, PAR bZIP family member decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TEF mRNA CTD PMID:22079614 NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:115,193,282...115,221,928 		JBrowse link
G Tent5a terminal nucleotidyltransferase 5A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TENT5A mRNA CTD PMID:22079614 NCBI chr 8:95,102,349...95,109,100
Ensembl chr 8:95,105,412...95,109,100 		JBrowse link
G Tesk1 testis associated actin remodelling kinase 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TESK1 mRNA CTD PMID:22079614 NCBI chr 5:62,487,763...62,493,492
Ensembl chr 5:62,487,763...62,493,492 		JBrowse link
G Testin testin gene decreases expression
multiple interactions 		EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TESTIN mRNA
lonidamine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TESTIN mRNA] 		CTD PMID:11090432 NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,852,404...3,864,993 		JBrowse link
G Tfpi2 tissue factor pathway inhibitor 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TFPI2 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB1 mRNA CTD PMID:16997883 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tgfb1i1 transforming growth factor beta 1 induced transcript 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TGFB1I1 mRNA CTD PMID:22079614 NCBI chr 1:192,258,992...192,265,903
Ensembl chr 1:192,258,598...192,265,903 		JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA CTD PMID:16997883 NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856 		JBrowse link
G Tgfb3 transforming growth factor, beta 3 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB3 mRNA CTD PMID:16997883 NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946 		JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TGFBR2 mRNA CTD PMID:22079614 NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469 		JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]] CTD PMID:21726595 NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657 		JBrowse link
G Tiparp TCDD-inducible poly(ADP-ribose) polymerase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TIPARP mRNA CTD PMID:22079614 NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406 		JBrowse link
G Tlcd3a TLC domain containing 3A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TLCD3A mRNA CTD PMID:22079614 NCBI chr10:61,556,193...61,563,529
Ensembl chr10:61,556,199...61,563,527 		JBrowse link
G Tmc5 transmembrane channel-like 5 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TMC5 mRNA CTD PMID:16997883 NCBI chr 1:182,349,102...182,433,679
Ensembl chr 1:182,355,473...182,433,679 		JBrowse link
G Tmod1 tropomodulin 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TMOD1 mRNA CTD PMID:20147733 NCBI chr 5:65,112,062...65,189,563
Ensembl chr 5:65,134,132...65,189,561 		JBrowse link
G Tmx4 thioredoxin-related transmembrane protein 4 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TMX4 mRNA CTD PMID:20147733 NCBI chr 3:142,309,026...142,352,415
Ensembl chr 3:142,309,033...142,352,415 		JBrowse link
G Tnc tenascin C multiple interactions
increases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNC mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNC mRNA 		CTD PMID:16997883 PMID:20147733 NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP 		8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] 		CTD PMID:10495789 PMID:11230753 PMID:21803157 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 increases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFAIP3 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFAIP3 mRNA 		CTD PMID:16997883 PMID:22079614 NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF10A mRNA CTD PMID:22079614 NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082 		JBrowse link
G Tnfrsf12a TNF receptor superfamily member 12A increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF12A mRNA CTD PMID:22079614 NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704 		JBrowse link
G Tnfrsf19 TNF receptor superfamily member 19 decreases expression
increases expression 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TNFRSF19 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF19 mRNA 		CTD PMID:20147733 PMID:22079614 NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438 		JBrowse link
G Tnfsf4 TNF superfamily member 4 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFSF4 mRNA CTD PMID:16997883 NCBI chr13:76,256,654...76,280,133
Ensembl chr13:76,256,654...76,280,133 		JBrowse link
G Tnnt2 troponin T2, cardiac type increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNNT2 mRNA CTD PMID:22079614 NCBI chr13:49,819,123...49,837,125
Ensembl chr13:49,822,304...49,837,125 		JBrowse link
G Tp53 tumor protein p53 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53 protein CTD PMID:10642304 PMID:11802967 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tph2 tryptophan hydroxylase 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TPH2 mRNA CTD PMID:22079614 NCBI chr 7:52,571,909...52,676,305
Ensembl chr 7:52,571,911...52,675,639 		JBrowse link
G Tpm1 tropomyosin 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TPM1 mRNA CTD PMID:16997883 NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:76,511,871...76,543,468 		JBrowse link
G Tpmt thiopurine S-methyltransferase increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TPMT mRNA CTD PMID:22079614 NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,850,279...17,868,976 		JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIB3 mRNA CTD PMID:22079614 NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802 		JBrowse link
G Trim2 tripartite motif-containing 2 multiple interactions
increases expression 		ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TRIM2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIM2 mRNA 		CTD PMID:16997883 PMID:20147733 NCBI chr 2:171,798,654...171,950,193
Ensembl chr 2:171,798,660...171,913,468 		JBrowse link
G Trim24 tripartite motif-containing 24 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIM24 mRNA CTD PMID:22079614 NCBI chr 4:67,534,240...67,659,014
Ensembl chr 4:67,534,335...67,684,226 		JBrowse link
G Trip10 thyroid hormone receptor interactor 10 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TRIP10 mRNA CTD PMID:22079614 NCBI chr 9:2,219,695...2,234,771
Ensembl chr 9:2,220,658...2,235,027 		JBrowse link
G Trpa1 transient receptor potential cation channel, subfamily A, member 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRPA1 mRNA CTD PMID:22079614 NCBI chr 5:9,163,060...9,217,325
Ensembl chr 5:9,163,060...9,217,325 		JBrowse link
G Tshz2 teashirt zinc finger homeobox 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TSHZ2 mRNA CTD PMID:20147733 NCBI chr 3:178,824,221...179,271,151
Ensembl chr 3:178,824,994...179,269,641 		JBrowse link
G Ttc9 tetratricopeptide repeat domain 9 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TTC9 mRNA CTD PMID:22079614 NCBI chr 6:107,064,527...107,099,361
Ensembl chr 6:107,064,527...107,099,361 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in decreased expression of TXN1 protein] CTD PMID:20453393 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of UGT2B17 mRNA CTD PMID:22079614 NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UGT2B7 mRNA CTD PMID:22079614 NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451 		JBrowse link
G Unc5b unc-5 netrin receptor B decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UNC5B mRNA CTD PMID:22079614 NCBI chr20:29,240,639...29,307,270
Ensembl chr20:29,240,650...29,307,270 		JBrowse link
G Ushbp1 USH1 protein network component harmonin binding protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of USHBP1 mRNA CTD PMID:22079614 NCBI chr16:18,091,311...18,101,927
Ensembl chr16:18,091,316...18,101,867 		JBrowse link
G Uts2 urotensin 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of UTS2 mRNA CTD PMID:22079614 NCBI chr 5:166,725,471...166,739,063
Ensembl chr 5:166,733,671...166,739,059 		JBrowse link
G Uty ubiquitously transcribed tetratricopeptide repeat containing, Y-linked decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UTY mRNA CTD PMID:22079614 NCBI chr  Y:1,018,111...1,178,493
Ensembl chr  Y:1,010,273...1,178,355 		JBrowse link
G Vdr vitamin D receptor increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VDR mRNA CTD PMID:22079614 NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
increases expression 		ISO [PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VEGFA mRNA 		CTD PMID:10788502 PMID:12821125 PMID:20147733 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vegfc vascular endothelial growth factor C increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VEGFC mRNA CTD PMID:22079614 NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887 		JBrowse link
G Vgf VGF nerve growth factor inducible increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VGF mRNA CTD PMID:22079614 NCBI chr12:25,274,004...25,281,803
Ensembl chr12:25,273,333...25,282,703 		JBrowse link
G Vgll3 vestigial-like family member 3 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VGLL3 mRNA CTD PMID:20147733 NCBI chr11:17,089,484...17,136,501
Ensembl chr11:17,089,597...17,138,937 		JBrowse link
G Vipr1 vasoactive intestinal peptide receptor 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VIPR1 mRNA CTD PMID:22079614 NCBI chr 8:130,181,219...130,217,098
Ensembl chr 8:130,187,731...130,217,096 		JBrowse link
G Vldlr very low density lipoprotein receptor decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VLDLR mRNA CTD PMID:22079614 NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154 		JBrowse link
G Vmo1 vitelline membrane outer layer 1 homolog increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VMO1 mRNA CTD PMID:20147733 NCBI chr10:55,726,572...55,733,432
Ensembl chr10:55,726,572...55,727,856 		JBrowse link
G Wdr17 WD repeat domain 17 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of WDR17 mRNA CTD PMID:22079614 NCBI chr16:43,792,989...43,924,187
Ensembl chr16:43,792,973...43,924,184 		JBrowse link
G Whrn whirlin increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of WHRN mRNA CTD PMID:22079614 NCBI chr 5:81,843,820...81,933,400
Ensembl chr 5:81,843,820...81,927,381 		JBrowse link
G Wif1 Wnt inhibitory factor 1 multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of WIF1 mRNA CTD PMID:16997883 NCBI chr 7:58,433,326...58,503,853
Ensembl chr 7:58,384,643...58,503,852 		JBrowse link
G Wnt4 Wnt family member 4 decreases expression
multiple interactions 		ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of WNT4 mRNA
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA] 		CTD PMID:22079614 PMID:23275455 NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128 		JBrowse link
G Wnt5b Wnt family member 5B multiple interactions ISO [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT5B mRNA CTD PMID:16997883 NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681 		JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of XBP1 mRNA CTD PMID:22079614 NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706 		JBrowse link
G Zbtb12 zinc finger and BTB domain containing 12 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZBTB12 mRNA CTD PMID:22079614 NCBI chr20:3,942,302...3,945,148
Ensembl chr20:3,941,411...3,945,020 		JBrowse link
G Zbtb18 zinc finger and BTB domain containing 18 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZBTB18 mRNA CTD PMID:22079614 NCBI chr13:91,971,602...91,980,058
Ensembl chr13:91,969,755...91,980,386 		JBrowse link
G Zbtb32 zinc finger and BTB domain containing 32 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZBTB32 mRNA CTD PMID:22079614 NCBI chr 1:94,969,374...94,978,553
Ensembl chr 1:94,969,374...94,971,679 		JBrowse link
G Zfp36l1 zinc finger protein 36, C3H type-like 1 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZFP36L1 mRNA CTD PMID:22079614 NCBI chr 6:104,663,396...104,669,815
Ensembl chr 6:104,663,399...104,687,979 		JBrowse link
G Zfp36l2 zinc finger protein 36, C3H type-like 2 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZFP36L2 mRNA CTD PMID:22079614 NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653 		JBrowse link
G Zfp46 zinc finger protein 46 decreases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZNF436 mRNA CTD PMID:22079614 NCBI chr 5:153,802,887...153,813,388
Ensembl chr 5:153,802,834...153,812,941 		JBrowse link
G Znf454 zinc finger protein 454 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZNF454 mRNA CTD PMID:22079614 NCBI chr10:35,684,741...35,701,281
Ensembl chr10:35,685,841...35,697,415 		JBrowse link
8-bromo-3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Arhgef17 Rho guanine nucleotide exchange factor 17 multiple interactions ISO [8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein CTD PMID:23195829 NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:164,642,690...164,702,241 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO 8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] CTD PMID:9388267 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cox4i1 cytochrome c oxidase subunit 4i1 increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of COX4I1 protein
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of COX4I1 protein] 		CTD PMID:24041027 NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624 		JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression ISO 8-bromocyclic GMP results in increased expression of DUSP10 mRNA; 8-bromocyclic GMP results in increased expression of DUSP10 protein CTD PMID:29165873 NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304 		JBrowse link
G Edn1 endothelin 1 multiple interactions EXP
ISO 		8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 protein] 		CTD PMID:16023617 PMID:29165873 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Edn3 endothelin 3 multiple interactions EXP 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] CTD PMID:16023617 NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:183,980,668...184,005,329 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions EXP 8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] CTD PMID:16023617 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] CTD PMID:29165873 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO 8-bromocyclic GMP results in increased expression of HMOX1 mRNA; 8-bromocyclic GMP results in increased expression of HMOX1 protein CTD PMID:24041027 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]] CTD PMID:8904084 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il4 interleukin 4 increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of IL4 mRNA
Cyclosporine inhibits the reaction [8-bromocyclic GMP results in increased expression of IL4 mRNA] 		CTD PMID:16533816 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO 8-bromocyclic GMP results in decreased phosphorylation of MAPK1 protein CTD PMID:17828804 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO 8-bromocyclic GMP results in decreased phosphorylation of MAPK3 protein CTD PMID:17828804 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases phosphorylation ISO 8-bromocyclic GMP results in decreased phosphorylation of MYC protein CTD PMID:17828804 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of NDUFB8 protein
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NDUFB8 protein] 		CTD PMID:24041027 NCBI chr 1:253,357,878...253,362,936
Ensembl chr 1:253,357,841...253,362,936 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 affects localization ISO 8-bromocyclic GMP affects the localization of NFATC1 protein CTD PMID:16533816 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Nrf1 nuclear respiratory factor 1 increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of NRF1 mRNA
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NRF1 mRNA] 		CTD PMID:24041027 NCBI chr 4:59,632,366...59,738,166
Ensembl chr 4:59,632,372...59,738,353 		JBrowse link
G Pde5a phosphodiesterase 5A multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein; [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein modified form CTD PMID:20613715 NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:213,542,923...213,684,298 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of PPARGC1A mRNA
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of PPARGC1A mRNA] 		CTD PMID:24041027 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Prkg1 protein kinase cGMP-dependent 1 increases expression
multiple interactions 		EXP
ISO 		8-bromocyclic GMP results in increased expression of PRKG1 protein
[8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein 		CTD PMID:12620371 PMID:23195829 NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:237,823,053...239,103,005 		JBrowse link
G Scnn1b sodium channel epithelial 1 subunit beta multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of SCNN1B protein CTD PMID:20613715 NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049 		JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP 8-bromocyclic GMP results in increased expression of SOD2 mRNA; 8-bromocyclic GMP results in increased expression of SOD2 protein CTD PMID:14996425 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP 8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] CTD PMID:20453393 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Srf serum response factor multiple interactions ISO [8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein CTD PMID:23195829 NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:21,924,076...21,933,337 		JBrowse link
G Sst somatostatin decreases secretion EXP 8-bromocyclic GMP results in decreased secretion of SST protein CTD PMID:17961553 NCBI chr11:90,461,546...90,462,823
Ensembl chr11:90,461,546...90,462,823 		JBrowse link
G Tfam transcription factor A, mitochondrial increases expression
multiple interactions 		ISO 8-bromocyclic GMP results in increased expression of TFAM mRNA
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of TFAM mRNA] 		CTD PMID:24041027 NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,355,363...17,369,877 		JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP 8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] CTD PMID:16023617 NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO 8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] CTD PMID:9388267 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tp53 tumor protein p53 increases expression EXP 8-bromocyclic GMP results in increased expression of TP53 protein CTD PMID:9888876 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 multiple interactions
increases phosphorylation 		EXP
ISO 		8-bromocyclic GMP inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein]
8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein
KT 5823 inhibits the reaction [8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein] 		CTD PMID:20177073 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP 8-bromocyclic GMP inhibits the reaction [Glucose results in decreased expression of TXN1 protein] CTD PMID:20453393 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Uqcrc1 ubiquinol-cytochrome c reductase core protein 1 multiple interactions
increases expression 		ISO tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of UQCRC1 protein] CTD PMID:24041027 NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:118,468,200...118,479,964 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 decreases expression ISO 8-bromocyclic GMP results in decreased expression of VCAM1 protein CTD PMID:17828804 NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO 8-bromocyclic GMP results in decreased expression of VEGFA protein CTD PMID:17828804 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
acetoacetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 affects binding ISO acetoacetyl CoA binds to HSD17B2 protein CTD PMID:25526675 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
acetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acly ATP citrate lyase increases abundance
affects abundance 		ISO ACLY protein results in increased abundance of Acetyl Coenzyme A
ACLY protein affects the abundance of Acetyl Coenzyme A 		CTD PMID:28077572 PMID:36933457 NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631 		JBrowse link
G App amyloid beta precursor protein affects localization
increases secretion
multiple interactions 		ISO APP protein affects the localization of Acetyl Coenzyme A
Acetyl Coenzyme A results in increased secretion of APP protein modified form
Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] 		CTD PMID:16122837 PMID:22906069 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Crat carnitine O-acetyltransferase decreases activity EXP Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein CTD PMID:8075222 NCBI chr 3:34,073,504...34,087,099
Ensembl chr 3:34,073,506...34,087,099 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance
multiple interactions 		ISO ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A
3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] 		CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO [Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A CTD PMID:33179799 NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] CTD PMID:16122837 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Kat2b lysine acetyltransferase 2B affects binding ISO Acetyl Coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator multiple interactions ISO METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] CTD PMID:30213948 NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions
affects binding 		ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]
Acetyl Coenzyme A binds to NAT1 protein 		CTD PMID:20545351 PMID:22835378 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
acryloyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506 		JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886 		JBrowse link
adenosine 3',5'-bismonophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions EXP Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein] CTD PMID:21130751 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 multiple interactions ISO [2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein] CTD PMID:23959441 NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 affects binding
multiple interactions 		ISO adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein
Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]] 		CTD PMID:24059442 NCBI chr 1:84,582,011...84,639,001 JBrowse link
adenosine 5'-(hexahydrogen pentaphosphate) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nudt11 nudix hydrolase 11 multiple interactions ISO [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate CTD PMID:12121577 NCBI chr  X:18,998,587...19,005,208
Ensembl chr  X:18,998,461...19,005,208 		JBrowse link
adenosine 5'-[gamma-thio]triphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd80 Cd80 molecule increases expression ISO adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein CTD PMID:15944274 NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540 		JBrowse link
G Cd86 CD86 molecule increases expression ISO adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein CTD PMID:15944274 NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361 		JBrowse link
G Il10 interleukin 10 decreases expression ISO adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein CTD PMID:15944274 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il12b interleukin 12B increases expression ISO adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein CTD PMID:15944274 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il1b interleukin 1 beta increases expression ISO adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein CTD PMID:15944274 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G P2rx7 purinergic receptor P2X 7 affects response to substance ISO P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate) CTD PMID:12873706 NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193 		JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity
multiple interactions 		EXP adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein
Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein] 		CTD PMID:11140687 NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021 		JBrowse link
adenosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 multiple interactions ISO Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] CTD PMID:11390963 NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO [4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein CTD PMID:10609638 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance ISO ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Kcnj11 potassium inwardly-rectifying channel, subfamily J, member 11 multiple interactions ISO Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] CTD PMID:11390963 NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169 		JBrowse link
G Nudt11 nudix hydrolase 11 multiple interactions ISO [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate CTD PMID:12121577 NCBI chr  X:18,998,587...19,005,208
Ensembl chr  X:18,998,461...19,005,208 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Adenosine Monophosphate results in increased expression of PPARGC1A mRNA CTD PMID:23056435 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
G Tp73 tumor protein p73 affects abundance ISO TP73 protein affects the abundance of Adenosine Monophosphate CTD PMID:25554796 NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552 		JBrowse link
Adenosine, cyclic 3',5'-[hydrogen [p(s)]-phosphorothioate] term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]] CTD PMID:7843740 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]] CTD PMID:16822680 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]] CTD PMID:16822680 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [LEP protein results in increased expression of CCL2] CTD PMID:11342529 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein] CTD PMID:15522277 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Lep leptin decreases response to substance
multiple interactions 		ISO adenosine-3',5'-cyclic phosphorothioate results in decreased susceptibility to LEP protein
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [LEP protein results in increased expression of CCL2] 		CTD PMID:11342529 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions EXP adenosine-3',5'-cyclic phosphorothioate results in increased phosphorylation of and results in increased activity of MAPK1 protein CTD PMID:12657697 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP adenosine-3',5'-cyclic phosphorothioate results in increased phosphorylation of and results in increased activity of MAPK3 protein CTD PMID:12657697 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Ppp1r9a protein phosphatase 1, regulatory subunit 9A increases phosphorylation EXP adenosine-3',5'-cyclic phosphorothioate results in increased phosphorylation of PPP1R9A protein CTD PMID:12052877 NCBI chr 4:33,936,949...34,258,927
Ensembl chr 4:33,988,827...34,258,927 		JBrowse link
G Sele selectin E multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased expression of SELE protein]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased secretion of SELE mRNA] CTD PMID:8780174 NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903 		JBrowse link
G Testin testin gene multiple interactions
decreases expression 		EXP adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]
adenosine-3',5'-cyclic phosphorothioate results in decreased expression of TESTIN mRNA 		CTD PMID:11090432 NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,852,404...3,864,993 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased expression of SELE protein]; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [TNF protein results in increased secretion of SELE mRNA] CTD PMID:8780174 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
ADP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions
affects binding 		ISO estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein]
Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form 		CTD PMID:18336795 NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions EXP Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Ak1 adenylate kinase 1 increases abundance ISO AK1 protein results in increased abundance of Adenosine Diphosphate CTD PMID:11390963 NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757 		JBrowse link
G Alb albumin decreases secretion
multiple interactions 		ISO Adenosine Diphosphate results in decreased secretion of ALB protein
Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein] 		CTD PMID:17303692 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G App amyloid beta precursor protein multiple interactions
increases abundance 		ISO PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate] 		CTD PMID:39172838 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Axl Axl receptor tyrosine kinase decreases response to substance ISO AXL protein results in decreased susceptibility to Adenosine Diphosphate CTD PMID:15733062 NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009 		JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] CTD PMID:16781456 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cd40lg CD40 ligand increases expression
multiple interactions 		ISO Adenosine Diphosphate results in increased expression of CD40LG protein
clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] 		CTD PMID:11297035 PMID:17043144 NCBI chr  X:140,164,341...140,176,057
Ensembl chr  X:140,164,302...140,176,475 		JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] CTD PMID:15684079 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 multiple interactions ISO Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] CTD PMID:23184943 NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] CTD PMID:16772608 PMID:18004210 PMID:18394438 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Dtymk deoxythymidylate kinase multiple interactions ISO DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate] CTD PMID:21128666 NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] CTD PMID:32941855 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions ISO Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] CTD PMID:32941855 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Epha4 Eph receptor A4 increases phosphorylation
multiple interactions 		ISO Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein
Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein] 		CTD PMID:22273509 NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases activity 		ISO Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein]
Adenosine Diphosphate results in decreased activity of ERN1 protein 		CTD PMID:25164867 NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791 		JBrowse link
G F2 coagulation factor II, thrombin increases abundance
multiple interactions 		ISO F2 protein results in increased abundance of Adenosine Diphosphate
Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate] 		CTD PMID:15342215 NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246 		JBrowse link
G Fga fibrinogen alpha chain multiple interactions
increases secretion 		ISO Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein] CTD PMID:17303692 NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577 		JBrowse link
G Fgb fibrinogen beta chain decreases secretion
multiple interactions 		ISO Adenosine Diphosphate results in decreased secretion of FGB protein
Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein] 		CTD PMID:17303692 NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434 		JBrowse link
G Fgg fibrinogen gamma chain increases secretion
multiple interactions 		ISO Adenosine Diphosphate results in increased secretion of FGG protein
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein] 		CTD PMID:17303692 NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gas6 growth arrest specific 6 increases response to substance ISO GAS6 protein results in increased susceptibility to Adenosine Diphosphate CTD PMID:15733062 NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO Adenosine Diphosphate binds to and affects the folding of HRAS protein CTD PMID:16388579 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 multiple interactions ISO Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] CTD PMID:23184943 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions 		ISO Adenosine Diphosphate results in increased expression of IL6 protein
MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein] 		CTD PMID:24849676 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions ISO ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate] CTD PMID:16214444 NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509 		JBrowse link
G Itga2b integrin subunit alpha 2b multiple interactions ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] CTD PMID:18404433 NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833 		JBrowse link
G Itgb1bp2 integrin subunit beta 1 binding protein 2 multiple interactions ISO Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] CTD PMID:23184943 NCBI chr  X:70,612,118...70,617,158
Ensembl chr  X:70,612,521...70,617,158 		JBrowse link
G Itgb3 integrin subunit beta 3 multiple interactions ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] CTD PMID:18404433 NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions 		ISO Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein
Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]] 		CTD PMID:15034929 PMID:32941855 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions 		ISO Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein
Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]] 		CTD PMID:15034929 PMID:32941855 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein] CTD PMID:24466103 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] CTD PMID:24466103 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions
increases abundance 		ISO PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Adenosine Diphosphate] CTD PMID:39172838 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Mertk MER proto-oncogene, tyrosine kinase increases response to substance ISO MERTK protein results in increased susceptibility to Adenosine Diphosphate CTD PMID:15733062 NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate] CTD PMID:11498454 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nt5e 5' nucleotidase, ecto decreases activity ISO Adenosine Diphosphate analog results in decreased activity of NT5E protein CTD PMID:18404487 NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645 		JBrowse link
G P2ry12 purinergic receptor P2Y12 affects response to substance
increases response to substance
multiple interactions 		ISO
EXP 		P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate
P2RY12 protein results in increased susceptibility to Adenosine Diphosphate
Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate]
P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein] 		CTD PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410 		JBrowse link
G Pdgfb platelet derived growth factor subunit B increases secretion
multiple interactions 		ISO Adenosine Diphosphate results in increased secretion of PDGFB protein
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein] 		CTD PMID:17303692 NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343 		JBrowse link
G Pf4 platelet factor 4 increases secretion
multiple interactions 		ISO Adenosine Diphosphate results in increased secretion of PF4 protein
silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein] 		CTD PMID:19428933 PMID:29439388 NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392 		JBrowse link
G Pfkm phosphofructokinase, muscle multiple interactions ISO Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] CTD PMID:23454376 NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248 		JBrowse link
G Pgp phosphoglycolate phosphatase decreases phosphorylation ISO PGP protein results in decreased phosphorylation of Adenosine Diphosphate CTD PMID:24338473 NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408 		JBrowse link
G Ppbp pro-platelet basic protein increases secretion ISO Adenosine Diphosphate results in increased secretion of PPBP protein CTD PMID:19428933 NCBI chr14:17,586,495...17,587,299
Ensembl chr14:17,586,495...17,587,299 		JBrowse link
G Ppp5c protein phosphatase 5, catalytic subunit multiple interactions ISO Adenosine Diphosphate binds to and affects the folding of PPP5C protein CTD PMID:23184943 NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate] CTD PMID:39172838 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Ptpn1 protein tyrosine phosphatase, non-receptor type 1 increases glutathionylation
multiple interactions 		EXP Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] 		CTD PMID:16781456 NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:177,057,659...177,106,416 		JBrowse link
G Selp selectin P multiple interactions
increases expression 		ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein] CTD PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987 		JBrowse link
G Sirt3 sirtuin 3 decreases abundance ISO SIRT3 protein results in decreased abundance of Adenosine Diphosphate CTD PMID:23166782 NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076 		JBrowse link
G Taldo1 transaldolase 1 increases abundance ISO TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Thbs1 thrombospondin 1 increases secretion ISO Adenosine Diphosphate results in increased secretion of THBS1 protein CTD PMID:17303692 NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
G Tyro3 TYRO3 protein tyrosine kinase increases response to substance ISO TYRO3 protein results in increased susceptibility to Adenosine Diphosphate CTD PMID:15733062 NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943 		JBrowse link
G Vasp vasodilator-stimulated phosphoprotein increases phosphorylation
multiple interactions 		ISO Adenosine Diphosphate results in increased phosphorylation of VASP protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein] 		CTD PMID:25329809 NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650 		JBrowse link
ADP-D-ribose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adprh ADP-ribosylarginine hydrolase increases hydrolysis ISO ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite CTD PMID:21498885 NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452 		JBrowse link
G Adprs ADP-ribosylserine hydrolase increases hydrolysis
multiple interactions 		ISO ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite
Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose] 		CTD PMID:21498885 NCBI chr 5:143,898,542...143,903,816
Ensembl chr 5:143,898,542...143,903,816 		JBrowse link
G Nos1 nitric oxide synthase 1 multiple interactions ISO NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose] CTD PMID:10318960 NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837 		JBrowse link
G Trpm2 transient receptor potential cation channel, subfamily M, member 2 multiple interactions
increases activity 		EXP
ISO 		Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]
Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein
2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]
4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium] 		CTD PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 PMID:33309544 More... NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,704,482...10,752,802 		JBrowse link
AMP-PNP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions EXP Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Cftr CF transmembrane conductance regulator affects activity ISO Adenylyl Imidodiphosphate affects the activity of CFTR protein CTD PMID:15657297 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Csnk2a1 casein kinase 2 alpha 1 affects binding ISO Adenylyl Imidodiphosphate binds to CSNK2A1 protein CTD PMID:34344863 NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698 		JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873 		JBrowse link
arachidonoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
ATP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 multiple interactions ISO Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] CTD PMID:12379217 NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO
EXP 		Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] CTD PMID:18245269 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
affects binding
increases hydrolysis 		ISO
EXP 		[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
Adenosine Triphosphate binds to ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate 		CTD PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 More... NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions
affects activity
increases hydrolysis
affects binding 		ISO [Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]
Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]
Adenosine Triphosphate binds to ABCC1 protein 		CTD PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 More... NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
affects activity
affects metabolic processing 		EXP
ISO 		Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat]
Adenosine Triphosphate affects the activity of ABCC2 protein
[Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide]
ABCC2 protein affects the metabolism of Adenosine Triphosphate
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine] 		CTD PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 More... NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] CTD PMID:18245269 NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions
affects activity
increases hydrolysis 		ISO [Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] CTD PMID:14978246 PMID:16156793 PMID:32472168 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 affects binding ISO Adenosine Triphosphate binds to ABCC6 protein CTD PMID:11880368 NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895 		JBrowse link
G Abcc8 ATP binding cassette subfamily C member 8 multiple interactions EXP Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]] CTD PMID:19095654 NCBI chr 1:105,734,992...105,816,272
Ensembl chr 1:105,734,992...105,815,982 		JBrowse link
G Abcc9 ATP binding cassette subfamily C member 9 multiple interactions EXP
ISO 		Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein]
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] 		CTD PMID:11390963 PMID:28842488 NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases hydrolysis
multiple interactions 		ISO ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate] 		CTD PMID:18829547 PMID:32003934 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
increases chemical synthesis 		ISO [ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate 		CTD PMID:19366808 PMID:33070465 NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846 		JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 multiple interactions ISO [ACSL5 protein affects the susceptibility to Palmitic Acid] which affects the abundance of Adenosine Triphosphate CTD PMID:32347412 NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein] CTD PMID:32721574 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases secretion EXP ADCYAP1 protein results in increased secretion of Adenosine Triphosphate CTD PMID:18563302 NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions
decreases expression 		EXP Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein] CTD PMID:21464294 NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions EXP Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases activity
multiple interactions 		ISO Adenosine Triphosphate results in decreased activity of AKT1 protein
Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein] 		CTD PMID:24300283 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 increases abundance ISO ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate CTD PMID:29031482 NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714 		JBrowse link
G Alk ALK receptor tyrosine kinase affects binding
multiple interactions 		ISO ALK protein binds to Adenosine Triphosphate
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate] 		CTD PMID:22072639 NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:28,632,197...29,349,721 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated increases response to substance
multiple interactions 		ISO ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate
ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] 		CTD PMID:27466191 NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167 		JBrowse link
G Anxa1 annexin A1 multiple interactions EXP [Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein] CTD PMID:20655937 NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831 		JBrowse link
G App amyloid beta precursor protein multiple interactions
increases secretion 		ISO Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate] 		CTD PMID:22906069 PMID:39172838 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions EXP Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein] CTD PMID:21464294 NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions EXP [Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate CTD PMID:19860742 NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832 		JBrowse link
G Asic2 acid sensing ion channel subunit 2 multiple interactions EXP [Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate CTD PMID:19860742 NCBI chr10:66,368,308...67,438,237
Ensembl chr10:66,368,310...66,636,245 		JBrowse link
G Asic3 acid sensing ion channel subunit 3 multiple interactions EXP [Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate CTD PMID:19860742 NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:11,652,946...11,657,367 		JBrowse link
G Atp7a ATPase copper transporting alpha multiple interactions ISO [Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein CTD PMID:20964302 NCBI chr  X:75,159,635...75,267,094
Ensembl chr  X:75,159,782...75,267,093 		JBrowse link
G Atp7b ATPase copper transporting beta multiple interactions
increases phosphorylation 		ISO [Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein
Adenosine Triphosphate results in increased phosphorylation of ATP7B protein 		CTD PMID:19405516 PMID:20964302 NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases hydrolysis EXP ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate CTD PMID:11584374 NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027 		JBrowse link
G Avp arginine vasopressin multiple interactions
increases secretion 		EXP Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] CTD PMID:11102496 NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein CTD PMID:21503959 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions ISO [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] CTD PMID:19366808 NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases abundance ISO BIRC5 protein results in increased abundance of Adenosine Triphosphate CTD PMID:32497533 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Cabin1 calcineurin binding protein 1 multiple interactions EXP CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein] CTD PMID:21464294 NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases secretion
multiple interactions 		EXP Adenosine Triphosphate results in increased secretion of CALCA protein
Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] 		CTD PMID:12044622 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Casp1 caspase 1 increases activity
multiple interactions 		EXP
ISO 		Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [Adenosine Triphosphate results in increased susceptibility to Lipopolysaccharides] which results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of CASP1 mRNA]; Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased activity of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein] 		CTD PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 More... NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions 		ISO Adenosine Triphosphate results in increased expression of CASP3
Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3] 		CTD PMID:19448140 PMID:24732427 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp4 caspase 4 multiple interactions ISO [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein]
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] 		CTD PMID:24149798 PMID:25288807 NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727 		JBrowse link
G Cat catalase increases expression ISO Adenosine Triphosphate results in increased expression of CAT mRNA CTD PMID:22129738 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases secretion
multiple interactions 		ISO Adenosine Triphosphate results in increased secretion of CCL3 protein
azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein] 		CTD PMID:26522449 NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439 		JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides] CTD PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 multiple interactions ISO Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]
Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] 		CTD PMID:23184943 NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein] CTD PMID:32721574 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Comt catechol-O-methyltransferase multiple interactions ISO [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate CTD PMID:14975680 NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 multiple interactions ISO [Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] CTD PMID:21816645 NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] CTD PMID:19366808 NCBI chr11:97,033,033...97,067,457
Ensembl chr11:97,024,782...97,067,457 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate CTD PMID:32347412 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Csnk2a1 casein kinase 2 alpha 1 multiple interactions
affects binding 		ISO silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] CTD PMID:21174434 NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698 		JBrowse link
G Csnk2b casein kinase 2 beta multiple interactions
affects binding 		ISO silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] CTD PMID:21174434 NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525 		JBrowse link
G Cstb cystatin B multiple interactions ISO Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] CTD PMID:25288807 NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199 		JBrowse link
G Ctsb cathepsin B increases activity
multiple interactions 		ISO Adenosine Triphosphate results in increased activity of CTSB protein
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein] 		CTD PMID:26522449 NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases secretion
multiple interactions 		ISO Adenosine Triphosphate results in increased secretion of CXCL2 protein
azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein] 		CTD PMID:26522449 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G Dmd dystrophin increases secretion
multiple interactions 		ISO DMD gene mutant form results in increased secretion of Adenosine Triphosphate
Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] 		CTD PMID:24349043 NCBI chr  X:51,070,098...53,437,845
Ensembl chr  X:51,070,273...53,437,835 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] CTD PMID:32941855 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] CTD PMID:32941855 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation 		ISO sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] CTD PMID:26104857 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression 		EXP Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA] CTD PMID:10723097 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] CTD PMID:26072274 NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957 		JBrowse link
G Enpp7 ectonucleotide pyrophosphatase/phosphodiesterase 7 decreases activity ISO Adenosine Triphosphate results in decreased activity of ENPP7 protein CTD PMID:12885774 NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,740,763...104,745,760 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance
multiple interactions 		ISO ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate] 		CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G F2 coagulation factor II, thrombin multiple interactions
increases transport
increases abundance
increases secretion 		ISO 2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]
F2 protein results in increased transport of Adenosine Triphosphate
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] 		CTD PMID:2030746 PMID:15342215 PMID:30696774 PMID:35288162 NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246 		JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases abundance 		ISO FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate] CTD PMID:26670611 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Fbp1 fructose-bisphosphatase 1 multiple interactions ISO [Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Adenosine Triphosphate CTD PMID:31974165 NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746 		JBrowse link
G Fbxo3 F-box protein 3 multiple interactions EXP FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] CTD PMID:35962723 NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:110,872,220...110,904,479 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions 		EXP
ISO 		Adenosine Triphosphate results in increased expression of FOS mRNA
ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
[Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] 		CTD PMID:10723097 PMID:19463813 PMID:27466191 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Foxp3 forkhead box P3 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in decreased expression of FOXP3 mRNA] CTD PMID:29545090 NCBI chr  X:17,580,380...17,601,181
Ensembl chr  X:17,580,380...17,595,894 		JBrowse link
G Fscn1 fascin actin-bundling protein 1 increases expression
multiple interactions 		ISO Adenosine Triphosphate results in increased expression of FSCN1 mRNA
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] 		CTD PMID:29733962 NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of GATA3 mRNA] CTD PMID:29545090 NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670 		JBrowse link
G Gh1 growth hormone 1 multiple interactions
increases secretion 		ISO
EXP 		oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] 		CTD PMID:12471042 NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859 		JBrowse link
G Gja1 gap junction protein, alpha 1 increases export ISO GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate CTD PMID:17687502 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Gsdmd gasdermin D multiple interactions ISO
EXP 		[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] 		CTD PMID:33851234 PMID:34212273 PMID:34217685 PMID:35962723 PMID:36577999 More... NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO [GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] CTD PMID:11196146 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase multiple interactions
affects binding 		ISO [Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] inhibits the reaction [HCK protein binds to Adenosine Triphosphate] CTD PMID:33617879 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein] CTD PMID:23624237 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hk1 hexokinase 1 multiple interactions ISO [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein] CTD PMID:37001609 NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814 		JBrowse link
G Hk2 hexokinase 2 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein CTD PMID:36577999 NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275 		JBrowse link
G Hmgb1 high mobility group box 1 affects chemical synthesis
multiple interactions 		ISO HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of HMGB1 mRNA]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of and results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] 		CTD PMID:21641551 PMID:29545090 PMID:31504961 PMID:34405489 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]] CTD PMID:34217685 PMID:38135199 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 multiple interactions ISO Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] CTD PMID:23184943 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein] CTD PMID:24149798 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 affects chemical synthesis ISO HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate CTD PMID:21641551 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 multiple interactions
increases expression 		EXP bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] CTD PMID:16178011 NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein] CTD PMID:18508964 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Ifng interferon gamma multiple interactions ISO Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] CTD PMID:14623498 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] CTD PMID:17707769 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13 interleukin 13 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of IL13 protein] CTD PMID:29545090 NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483 		JBrowse link
G Il18 interleukin 18 multiple interactions
increases secretion 		ISO
EXP 		[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] 		CTD PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 PMID:29378952 More... NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] CTD PMID:26068648 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
increases secretion
decreases abundance 		EXP
ISO 		[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]
Adenosine Triphosphate results in increased expression of IL1B protein
Adenosine Triphosphate results in increased secretion of IL1B protein
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Dietary Fats co-treated with Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; tabersonine inhibits the reaction [Adenosine Triphosphate results in increased expression of IL1B protein]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA] 		CTD PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 More... NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of IL4 protein] CTD PMID:29545090 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of IL5 protein] CTD PMID:29545090 NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression 		ISO
EXP 		[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]
Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]
[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] 		CTD PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 More... NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Ins1 insulin 1 multiple interactions
increases secretion 		ISO
EXP 		Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein]
Adenosine Triphosphate results in increased secretion of INS1 protein
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein] 		CTD PMID:10535451 PMID:10780946 PMID:16366736 PMID:22221676 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO [ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate] CTD PMID:17965850 PMID:26739624 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
G Irf2 interferon regulatory factor 2 multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA] CTD PMID:34212273 NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627 		JBrowse link
G Itgb1bp2 integrin subunit beta 1 binding protein 2 multiple interactions ISO Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]]
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] 		CTD PMID:23184943 NCBI chr  X:70,612,118...70,617,158
Ensembl chr  X:70,612,521...70,617,158 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein] CTD PMID:24149798 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions
increases abundance 		ISO [[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate
KCND2 protein results in increased abundance of Adenosine Triphosphate 		CTD PMID:34418280 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein CTD PMID:12531891 NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421 		JBrowse link
G Kcnj11 potassium inwardly-rectifying channel, subfamily J, member 11 multiple interactions
decreases response to substance 		ISO Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate 		CTD PMID:11390963 PMID:28842488 NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:105,727,570...105,731,169 		JBrowse link
G Kcnj15 potassium inwardly-rectifying channel, subfamily J, member 15 increases activity ISO Adenosine Triphosphate results in increased activity of KCNJ15 protein CTD PMID:15328350 NCBI chr11:48,046,953...48,091,285
Ensembl chr11:48,035,655...48,092,457 		JBrowse link
G Kcnj8 potassium inwardly-rectifying channel, subfamily J, member 8 multiple interactions
decreases response to substance 		EXP Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein]
KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate 		CTD PMID:28842488 NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:177,239,908...177,246,531 		JBrowse link
G Khk ketohexokinase multiple interactions ISO KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate] CTD PMID:19158351 NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481 		JBrowse link
G Kif5a kinesin family member 5A multiple interactions
increases hydrolysis 		ISO Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]] CTD PMID:24239783 PMID:28122263 NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:64,934,740...64,978,272 		JBrowse link
G Lep leptin multiple interactions EXP [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein CTD PMID:10780946 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lipe lipase E, hormone sensitive type increases activity ISO Adenosine Triphosphate results in increased activity of LIPE protein CTD PMID:7155675 NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117 		JBrowse link
G Lpl lipoprotein lipase affects response to substance ISO LPL protein affects the susceptibility to Adenosine Triphosphate CTD PMID:11786490 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 affects binding ISO Adenosine Triphosphate binds to MAP2K1 protein CTD PMID:17693661 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
increases activity 		ISO
EXP 		1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]
1-palmitoyl-2-lysophosphatidylcholine promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; 2',3'-dialdehyde ATP affects the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; 2',3'-dialdehyde ATP inhibits the reaction [1-palmitoyl-2-lysophosphatidylcholine promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein] 		CTD PMID:12513686 PMID:15034929 PMID:17437542 PMID:21503959 PMID:24300283 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
increases activity 		ISO
EXP 		1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]
1-palmitoyl-2-lysophosphatidylcholine promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; 2',3'-dialdehyde ATP affects the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; 2',3'-dialdehyde ATP inhibits the reaction [1-palmitoyl-2-lysophosphatidylcholine promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein] 		CTD PMID:12513686 PMID:15034929 PMID:17437542 PMID:21503959 PMID:24300283 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions
decreases abundance 		EXP
ISO 		[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein
MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate] 		CTD PMID:17634376 PMID:39172838 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator multiple interactions ISO METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate] CTD PMID:30213948 NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135 		JBrowse link
G Mfn2 mitofusin 2 decreases response to substance
multiple interactions
increases chemical synthesis 		ISO
EXP 		MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency
MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate]
MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]
MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate 		CTD PMID:22292091 PMID:24898700 PMID:25416777 NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495 		JBrowse link
G Mir219a1 microRNA 219a-1 multiple interactions EXP [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] CTD PMID:35962723 NCBI chr20:4,831,580...4,831,689
Ensembl chr20:4,831,580...4,831,689 		JBrowse link
G Mir23b microRNA 23b multiple interactions
decreases abundance 		ISO [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate
MIR23B mRNA results in decreased abundance of Adenosine Triphosphate 		CTD PMID:34418280 NCBI chr17:1,819,386...1,819,482 JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA] CTD PMID:36847822 NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp9 matrix metallopeptidase 9 increases activity
multiple interactions
increases secretion 		ISO
EXP 		Adenosine Triphosphate results in increased activity of MMP9 protein
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA]
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein]
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]
Adenosine Triphosphate results in increased secretion of MMP9 protein 		CTD PMID:20195827 PMID:26522449 PMID:36847822 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mt-atp6 mitochondrially encoded ATP synthase membrane subunit 6 affects abundance EXP ATP6 protein affects the abundance of Adenosine Triphosphate CTD PMID:18273840 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,904...8,584 		JBrowse link
G Mt-co3 mitochondrially encoded cytochrome c oxidase III increases abundance ISO COX3 protein results in increased abundance of Adenosine Triphosphate CTD PMID:17428446 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,584...9,367 		JBrowse link
G Mvd mevalonate diphosphate decarboxylase increases hydrolysis ISO MVD protein results in increased hydrolysis of Adenosine Triphosphate CTD PMID:9392419 NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366 		JBrowse link
G Mvk mevalonate kinase increases hydrolysis
multiple interactions 		ISO MVK protein results in increased hydrolysis of Adenosine Triphosphate
3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate] 		CTD PMID:9392419 NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein] CTD PMID:34405489 PMID:37544346 NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230 		JBrowse link
G Myh7 myosin heavy chain 7 increases abundance ISO MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate CTD PMID:29741611 NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194 		JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207 		JBrowse link
G Ncs1 neuronal calcium sensor 1 multiple interactions
increases response to substance 		EXP NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]]
NCS1 protein results in increased susceptibility to Adenosine Triphosphate 		CTD PMID:12471042 NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:34,920,971...34,968,711 		JBrowse link
G Nek7 NIMA-related kinase 7 multiple interactions ISO [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein] CTD PMID:36627344 NCBI chr13:52,573,730...52,700,869
Ensembl chr13:52,573,730...52,700,823 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 affects localization
multiple interactions 		EXP
ISO 		Adenosine Triphosphate affects the localization of NFATC1 protein
azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein] 		CTD PMID:21464294 PMID:26522449 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Nfatc3 nuclear factor of activated T-cells 3 affects localization EXP Adenosine Triphosphate affects the localization of NFATC3 protein CTD PMID:21464294 NCBI chr19:50,870,464...50,944,992
Ensembl chr19:50,870,489...50,944,992 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]] CTD PMID:34217685 PMID:38135199 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP
ISO 		Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein] 		CTD PMID:21464294 PMID:24149798 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Ngf nerve growth factor multiple interactions EXP [NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium CTD PMID:1374475 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Nlrp1a NLR family, pyrin domain containing 1A multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA CTD PMID:24149798 NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO
EXP 		[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to NEK7 protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]; Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased activity of NLRP3 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] 		CTD PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 More... NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G Nolc1 nucleolar and coiled-body phosphoprotein 1 multiple interactions ISO Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein] CTD PMID:17129415 NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression 		ISO
EXP 		[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein]
azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide] 		CTD PMID:21464294 PMID:26522449 PMID:36847822 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein] CTD PMID:24300283 NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664 		JBrowse link
G Npy neuropeptide Y affects response to substance ISO NPY protein affects the susceptibility to Adenosine Triphosphate CTD PMID:15003356 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 increases expression EXP Adenosine Triphosphate results in increased expression of NR4A1 mRNA CTD PMID:10723097 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A multiple interactions ISO [OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate CTD PMID:15732009 NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128 		JBrowse link
G Oxt oxytocin/neurophysin I prepropeptide multiple interactions
increases secretion 		EXP Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein] CTD PMID:11102496 NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594 		JBrowse link
G P2rx1 purinergic receptor P2X 1 multiple interactions
affects binding 		EXP geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]
ATP binds to P2rx1 protein 		CTD
RGD		 PMID:11930156 PMID:12237343 RGD:727431 NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164 		JBrowse link
G P2rx2 purinergic receptor P2X 2 multiple interactions
affects activity
increases activity
affects response to substance 		EXP
ISO 		1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]
ATP affects activity of rat P2x2 receptor in transfected glial cells
P2RX2 protein affects the susceptibility to Adenosine Triphosphate 		CTD
RGD		 PMID:10860929 PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 More... RGD:1642662 NCBI chr12:51,999,107...52,002,627
Ensembl chr12:51,999,372...52,002,627 		JBrowse link
G P2rx3 purinergic receptor P2X 3 multiple interactions
increases activity
affects activity 		EXP Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate]
Adenosine Triphosphate results in increased activity of P2RX3 protein 		CTD PMID:19967073 PMID:27481062 NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794 		JBrowse link
G P2rx4 purinergic receptor P2X 4 multiple interactions
increases activity 		EXP
ISO 		[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside compound K co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside compound K promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 		CTD PMID:10737610 PMID:10860929 PMID:15629187 PMID:19793987 PMID:21638035 More... NCBI chr12:39,505,438...39,523,349
Ensembl chr12:39,505,438...39,523,094 		JBrowse link
G P2rx5 purinergic receptor P2X 5 affects transport EXP ATP affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935 		JBrowse link
G P2rx7 purinergic receptor P2X 7 multiple interactions
increases response to substance
increases expression
decreases response to substance
increases activity 		ISO
EXP 		[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]
P2RX7 protein results in increased susceptibility to Adenosine Triphosphate
Adenosine Triphosphate results in increased expression of P2RX7 protein
P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] 		CTD PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 More... NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions
affects activity 		ISO
EXP 		[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium]
[N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium]
Adenosine Triphosphate affects the activity of P2RY1 protein 		CTD PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738 NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027 		JBrowse link
G P2ry13 purinergic receptor P2Y13 multiple interactions ISO MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] CTD PMID:22129738 NCBI chr 2:145,620,321...145,624,730
Ensembl chr 2:145,619,655...145,622,787 		JBrowse link
G P2ry2 purinergic receptor P2Y2 multiple interactions
affects activity
increases activity 		ISO
EXP 		[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium
Adenosine Triphosphate affects the activity of P2RY2 protein 		CTD PMID:11527950 PMID:15243297 PMID:17003265 NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:164,759,213...164,781,852 		JBrowse link
G P2ry4 pyrimidinergic receptor P2Y4 multiple interactions ISO [Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium] CTD PMID:12694404 NCBI chr  X:69,722,604...69,757,726
Ensembl chr  X:69,721,753...69,753,510 		JBrowse link
G P2ry6 pyrimidinergic receptor P2Y6 multiple interactions ISO N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] CTD PMID:22129738 NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:164,706,116...164,743,588 		JBrowse link
G Panx1 Pannexin 1 decreases activity
multiple interactions
increases export 		ISO Adenosine Triphosphate results in decreased activity of PANX1 protein
Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate] 		CTD PMID:19023039 PMID:19213873 NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression 		ISO PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate]
PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate]
Adenosine Triphosphate results in increased expression of PARP1 protein 		CTD PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions
affects response to substance 		ISO [PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium] CTD PMID:28887310 NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145 		JBrowse link
G Pfkm phosphofructokinase, muscle multiple interactions ISO Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein] CTD PMID:23454376 NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248 		JBrowse link
G Pgp phosphoglycolate phosphatase decreases phosphorylation ISO PGP protein results in decreased phosphorylation of Adenosine Triphosphate CTD PMID:24338473 NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha multiple interactions
affects binding 		ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] CTD PMID:17550345 PMID:18754654 NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] CTD PMID:17550345 NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347 		JBrowse link
G Pla2g4a phospholipase A2 group 4A increases activity ISO Adenosine Triphosphate results in increased activity of PLA2G4A protein CTD PMID:10535451 NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641 		JBrowse link
G Plau plasminogen activator, urokinase increases secretion ISO Adenosine Triphosphate results in increased secretion of PLAU protein CTD PMID:20177776 NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030 		JBrowse link
G Plpp3 phospholipid phosphatase 3 decreases chemical synthesis ISO PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate CTD PMID:28982073 NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667 		JBrowse link
G Pml PML nuclear body scaffold multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein] CTD PMID:23430110 NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083 		JBrowse link
G Pmvk phosphomevalonate kinase increases hydrolysis ISO PMVK protein results in increased hydrolysis of Adenosine Triphosphate CTD PMID:9392419 NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:177,174,335...177,184,080 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate CTD PMID:19593819 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
decreases abundance 		ISO FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]
PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate 		CTD PMID:26670611 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein] CTD PMID:38135199 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Ppp5c protein phosphatase 5, catalytic subunit multiple interactions ISO Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein] CTD PMID:23184943 NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950 		JBrowse link
G Prdx2 peroxiredoxin 2 increases expression EXP Adenosine Triphosphate results in increased expression of PRDX2 protein modified form CTD PMID:16178011 NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO [[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate CTD PMID:31974165 NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450 		JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO [[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate CTD PMID:31974165 NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO [[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin CTD PMID:16087181 NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate] CTD PMID:39172838 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein] CTD PMID:24149798 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO
EXP 		[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of PYCARD mRNA]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of PYCARD protein]; Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; tabersonine inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased polymerization of PYCARD protein] 		CTD PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 PMID:29378952 More... NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Ralbp1 ralA binding protein 1 multiple interactions ISO [[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4] CTD PMID:15386349 PMID:16087181 NCBI chr 9:112,903,289...112,940,093
Ensembl chr 9:112,903,302...112,939,659 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO 		[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein] 		CTD PMID:21464294 PMID:24149798 PMID:33524445 PMID:34217685 PMID:34405489 More... NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Rhof ras homolog family member F, filopodia associated multiple interactions
increases expression 		ISO Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA] CTD PMID:29733962 NCBI chr12:39,082,413...39,107,528
Ensembl chr12:39,091,979...39,107,528 		JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in increased expression of RORC mRNA] CTD PMID:29545090 NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566 		JBrowse link
G S100a10 S100 calcium binding protein A10 increases expression ISO Adenosine Triphosphate results in increased expression of S100A10 mRNA CTD PMID:29733962 NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103 		JBrowse link
G S100a11 S100 calcium binding protein A11 increases expression ISO Adenosine Triphosphate results in increased expression of S100A11 mRNA CTD PMID:29733962 NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541 		JBrowse link
G S100a4 S100 calcium-binding protein A4 multiple interactions
increases expression 		ISO Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein]
Adenosine Triphosphate results in increased expression of S100A4 mRNA 		CTD PMID:29733962 NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837 		JBrowse link
G S100a6 S100 calcium binding protein A6 increases expression ISO Adenosine Triphosphate results in increased expression of S100A6 mRNA CTD PMID:29733962 NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762 		JBrowse link
G Sell selectin L multiple interactions ISO P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein] CTD PMID:11003599 NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600 		JBrowse link
G Sftpa1 surfactant protein A1 multiple interactions ISO [SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] CTD PMID:15065867 NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,042,255...17,045,769 		JBrowse link
G Sftpb surfactant protein B increases secretion
multiple interactions 		ISO
EXP 		Adenosine Triphosphate results in increased secretion of SFTPB protein
Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein] 		CTD PMID:11704537 PMID:14565945 NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646 		JBrowse link
G Sftpc surfactant protein C increases secretion
multiple interactions 		EXP
ISO 		Adenosine Triphosphate results in increased secretion of SFTPC protein
Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein] 		CTD PMID:11704537 PMID:14565945 NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP
ISO 		[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]
[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein 		CTD PMID:16366736 PMID:34216621 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate] CTD PMID:23166782 NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076 		JBrowse link
G Slc25a14 solute carrier family 25 member 14 decreases chemical synthesis ISO SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate CTD PMID:20600837 NCBI chr  X:132,685,518...132,723,705
Ensembl chr  X:132,676,818...132,723,703 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 decreases stability ISO Adenosine Triphosphate results in decreased stability of SLC2A1 protein CTD PMID:11420438 NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 increases abundance ISO SLC2A4 protein results in increased abundance of Adenosine Triphosphate CTD PMID:34904774 NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270 		JBrowse link
G Slc46a1 solute carrier family 46 member 1 multiple interactions ISO [SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate CTD PMID:21879757 NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869 		JBrowse link
G Slc5a5 solute carrier family 5 member 5 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] CTD PMID:16439463 NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691 		JBrowse link
G Snca synuclein alpha multiple interactions
decreases abundance 		ISO GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate] CTD PMID:24989254 NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315 		JBrowse link
G Sod1 superoxide dismutase 1 increases expression EXP
ISO 		Adenosine Triphosphate results in increased expression of SOD1 protein CTD PMID:16178011 PMID:22129738 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 affects chemical synthesis
decreases abundance
multiple interactions 		ISO SOD2 protein affects the chemical synthesis of Adenosine Triphosphate
SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate
MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate] 		CTD PMID:20638473 PMID:25362851 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Srr serine racemase multiple interactions ISO Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid] CTD PMID:27387750 NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100 		JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO [STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein CTD PMID:34216621 NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965 		JBrowse link
G Stxbp2 syntaxin binding protein 2 multiple interactions ISO STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] CTD PMID:30696774 NCBI chr12:6,487,265...6,498,351
Ensembl chr12:6,487,297...6,504,212 		JBrowse link
G Sugt1 SGT1 homolog, MIS12 kinetochore complex assembly cochaperone multiple interactions ISO Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] CTD PMID:23184943 NCBI chr15:61,400,478...61,441,303
Ensembl chr15:61,400,004...61,468,852 		JBrowse link
G Syn2 synapsin II multiple interactions ISO SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium] CTD PMID:18701217 NCBI chr 4:149,858,919...150,016,845
Ensembl chr 4:149,851,520...150,019,650 		JBrowse link
G Tac1 tachykinin, precursor 1 increases secretion
multiple interactions 		EXP Adenosine Triphosphate results in increased secretion of TAC1 protein
Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein] 		CTD PMID:16039053 NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546 		JBrowse link
G Taldo1 transaldolase 1 increases abundance ISO TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tas2r145 taste receptor, type 2, member 145 increases activity ISO Adenosine Triphosphate results in increased activity of TAS2R131 protein CTD PMID:29347925 NCBI chr 4:167,869,406...167,870,356
Ensembl chr 4:167,869,358...167,870,544 		JBrowse link
G Tbx21 T-box transcription factor 21 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Ovalbumin results in decreased expression of TBX21 mRNA] CTD PMID:29545090 NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,578,751...82,595,253 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased abundance of Adenosine Triphosphate CTD PMID:35366062 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Timm17a translocase of inner mitochondrial membrane 17A multiple interactions
decreases expression 		ISO 1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein] CTD PMID:24315374 NCBI chr13:49,282,918...49,296,363
Ensembl chr13:49,282,918...49,307,904 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 decreases secretion
multiple interactions 		ISO Adenosine Triphosphate results in decreased secretion of TIMP1 protein
azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein] 		CTD PMID:26522449 NCBI chr  X:3,766,509...3,772,578
Ensembl chr  X:3,766,510...3,771,135 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein] CTD PMID:34405489 PMID:37544346 NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases chemical synthesis 		ISO
EXP 		[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]
Adenosine Triphosphate inhibits the reaction [Sunitinib results in increased expression of TNF protein]; TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate]
TNF protein results in decreased chemical synthesis of Adenosine Triphosphate
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate] 		CTD PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 More... NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tnfsf11 TNF superfamily member 11 increases abundance ISO TNFSF11 protein results in increased abundance of Adenosine Triphosphate CTD PMID:26287518 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
G Top2a DNA topoisomerase II alpha multiple interactions
increases hydrolysis 		ISO Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]
TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate 		CTD PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108 NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366 		JBrowse link
G Top2b DNA topoisomerase II beta increases hydrolysis
multiple interactions 		ISO TOP2B protein results in increased hydrolysis of Adenosine Triphosphate
cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] 		CTD PMID:29272108 NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases abundance 		ISO TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate]
TP53 gene mutant form results in increased abundance of Adenosine Triphosphate 		CTD PMID:21042727 PMID:33070465 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
G Trpc3 transient receptor potential cation channel, subfamily C, member 3 multiple interactions
increases activity 		ISO ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein] CTD PMID:19289841 NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:121,409,436...121,475,823 		JBrowse link
G Trpc5 transient receptor potential cation channel, subfamily C, member 5 increases activity ISO Adenosine Triphosphate results in increased activity of TRPC5 protein CTD PMID:19289841 NCBI chr  X:112,742,828...113,027,638
Ensembl chr  X:112,742,828...113,027,638 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 increases activity ISO Adenosine Triphosphate results in increased activity of TRPC6 protein CTD PMID:19289841 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
G Trpc7 transient receptor potential cation channel, subfamily C, member 7 increases activity ISO Adenosine Triphosphate results in increased activity of TRPC7 protein CTD PMID:19289841 NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,714,505...7,838,745 		JBrowse link
G Trpm4 transient receptor potential cation channel, subfamily M, member 4 decreases activity ISO
EXP 		Adenosine Triphosphate results in decreased activity of TRPM4 protein CTD PMID:16966582 PMID:17188667 NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions EXP [Capsaicin binds to and affects the activity of TRPV1 protein] which results in increased secretion of Adenosine Triphosphate CTD PMID:19860742 NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021 		JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions ISO Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] CTD PMID:16439463 NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984 		JBrowse link
G Txn1 thioredoxin 1 increases expression ISO Adenosine Triphosphate results in increased expression of TXN protein CTD PMID:22129738 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Txnip thioredoxin interacting protein increases activity EXP Adenosine Triphosphate results in increased activity of TXNIP mRNA CTD PMID:21832250 NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731 		JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions
decreases abundance 		EXP
ISO 		Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons]
UCP1 results in decreased abundance of Adenosine Triphosphate
UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] 		CTD PMID:12734183 PMID:26670611 NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420 		JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO
EXP 		Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons]
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] 		CTD PMID:12734183 PMID:16366736 NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743 		JBrowse link
G Ucp3 uncoupling protein 3 multiple interactions ISO Adenosine Triphosphate inhibits the reaction [UCP3 protein results in increased transport of Protons] CTD PMID:12734183 NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:164,227,882...164,241,210 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO VDAC1 mutant form inhibits the reaction [chromium hexavalent ion results in decreased abundance of Adenosine Triphosphate] CTD PMID:22858589 NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 multiple interactions
increases abundance
decreases abundance 		ISO Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate] CTD PMID:30998386 NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613 		JBrowse link
bucladesine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] CTD PMID:20083572 PMID:23227865 PMID:23362264 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions EXP Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] CTD PMID:16452108 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases activity
affects localization
increases expression 		EXP
ISO 		Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]
Bucladesine results in increased activity of ABCC2 protein
Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein] 		CTD PMID:12029626 PMID:26049102 PMID:29052767 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Ache acetylcholinesterase increases activity
increases expression 		EXP Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form
Bucladesine results in increased expression of ACHE mRNA 		CTD PMID:18514641 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA CTD PMID:20823114 NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390 		JBrowse link
G Adm adrenomedullin decreases expression ISO Bucladesine results in decreased expression of ADM mRNA CTD PMID:19253104 NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371 		JBrowse link
G Agt angiotensinogen multiple interactions ISO AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] CTD PMID:36682589 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Ahr aryl hydrocarbon receptor affects localization
increases activity
multiple interactions 		ISO Bucladesine affects the localization of AHR protein
Bucladesine results in increased activity of AHR protein
Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] 		CTD PMID:15972329 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor multiple interactions ISO Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] CTD PMID:21979172 NCBI chr 1:30,822,219...30,917,251
Ensembl chr 1:30,810,866...30,952,866 		JBrowse link
G Ak5 adenylate kinase 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA CTD PMID:20823114 NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366 		JBrowse link
G Alas1 5'-aminolevulinate synthase 1 multiple interactions ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA CTD PMID:22859313 NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA CTD PMID:20823114 NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892 		JBrowse link
G Anxa2 annexin A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA CTD PMID:20823114 NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] CTD PMID:20083572 PMID:23227865 NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729 		JBrowse link
G Ar androgen receptor multiple interactions EXP [Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA CTD PMID:23200735 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA CTD PMID:20823114 NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646 		JBrowse link
G Atf1 activating transcription factor 1 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] CTD PMID:12164941 NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression 		ISO Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form]
Bucladesine results in increased phosphorylation of ATF2 protein 		CTD PMID:26049102 NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745 		JBrowse link
G Atp11a ATPase phospholipid transporting 11A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA CTD PMID:20823114 NCBI chr16:83,359,884...83,469,807
Ensembl chr16:83,359,884...83,469,767 		JBrowse link
G Atp2b1 ATPase plasma membrane Ca2+ transporting 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA CTD PMID:20823114 NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904 		JBrowse link
G Atp6v0c ATPase H+ transporting V0 subunit C multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA CTD PMID:20823114 NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] CTD PMID:16822680 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcat1 branched chain amino acid transaminase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA CTD PMID:20823114 NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288 		JBrowse link
G Bckdk branched chain ketoacid dehydrogenase kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA CTD PMID:20823114 NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:191,946,471...191,953,453 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Bucladesine results in decreased expression of BCL2 protein 		CTD PMID:10697531 PMID:16822680 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l13 Bcl2-like 13 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA CTD PMID:20823114 NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
increases expression 		ISO 1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:19189864 PMID:29698629 NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657 		JBrowse link
G Bet1l Bet1 golgi vesicular membrane trafficking protein-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA CTD PMID:20823114 NCBI chr 1:205,361,041...205,365,036
Ensembl chr 1:205,361,041...205,364,706 		JBrowse link
G Bicd1 BICD cargo adaptor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA CTD PMID:20823114 NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391 		JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172 		JBrowse link
G Bsnd barttin CLCNK type accessory subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA CTD PMID:20823114 NCBI chr 5:126,480,590...126,489,389
Ensembl chr 5:126,480,592...126,489,389 		JBrowse link
G C1r complement C1r multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA CTD PMID:20823114 NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:159,098,918...159,109,714 		JBrowse link
G Calm1 calmodulin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA CTD PMID:20823114 NCBI chr 6:125,217,191...125,227,855
Ensembl chr 6:125,217,246...125,225,381 		JBrowse link
G Calr calreticulin increases stability ISO Bucladesine results in increased stability of CALR protein CTD PMID:9473613 NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236 		JBrowse link
G Capn2 calpain 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA CTD PMID:20823114 NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] CTD PMID:10697531 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cast calpastatin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA CTD PMID:20823114 NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:5,707,640...5,817,180 		JBrowse link
G Cav2 caveolin 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA CTD PMID:20823114 NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] CTD PMID:12538206 NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA CTD PMID:20823114 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein CTD PMID:22534328 NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225 		JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions 		EXP
ISO 		Bucladesine results in increased expression of CCND1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein 		CTD PMID:16718685 PMID:21693435 PMID:22534328 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccnd3 cyclin D3 increases expression EXP Bucladesine results in increased expression of CCND3 protein CTD PMID:16718685 NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033 		JBrowse link
G Cd69 Cd69 molecule decreases expression ISO Bucladesine results in decreased expression of CD69 protein CTD PMID:25433234 NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509 		JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] CTD PMID:12538815 NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540 		JBrowse link
G Cdc42bpa CDC42 binding protein kinase alpha multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA CTD PMID:20823114 NCBI chr13:94,215,359...94,435,681
Ensembl chr13:94,215,959...94,435,681 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions 		EXP
ISO 		Bucladesine results in increased expression of CDKN1A protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein] 		CTD PMID:16718685 PMID:20823114 PMID:22534328 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression EXP Bucladesine results in increased expression of CDKN1B protein CTD PMID:16718685 PMID:21693435 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions 		ISO Bucladesine results in increased expression of CEBPB protein
Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein] 		CTD PMID:19282384 PMID:19698295 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpz CCAAT/enhancer binding protein zeta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA CTD PMID:20823114 NCBI chr 6:21,872,071...21,889,755
Ensembl chr 6:21,872,025...21,889,749 		JBrowse link
G Chat choline O-acetyltransferase multiple interactions
increases expression 		ISO
EXP 		[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein
Bucladesine results in increased expression of CHAT protein
Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein] 		CTD PMID:16724269 PMID:20361958 PMID:29665406 NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,663,665...7,723,416 		JBrowse link
G Cldn5 claudin 5 increases expression ISO Bucladesine results in increased expression of CLDN5 mRNA CTD PMID:20711499 NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322 		JBrowse link
G Cngb1 cyclic nucleotide gated channel subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA CTD PMID:20823114 NCBI chr19:9,732,646...9,798,864
Ensembl chr19:9,732,646...9,797,224 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:11576339 PMID:16430859 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD PMID:11576339 NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232 		JBrowse link
G Col6a2 collagen type VI alpha 2 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA CTD PMID:20823114 NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,265...12,057,042 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA CTD PMID:20823114 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA CTD PMID:20823114 NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:192,218,970...192,219,716 		JBrowse link
G Cplx1 complexin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA CTD PMID:20823114 NCBI chr14:1,329,073...1,360,781
Ensembl chr14:1,329,032...1,360,769 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions 		ISO Bucladesine results in increased phosphorylation of CREB1 protein
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein] 		CTD PMID:12164941 PMID:18787026 PMID:19282384 PMID:36565944 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crebbp CREB binding protein multiple interactions ISO [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]] 		CTD PMID:19282384 PMID:20685861 PMID:36565944 NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266 		JBrowse link
G Crem cAMP responsive element modulator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA CTD PMID:20823114 NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160 		JBrowse link
G Cryab crystallin, alpha B multiple interactions EXP Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] CTD PMID:8769853 NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528 		JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions ISO Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] CTD PMID:8445950 NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806 		JBrowse link
G Ctbp1 C-terminal binding protein 1 multiple interactions
affects localization 		ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]
Bucladesine affects the localization of CTBP1 protein 		CTD PMID:18184656 NCBI chr14:81,679,956...81,707,331
Ensembl chr14:81,679,765...81,707,554 		JBrowse link
G Ctbp2 C-terminal binding protein 2 affects localization
multiple interactions 		ISO Bucladesine affects the localization of CTBP2 protein
Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] 		CTD PMID:18184656 NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:197,212,133...197,254,261 		JBrowse link
G Ctnnb1 catenin beta 1 increases phosphorylation EXP Bucladesine results in increased phosphorylation of CTNNB1 protein CTD PMID:26964897 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Ctps2 CTP synthase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA CTD PMID:20823114 NCBI chr  X:35,277,658...35,418,505
Ensembl chr  X:35,277,658...35,418,505 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression ISO Bucladesine results in decreased expression of CXCL12 mRNA CTD PMID:20711499 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cyb5d1 cytochrome b5 domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA CTD PMID:20823114 NCBI chr10:54,612,230...54,616,375
Ensembl chr10:54,612,230...54,616,713 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression
multiple interactions 		EXP
ISO 		Bucladesine results in increased expression of CYP11A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA]
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA] 		CTD PMID:21693180 PMID:21979172 PMID:23200735 PMID:35987080 NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp11b2 cytochrome P450, family 11, subfamily b, polypeptide 2 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of CYP11B1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11B1 mRNA] 		CTD PMID:35987080 NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763 		JBrowse link
G Cyp11b3 cytochrome P450, family 11, subfamily b, polypeptide 3 multiple interactions
increases expression 		ISO fluorene-9-bisphenol affects the reaction [Bucladesine results in increased expression of CYP11B2 mRNA] CTD PMID:35987080 NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression
increases expression
multiple interactions 		EXP
ISO 		Bucladesine results in decreased expression of CYP17A1 mRNA
Bucladesine results in increased expression of CYP17A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA]
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP17A1 mRNA] 		CTD PMID:21458522 PMID:21693180 PMID:23200735 PMID:35987080 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of CYP19A1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP19A1 mRNA] 		CTD PMID:35987080 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP
ISO 		Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] 		CTD PMID:1849469 PMID:16901605 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] CTD PMID:1849469 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO Bucladesine results in increased expression of CYP1B1 mRNA CTD PMID:11559018 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] CTD PMID:8531136 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Dcn decorin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] CTD PMID:20823114 NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926 		JBrowse link
G Ddx27 DEAD-box helicase 27 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA CTD PMID:20823114 NCBI chr 3:176,163,220...176,182,418
Ensembl chr 3:176,163,203...176,182,410 		JBrowse link
G Des desmin multiple interactions EXP
ISO 		[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA 		CTD PMID:19089455 PMID:20823114 NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347 		JBrowse link
G Dhx9 DExH-box helicase 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA CTD PMID:20823114 NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546 		JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA CTD PMID:20823114 NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594 		JBrowse link
G Dtymk deoxythymidylate kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA CTD PMID:20823114 NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504 		JBrowse link
G Eda ectodysplasin-A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA CTD PMID:20823114 NCBI chr  X:69,118,577...69,520,274
Ensembl chr  X:69,118,796...69,520,274 		JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA CTD PMID:20823114 NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072 		JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA CTD PMID:20823114 NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egr2 early growth response 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA CTD PMID:20823114 NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748 		JBrowse link
G Eno2 enolase 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA CTD PMID:29698629 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Epb41l4a erythrocyte membrane protein band 4.1 like 4A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA CTD PMID:20823114 NCBI chr18:25,680,169...25,890,998
Ensembl chr18:25,680,171...25,888,498 		JBrowse link
G Epha3 Eph receptor A3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA CTD PMID:20823114 NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425 		JBrowse link
G Esr1 estrogen receptor 1 increases expression
multiple interactions 		EXP Bucladesine results in increased expression of ESR1 mRNA
[Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA] 		CTD PMID:21693180 PMID:23200735 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA CTD PMID:20823114 NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] CTD PMID:36565944 NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183 		JBrowse link
G Fads2 fatty acid desaturase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA CTD PMID:20823114 NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066 		JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions 		EXP Bucladesine results in increased expression of FAS mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA] 		CTD PMID:12414803 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Fbxo11 F-box protein 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA CTD PMID:20823114 NCBI chr 6:12,240,348...12,316,223
Ensembl chr 6:12,239,801...12,316,221 		JBrowse link
G Fbxw5 F-box and WD repeat domain containing 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA CTD PMID:20823114 NCBI chr 3:28,720,670...28,725,237
Ensembl chr 3:28,720,778...28,725,235 		JBrowse link
G Fcer2 Fc epsilon receptor II decreases expression ISO Bucladesine results in decreased expression of FCER2 protein CTD PMID:1328389 NCBI chr12:6,540,697...6,552,364
Ensembl chr12:6,540,703...6,549,374 		JBrowse link
G Fgd1 FYVE, RhoGEF and PH domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA CTD PMID:20823114 NCBI chr  X:23,466,791...23,509,773
Ensembl chr  X:23,467,530...23,509,979 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] CTD PMID:22798350 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Filip1l filamin A interacting protein 1-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA CTD PMID:20823114 NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] CTD PMID:26427651 NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA CTD PMID:20823114 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit affects expression
multiple interactions
increases expression 		ISO Bucladesine affects the expression of FOS protein
Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein]
Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein 		CTD PMID:7798212 PMID:9187264 PMID:19282384 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein] CTD PMID:20823114 PMID:36682589 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Fscn2 fascin actin-bundling protein 2, retinal multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA CTD PMID:20823114 NCBI chr10:106,121,038...106,139,683
Ensembl chr10:106,133,144...106,139,683 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions
increases expression 		ISO IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]]
Bucladesine results in increased expression of G6PC1 mRNA; Bucladesine results in increased expression of G6PC1 protein 		CTD PMID:22859313 PMID:26064446 NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA CTD PMID:20823114 NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876 		JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA CTD PMID:20823114 NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638 		JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA CTD PMID:20823114 NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810 		JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA CTD PMID:20823114 NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989 		JBrowse link
G Gdf3 growth differentiation factor 3 affects expression
multiple interactions 		ISO Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein
bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein] 		CTD PMID:31400064 NCBI chr 4:157,503,547...157,507,923
Ensembl chr 4:157,502,884...157,507,907 		JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions ISO [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] CTD PMID:36565944 NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240 		JBrowse link
G Gipc1 GIPC PDZ domain containing family, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA CTD PMID:20823114 NCBI chr19:41,380,125...41,392,078
Ensembl chr19:41,380,125...41,391,725 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions
increases expression 		EXP GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] CTD PMID:11741589 PMID:16718685 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] CTD PMID:1976021 NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368 		JBrowse link
G Gpkow G patch domain and KOW motifs multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA CTD PMID:20823114 NCBI chr  X:17,463,521...17,478,298
Ensembl chr  X:17,463,525...17,478,298 		JBrowse link
G Gpnmb glycoprotein nmb multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA CTD PMID:20823114 NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions
increases expression 		ISO KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] CTD PMID:26049102 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of GSTA2 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA] 		CTD PMID:26049102 NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of GSTA4 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA] 		CTD PMID:26049102 NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bucladesine results in increased expression of HIF1A mRNA CTD PMID:18591213 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions
increases expression 		ISO [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA] CTD PMID:35987080 PMID:38603619 NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] CTD PMID:20823114 NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 decreases expression
multiple interactions 		ISO Bucladesine results in decreased expression of HSD17B1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in decreased expression of HSD17B1 mRNA] 		CTD PMID:35987080 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 increases expression EXP Bucladesine results in increased expression of HSD17B12 mRNA CTD PMID:21458522 NCBI chr 3:100,445,393...100,568,898
Ensembl chr 3:100,445,400...100,568,938 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression EXP Bucladesine results in increased expression of HSD3B1 mRNA CTD PMID:21458522 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of HSD3B2 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HSD3B2 mRNA] 		CTD PMID:35987080 NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression
increases phosphorylation 		EXP
ISO 		Bucladesine results in increased expression of HSP27 protein
Bucladesine results in increased phosphorylation of HSPB1 protein 		CTD PMID:7541446 PMID:10559386 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA CTD PMID:20823114 NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760 		JBrowse link
G Iapp islet amyloid polypeptide increases expression EXP Bucladesine results in increased expression of IAPP mRNA CTD PMID:9142872 NCBI chr 4:176,968,097...176,975,363
Ensembl chr 4:176,968,097...176,975,363 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] CTD PMID:12538815 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Id1 inhibitor of DNA binding 1 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of ID1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA] 		CTD PMID:20522807 NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685 		JBrowse link
G Ifrd2 interferon-related developmental regulator 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA CTD PMID:20823114 NCBI chr 8:117,139,612...117,144,834
Ensembl chr 8:117,139,550...117,144,836 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] CTD PMID:22798350 NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of IGFBP1
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] 		CTD PMID:12093828 PMID:20823114 PMID:30328349 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA CTD PMID:20823114 NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA CTD PMID:20823114 NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473 		JBrowse link
G Ighe immunoglobulin heavy constant epsilon multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] CTD PMID:12230500
G Il10 interleukin 10 decreases expression
multiple interactions 		ISO Bucladesine results in decreased expression of IL10
Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein] 		CTD PMID:11301049 PMID:19273625 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA CTD PMID:20823114 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194 		JBrowse link
G Il13 interleukin 13 decreases expression
decreases secretion 		ISO Bucladesine results in decreased expression of IL13 mRNA
Bucladesine results in decreased secretion of IL13 protein 		CTD PMID:16083514 NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] CTD PMID:8904084 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il23a interleukin 23 subunit alpha increases expression
multiple interactions 		ISO Bucladesine results in increased expression of IL23A mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA 		CTD PMID:19273625 PMID:20823114 NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434 		JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Bucladesine results in decreased expression of IL2RA protein CTD PMID:1709825 PMID:25433234 NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] CTD PMID:11886533 PMID:12230500 NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] CTD PMID:11886533 NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] CTD PMID:20388727 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Inha inhibin subunit alpha decreases expression
multiple interactions 		EXP Bucladesine results in decreased expression of INHA mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA] 		CTD PMID:21693180 PMID:23200735 NCBI chr 9:84,443,109...84,446,010
Ensembl chr 9:84,443,109...84,446,009 		JBrowse link
G Insl3 insulin-like 3 multiple interactions
increases expression 		EXP [Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] CTD PMID:21458522 PMID:21693180 PMID:23200735 NCBI chr16:18,432,668...18,434,539 JBrowse link
G Ints7 integrator complex subunit 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA CTD PMID:20823114 NCBI chr13:105,686,208...105,739,609
Ensembl chr13:105,686,128...105,739,608 		JBrowse link
G Irf9 interferon regulatory factor 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA CTD PMID:20823114 NCBI chr15:33,065,422...33,071,881
Ensembl chr15:33,065,659...33,071,879 		JBrowse link
G Isg20l2 interferon stimulated exonuclease gene 20-like 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA CTD PMID:20823114 NCBI chr 2:175,694,638...175,704,125
Ensembl chr 2:175,695,615...175,705,095 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA CTD PMID:20823114 NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA CTD PMID:20823114 NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions 		ISO Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein
Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form
Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein]
[Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein] 		CTD PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kat2a lysine acetyltransferase 2A multiple interactions ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] CTD PMID:18184656 NCBI chr10:86,132,535...86,140,877
Ensembl chr10:86,132,535...86,140,485 		JBrowse link
G Kcnc4 potassium voltage-gated channel subfamily C member 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA CTD PMID:20823114 NCBI chr 2:197,747,095...197,788,467
Ensembl chr 2:197,759,010...197,788,433 		JBrowse link
G Kng1 kininogen 1 increases activity EXP Bucladesine results in increased activity of KNG1 CTD PMID:1334751 NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148 		JBrowse link
G Krt8 keratin 8 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] CTD PMID:20823114 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G Lamb2 laminin subunit beta 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA CTD PMID:20823114 NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA CTD PMID:20823114 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Lep leptin decreases expression ISO Bucladesine results in decreased expression of LEP mRNA CTD PMID:9002984 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lgals3 galectin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA CTD PMID:20823114 NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor decreases expression
multiple interactions 		EXP Bucladesine results in decreased expression of LHCGR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA] 		CTD PMID:21693180 PMID:23200735 NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061 		JBrowse link
G Lipe lipase E, hormone sensitive type affects localization
increases activity
increases expression
multiple interactions 		EXP
ISO 		Bucladesine affects the localization of LIPE protein
Bucladesine results in increased activity of LIPE protein
Bucladesine results in increased expression of LIPE mRNA
[Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] 		CTD PMID:11160373 PMID:23362264 NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117 		JBrowse link
G LOC120095955 mucin-12-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MUC12 mRNA CTD PMID:20823114 NCBI chr12:25,127,100...25,137,925 JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA CTD PMID:20823114 NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:237,787,766...237,854,197 		JBrowse link
G Ltbp1 latent transforming growth factor beta binding protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA CTD PMID:20823114 NCBI chr 6:25,781,625...26,177,346
Ensembl chr 6:25,781,638...26,454,036 		JBrowse link
G Ltc4s leukotriene C4 synthase decreases secretion ISO Bucladesine results in decreased secretion of LTC4S protein CTD PMID:16083514 NCBI chr10:35,060,002...35,066,466
Ensembl chr10:35,061,437...35,063,768 		JBrowse link
G Map1a microtubule-associated protein 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA CTD PMID:20823114 NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:128,716,940...128,740,159 		JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA CTD PMID:29698629 NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA CTD PMID:20823114 NCBI chr 9:49,696,573...49,822,353
Ensembl chr 9:49,696,700...49,822,353 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein
Bucladesine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]] 		CTD PMID:8526880 PMID:19282384 PMID:22875961 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein
Bucladesine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]] 		CTD PMID:8526880 PMID:19282384 PMID:22875961 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mgat4b alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA CTD PMID:20823114 NCBI chr10:35,049,421...35,060,307
Ensembl chr10:35,050,512...35,060,309 		JBrowse link
G Mir125a microRNA 125a decreases expression EXP
ISO 		Bucladesine results in decreased expression of MIR125A mRNA CTD PMID:23045399 NCBI chr 1:67,350,675...67,350,759
Ensembl chr 1:67,350,675...67,350,759 		JBrowse link
G Mir145 microRNA 145 decreases expression EXP
ISO 		Bucladesine results in decreased expression of MIR145 mRNA CTD PMID:23045399 NCBI chr18:57,369,983...57,370,070 JBrowse link
G Mir27b microRNA 27b multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA CTD PMID:30328349 NCBI chr17:1,819,147...1,819,243 JBrowse link
G Mir455 microRNA 455 decreases expression EXP
ISO 		Bucladesine results in decreased expression of MIR455 mRNA CTD PMID:23045399 NCBI chr 5:81,704,834...81,704,911
Ensembl chr 5:81,704,834...81,704,911 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression EXP Bucladesine results in decreased expression of MKI67 protein CTD PMID:16718685 NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA CTD PMID:20823114 NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA CTD PMID:20823114 NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350 		JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA CTD PMID:20823114 NCBI chr17:62,911,705...62,996,544
Ensembl chr17:62,911,771...62,996,541 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein CTD PMID:7798212 PMID:9187264 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Myh9 myosin, heavy chain 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA CTD PMID:20823114 NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963 		JBrowse link
G Myl12a myosin light chain 12A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA CTD PMID:20823114 NCBI chr 9:118,338,592...118,346,277
Ensembl chr 9:118,338,604...118,342,634 		JBrowse link
G Myl12b myosin light chain 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA CTD PMID:20823114 NCBI chr 9:118,320,479...118,334,810
Ensembl chr 9:118,320,489...118,324,418 		JBrowse link
G Mylk myosin light chain kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA CTD PMID:20823114 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Myof myoferlin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA CTD PMID:20823114 NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA CTD PMID:20823114 NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079 		JBrowse link
G Ndst1 N-deacetylase and N-sulfotransferase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA CTD PMID:20823114 NCBI chr18:56,407,308...56,470,007
Ensembl chr18:56,411,200...56,448,612 		JBrowse link
G Nefl neurofilament light chain multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA CTD PMID:29698629 NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515 		JBrowse link
G Nefm neurofilament medium chain multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163 		JBrowse link
G Neurog1 neurogenin 1 multiple interactions
affects expression 		ISO bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein]
Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein 		CTD PMID:31400064 NCBI chr17:8,368,096...8,369,615
Ensembl chr17:8,368,096...8,369,615 		JBrowse link
G Nexn nexilin (F actin binding protein) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA CTD PMID:20823114 NCBI chr 2:243,846,736...243,878,268
Ensembl chr 2:243,846,433...243,887,114 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases response to substance 		ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA] CTD PMID:22859313 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Ngf nerve growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834 		JBrowse link
G Nom1 nucleolar protein with MIF4G domain 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA CTD PMID:20823114 NCBI chr 4:6,562,931...6,586,093
Ensembl chr 4:6,567,836...6,585,036 		JBrowse link
G Nphp1 nephrocystin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA CTD PMID:20823114 NCBI chr 3:135,413,927...135,469,505
Ensembl chr 3:135,413,927...135,469,505 		JBrowse link
G Nptxr neuronal pentraxin receptor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA CTD PMID:20823114 NCBI chr 7:113,217,046...113,235,122
Ensembl chr 7:113,217,050...113,235,156 		JBrowse link
G Npy neuropeptide Y increases expression EXP Bucladesine results in increased expression of NPY mRNA CTD PMID:19912776 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Nr0b1 nuclear receptor subfamily 0, group B, member 1 decreases expression
multiple interactions 		ISO Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]] 		CTD PMID:18787026 PMID:19282384 NCBI chr  X:54,707,658...54,711,786
Ensembl chr  X:54,707,639...54,712,083 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA CTD PMID:20823114 NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions
increases expression 		ISO NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein]
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] 		CTD PMID:18787026 PMID:19282384 PMID:36565944 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions
increases expression 		ISO Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 protein]
NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]
Bucladesine results in increased expression of NR5A1 mRNA; Bucladesine results in increased expression of NR5A1 protein 		CTD PMID:18184656 PMID:18787026 PMID:35987080 NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:42,875,221...42,896,046 		JBrowse link
G Nrip1 nuclear receptor interacting protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA CTD PMID:20823114 NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353 		JBrowse link
G Nt5e 5' nucleotidase, ecto multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA CTD PMID:20823114 NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645 		JBrowse link
G Ntf3 neurotrophin 3 increases expression EXP Bucladesine results in increased expression of NTF3 protein CTD PMID:19854260 NCBI chr 4:160,601,161...160,670,623
Ensembl chr 4:160,600,770...160,676,349 		JBrowse link
G Nts neurotensin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA CTD PMID:20823114 NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:39,451,073...39,460,961 		JBrowse link
G Nup155 nucleoporin 155 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA CTD PMID:20823114 NCBI chr 2:58,927,171...58,980,162
Ensembl chr 2:58,928,537...58,981,242 		JBrowse link
G Odc1 ornithine decarboxylase 1 multiple interactions
decreases activity 		ISO 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] CTD PMID:6284819 NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146 		JBrowse link
G Ogfrl1 opioid growth factor receptor-like 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA CTD PMID:20823114 NCBI chr 9:33,320,501...33,338,742
Ensembl chr 9:33,324,392...33,339,237 		JBrowse link
G Or8b8 olfactory receptor family 8 subfamily B member 8 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA CTD PMID:20823114 NCBI chr 8:45,882,321...45,883,253
Ensembl chr 8:45,882,321...45,883,253 		JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA CTD PMID:20823114 NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911 		JBrowse link
G Paep progestagen associated endometrial protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA CTD PMID:20823114 NCBI chr 3:28,929,252...28,932,592 JBrowse link
G Pakap paralemmin A kinase anchor protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA CTD PMID:20823114 NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:76,977,112...77,443,656 		JBrowse link
G Pax6 paired box 6 multiple interactions
affects expression 		ISO bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein]
Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein 		CTD PMID:31400064 NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763 		JBrowse link
G Pcdh18 protocadherin 18 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA CTD PMID:20823114 NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826 		JBrowse link
G Pcdhb5 protocadherin beta 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA CTD PMID:20823114 NCBI chr18:29,302,466...29,305,048 JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions
increases expression 		ISO
EXP 		Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] 		CTD PMID:1371108 PMID:24428821 NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561 		JBrowse link
G Pdgfa platelet derived growth factor subunit A decreases expression ISO Bucladesine results in decreased expression of PDGFA mRNA CTD PMID:1650039 NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA CTD PMID:20823114 NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145 		JBrowse link
G Pf4 platelet factor 4 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of PF4 mRNA
[Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA 		CTD PMID:21979172 NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392 		JBrowse link
G Pgrmc2 progesterone receptor membrane component 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA CTD PMID:20823114 NCBI chr 2:125,996,190...126,012,090
Ensembl chr 2:125,996,193...126,012,090 		JBrowse link
G Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA CTD PMID:20823114 NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,663,260...92,928,344 		JBrowse link
G Pkd2l1 polycystin 2 like 1, transient receptor potential cation channel multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA CTD PMID:20823114 NCBI chr 1:252,982,096...253,019,235
Ensembl chr 1:252,982,096...253,023,359 		JBrowse link
G Plat plasminogen activator, tissue type multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA CTD PMID:20823114 NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696 		JBrowse link
G Plekhg3 pleckstrin homology and RhoGEF domain containing G3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA CTD PMID:20823114 NCBI chr 6:100,998,965...101,042,120
Ensembl chr 6:100,994,417...101,042,118 		JBrowse link
G Plin1 perilipin 1 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of PLIN1 mRNA
LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA] 		CTD PMID:23362264 NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:143,074,214...143,086,206 		JBrowse link
G Pls3 plastin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA CTD PMID:20823114 NCBI chr  X:116,401,247...116,495,898
Ensembl chr  X:116,401,293...116,495,893 		JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions
increases activity 		ISO Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] CTD PMID:15034573 NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940 		JBrowse link
G Pnpla6 patatin-like phospholipase domain containing 6 increases expression
multiple interactions 		ISO Bucladesine results in increased expression of PNPLA6 mRNA
Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein] 		CTD PMID:20380879 NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631 		JBrowse link
G Pomc proopiomelanocortin increases expression ISO Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form CTD PMID:1325994 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 affects expression
multiple interactions 		ISO Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein
bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein] 		CTD PMID:31400064 NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions 		ISO Bucladesine results in increased expression of PPARG protein
[ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein 		CTD PMID:19698295 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions 		ISO Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA] 		CTD PMID:24428821 PMID:26064446 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Ppia peptidylprolyl isomerase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA CTD PMID:20823114 NCBI chr14:85,491,223...85,496,884
Ensembl chr14:85,492,484...85,497,115 		JBrowse link
G Prima1 proline rich membrane anchor 1 increases expression EXP Bucladesine results in increased expression of PRIMA1 mRNA CTD PMID:18514641 NCBI chr 6:128,094,686...128,155,592
Ensembl chr 6:128,103,175...128,154,865 		JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
increases activity 		EXP KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] CTD PMID:31300867 NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494 		JBrowse link
G Prl prolactin multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] CTD PMID:20823114 PMID:30328349 PMID:36682589 NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217 		JBrowse link
G Prl8a2 prolactin family 8, subfamily A, member 2 multiple interactions EXP [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of PRL8A2 mRNA CTD PMID:19089455 NCBI chr17:37,821,651...37,830,676
Ensembl chr17:37,821,651...37,830,676 		JBrowse link
G Prss12 serine protease 12 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA CTD PMID:20823114 NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] 		CTD PMID:11095985 PMID:12164941 PMID:24003391 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptk7 protein tyrosine kinase 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA CTD PMID:20823114 NCBI chr 9:21,849,756...21,916,077
Ensembl chr 9:21,849,801...21,916,078 		JBrowse link
G Ptpa protein phosphatase 2 phosphatase activator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA CTD PMID:20823114 NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772 		JBrowse link
G Rab1b RAB1B, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA CTD PMID:20823114 NCBI chr 1:211,835,133...211,843,408
Ensembl chr 1:211,835,073...211,843,337
Ensembl chr  X:211,835,073...211,843,337 		JBrowse link
G Rab31 RAB31, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA CTD PMID:20823114 NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092 		JBrowse link
G Ran RAN, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA CTD PMID:20823114 NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases activity
decreases phosphorylation
multiple interactions 		ISO
EXP 		Bucladesine results in decreased activity of RB1 protein
Bucladesine results in decreased phosphorylation of RB1 protein
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein] 		CTD PMID:10697531 PMID:16718685 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Ren renin increases secretion
increases expression 		ISO Bucladesine results in increased secretion of REN protein
Bucladesine results in increased expression of REN mRNA 		CTD PMID:9256163 NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543 		JBrowse link
G Ret ret proto-oncogene multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA CTD PMID:20823114 NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556 		JBrowse link
G Rgs10 regulator of G-protein signaling 10 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA CTD PMID:20823114 NCBI chr 1:192,376,772...192,422,640
Ensembl chr 1:192,376,774...192,418,904 		JBrowse link
G Rhobtb3 Rho-related BTB domain containing 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA CTD PMID:20823114 NCBI chr 2:7,094,972...7,201,507
Ensembl chr 2:7,095,253...7,150,906 		JBrowse link
G Rin1 Ras and Rab interactor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA CTD PMID:20823114 NCBI chr 1:211,785,107...211,789,755
Ensembl chr 1:211,784,943...211,791,368 		JBrowse link
G Rpn1 ribophorin I multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA CTD PMID:20823114 NCBI chr 4:122,100,976...122,122,382
Ensembl chr 4:122,100,813...122,122,382 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA CTD PMID:20823114 NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238 		JBrowse link
G Rpsa ribosomal protein SA multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA CTD PMID:20823114 NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:128,728,862...128,732,737 		JBrowse link
G S100a14 S100 calcium binding protein A14 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA CTD PMID:20823114 NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:178,306,025...178,307,999 		JBrowse link
G Saraf store-operated calcium entry-associated regulatory factor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA CTD PMID:20823114 NCBI chr16:64,720,404...64,738,653
Ensembl chr16:64,720,418...64,738,653 		JBrowse link
G Scamp4 secretory carrier membrane protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA CTD PMID:20823114 NCBI chr 7:9,752,193...9,764,614
Ensembl chr 7:9,752,193...9,778,736 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
increases expression 		ISO
EXP 		LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] CTD PMID:23045399 PMID:23362264 NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980 		JBrowse link
G Sdcbp syndecan binding protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA CTD PMID:20823114 NCBI chr 5:24,245,279...24,314,712
Ensembl chr 5:24,245,033...24,326,197 		JBrowse link
G Selenot selenoprotein T multiple interactions
increases expression 		EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] CTD PMID:18198219 NCBI chr 2:144,954,324...144,971,375
Ensembl chr 2:144,954,312...144,971,369 		JBrowse link
G Sema3a semaphorin 3A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA CTD PMID:20823114 NCBI chr 4:22,239,418...22,709,907
Ensembl chr 4:22,245,322...22,535,774 		JBrowse link
G Septin11 septin 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA CTD PMID:20823114 NCBI chr14:15,119,760...15,275,222
Ensembl chr14:15,128,951...15,275,200 		JBrowse link
G Sfn stratifin multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein CTD PMID:22534328 NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995 		JBrowse link
G Sik3 SIK family kinase 3 multiple interactions
increases phosphorylation 		ISO yakuchinone-A inhibits the reaction [Bucladesine results in increased phosphorylation of SIK3 protein] CTD PMID:38164184 NCBI chr 8:55,208,969...55,419,138
Ensembl chr 8:55,208,815...55,419,138 		JBrowse link
G Slc18a3 solute carrier family 18 member A3 increases expression
multiple interactions 		EXP Bucladesine results in increased expression of SLC18A3 protein
Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein] 		CTD PMID:20361958 NCBI chr16:7,719,953...7,722,814 JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO [Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein CTD PMID:18948400 NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742 		JBrowse link
G Slc2a5 solute carrier family 2 member 5 multiple interactions ISO Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] CTD PMID:12820898 NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:165,866,172...165,894,038 		JBrowse link
G Smad6 SMAD family member 6 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr 8:73,345,457...73,414,985
Ensembl chr 8:73,345,460...73,414,149 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
increases activity 		ISO Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] CTD PMID:12093828 PMID:20685861 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox1 SRY-box transcription factor 1 multiple interactions
affects expression 		ISO bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein]
Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein 		CTD PMID:31400064 NCBI chr16:83,837,689...83,841,703
Ensembl chr16:83,802,160...83,841,775 		JBrowse link
G Srebf2 sterol regulatory element binding transcription factor 2 multiple interactions
increases expression 		ISO Organophosphates inhibits the reaction [Bucladesine results in increased expression of SREBF2 mRNA] CTD PMID:38603619 NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943 		JBrowse link
G Srsf7 serine and arginine rich splicing factor 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA CTD PMID:20823114 NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:20,564,044...20,571,212 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
decreases expression 		ISO
EXP 		27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]]
Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein
Bucladesine results in decreased expression of STAR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA]
[IMOL S-140 co-treated with triphenyl phosphate co-treated with tris(chloroethyl)phosphate co-treated with diphenylcresyl phosphate co-treated with tert-butylphenyl diphenyl phosphate co-treated with tri-xylenyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Organophosphates inhibits the reaction [Bucladesine results in increased expression of STAR mRNA] 		CTD PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 More... NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] CTD PMID:26064446 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Stk38 serine/threonine kinase 38 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA CTD PMID:20823114 NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,035,933...7,069,711 		JBrowse link
G Sulf1 sulfatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA CTD PMID:20823114 NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:11,145,950...11,308,643 		JBrowse link
G Tagln transgelin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA CTD PMID:20823114 NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:55,121,301...55,127,563 		JBrowse link
G Tcea1 transcription elongation factor A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA CTD PMID:20823114 NCBI chr 5:19,414,351...19,466,629
Ensembl chr15:12,831,339...12,834,156
Ensembl chr 5:12,831,339...12,834,156 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA CTD PMID:20823114 NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111 		JBrowse link
G Testin testin gene decreases expression
multiple interactions 		EXP Bucladesine results in decreased expression of TESTIN mRNA
Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA] 		CTD PMID:11090432 NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,852,404...3,864,993 		JBrowse link
G Tfrc transferrin receptor decreases expression ISO Bucladesine results in decreased expression of TFRC protein CTD PMID:2989362 NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318 		JBrowse link
G Tgfa transforming growth factor alpha decreases expression EXP Bucladesine results in decreased expression of TGFA mRNA CTD PMID:11843059 NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD PMID:11576339 PMID:16430859 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tgm2 transglutaminase 2 multiple interactions ISO [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein CTD PMID:32749514 NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Th tyrosine hydroxylase increases expression EXP Bucladesine results in increased expression of TH mRNA CTD PMID:19912776 NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions EXP Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein] CTD PMID:16716901 NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158 		JBrowse link
G Tnc tenascin C multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA CTD PMID:20823114 NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP 		Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein] 		CTD PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein CTD PMID:22534328 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tpi1 triosephosphate isomerase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA CTD PMID:20823114 NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:159,301,562...159,305,413 		JBrowse link
G Tpsg1 tryptase gamma 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA CTD PMID:20823114 NCBI chr10:14,889,838...14,895,605
Ensembl chr10:14,890,734...14,894,786 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA CTD PMID:20823114 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Ube2d2b ubiquitin-conjugating enzyme E2D 2B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA CTD PMID:20823114 NCBI chr14:2,060,926...2,062,400
Ensembl chr14:2,048,235...2,063,764 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression
multiple interactions 		EXP Bucladesine results in increased expression of UCP1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] 		CTD PMID:12414803 NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420 		JBrowse link
G Ugcg UDP-glucose ceramide glucosyltransferase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA CTD PMID:20823114 NCBI chr 5:78,828,006...78,860,725
Ensembl chr 5:78,828,006...78,860,417 		JBrowse link
G Usp12 ubiquitin specific peptidase 12 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA CTD PMID:20823114 NCBI chr12:13,423,625...13,477,547
Ensembl chr12:13,422,427...13,477,547 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Bucladesine results in increased expression of VEGFA mRNA CTD PMID:18591213 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vim vimentin multiple interactions ISO [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein CTD PMID:20823114 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
G Vps39 VPS39 subunit of HOPS complex multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA CTD PMID:20823114 NCBI chr 3:127,721,076...127,758,658
Ensembl chr 3:127,721,076...127,758,768 		JBrowse link
G Wnt5a Wnt family member 5A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA CTD PMID:20823114 NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860 		JBrowse link
G Wwtr1 WW domain containing transcription regulator 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA CTD PMID:20823114 NCBI chr 2:143,801,181...143,916,941
Ensembl chr 2:143,801,181...143,991,950 		JBrowse link
G Zbtb45 zinc finger and BTB domain containing 45 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA CTD PMID:20823114 NCBI chr 1:82,707,633...82,712,926
Ensembl chr 1:82,707,634...82,710,277 		JBrowse link
G Zscan10 zinc finger and SCAN domain containing 10 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA CTD PMID:20823114 NCBI chr10:13,140,929...13,150,897
Ensembl chr10:13,140,929...13,150,897 		JBrowse link
G Zscan20 zinc finger and SCAN domain containing 20 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA CTD PMID:20823114 NCBI chr 5:146,214,023...146,240,678
Ensembl chr 5:146,215,082...146,240,777 		JBrowse link
butyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO butyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
c-di-GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tdrd7 tudor domain containing 7 increases expression ISO bis(3',5')-cyclic diguanylic acid results in increased expression of TDRD7 mRNA CTD PMID:32273341 NCBI chr 5:65,034,317...65,108,165
Ensembl chr 5:65,034,341...65,108,161 		JBrowse link
cangrelor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F3 coagulation factor III, tissue factor multiple interactions ISO cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein] CTD PMID:20200314 NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369 		JBrowse link
G Gpr17 G protein-coupled receptor 17 multiple interactions ISO cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G Itga2b integrin subunit alpha 2b multiple interactions ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] CTD PMID:18404433 NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,908,697...87,925,833 		JBrowse link
G Itgb3 integrin subunit beta 3 multiple interactions ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] CTD PMID:18404433 NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800 		JBrowse link
G P2ry12 purinergic receptor P2Y12 multiple interactions
affects response to substance
decreases activity 		ISO [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein
P2RY12 gene polymorphism affects the susceptibility to cangrelor
cangrelor results in decreased activity of P2RY12 protein 		CTD PMID:12606772 PMID:20126830 PMID:22273509 NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410 		JBrowse link
G Pf4 platelet factor 4 multiple interactions ISO cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein] CTD PMID:22273509 NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392 		JBrowse link
G Selp selectin P multiple interactions ISO cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]] CTD PMID:18404433 NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987 		JBrowse link
G Syk spleen associated tyrosine kinase multiple interactions ISO [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein CTD PMID:12606772 NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278 		JBrowse link
CDP-choline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 decreases expression ISO Cytidine Diphosphate Choline results in decreased expression of CASP3 protein CTD PMID:12443983 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Icam1 intercellular adhesion molecule 1 decreases expression EXP Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA CTD PMID:16193989 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Nceh1 neutral cholesterol ester hydrolase 1 multiple interactions ISO NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] CTD PMID:18164358 NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 decreases expression ISO Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form CTD PMID:12443983 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions 		EXP Cytidine Diphosphate Choline results in increased expression of SIRT1 protein
Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein 		CTD PMID:23600725 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
CMP-N-acetyl-beta-neuraminic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cmas cytidine monophosphate N-acetylneuraminic acid synthetase affects abundance ISO CMAS protein affects the abundance of Cytidine Monophosphate N-Acetylneuraminic Acid CTD PMID:27380425 NCBI chr 4:177,449,801...177,468,117
Ensembl chr 4:177,449,732...177,476,291 		JBrowse link
coenzyme A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot8 acyl-CoA thioesterase 8 affects hydrolysis ISO ACOT8 protein affects the hydrolysis of Coenzyme A analog CTD PMID:16141203 NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570 		JBrowse link
G Kat2b lysine acetyltransferase 2B affects binding ISO Coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
CTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions EXP Cytidine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G App amyloid beta precursor protein increases secretion ISO Cytidine Triphosphate results in increased secretion of APP protein modified form CTD PMID:22906069 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G P2rx1 purinergic receptor P2X 1 affects binding EXP CTP binds to P2rx1 protein RGD PMID:12237343 RGD:727431 NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164 		JBrowse link
G P2rx5 purinergic receptor P2X 5 affects transport EXP CTP affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935 		JBrowse link
cyclic ADP-beta-D-ribose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd38 CD38 molecule decreases abundance ISO CD38 gene mutant form results in decreased abundance of Cyclic ADP-Ribose CTD PMID:23343681 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Homer1 homer scaffold protein 1 multiple interactions EXP HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] CTD PMID:12887973 NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657 		JBrowse link
G Ryr2 ryanodine receptor 2 multiple interactions EXP HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] CTD PMID:12887973 NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705 		JBrowse link
cytidine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 1:191,013,632...191,017,943
Ensembl chr 1:191,013,463...191,017,971 		JBrowse link
dCTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dck deoxycytidine kinase increases metabolic processing
affects activity 		ISO DCK protein results in increased metabolism of 2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate affects the activity of DCK protein 		CTD PMID:9586059 NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,589,298...19,610,326 		JBrowse link
G Polk DNA polymerase kappa multiple interactions
affects binding 		ISO 2'-deoxycytidine 5'-triphosphate promotes the reaction [N(2)-furfuryl-deoxyguanosine results in increased stability of POLK protein]; N-(2'-deoxyguanosin-8-yl)-3-aminobenzanthrone inhibits the reaction [POLK protein binds to 2'-deoxycytidine 5'-triphosphate] CTD PMID:28823149 PMID:31286773 NCBI chr 2:29,556,831...29,616,960
Ensembl chr 2:29,557,336...29,616,960 		JBrowse link
decanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806 		JBrowse link
dGTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Samhd1 SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 decreases abundance ISO SAMHD1 protein results in decreased abundance of deoxyguanosine triphosphate CTD PMID:26342080 NCBI chr 3:166,179,742...166,214,448
Ensembl chr 3:166,181,588...166,214,410 		JBrowse link
dTDP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO thymidine 5'-diphosphate binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
dTMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Thymidine Monophosphate] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Tyms thymidylate synthetase multiple interactions ISO [Fluorouracil results in decreased activity of TYMS protein] which results in decreased abundance of Thymidine Monophosphate CTD PMID:29258758 NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097 		JBrowse link
dUMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc5 ATP binding cassette subfamily C member 5 increases export ISO ABCC5 protein results in increased export of 2'-deoxyuridylic acid CTD PMID:15897250 NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655 		JBrowse link
G Tyms thymidylate synthetase multiple interactions ISO [Fluorouracil results in decreased activity of TYMS protein] which results in increased abundance of 2'-deoxyuridylic acid CTD PMID:29258758 NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097 		JBrowse link
FAD term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ndufa9 NADH:ubiquinone oxidoreductase subunit A9 multiple interactions ISO Flavin-Adenine Dinucleotide binds to and results in increased activity of NDUFA9 protein CTD PMID:25526675 NCBI chr 4:161,345,398...161,374,188
Ensembl chr 4:161,345,400...161,375,025 		JBrowse link
G Rfk riboflavin kinase increases abundance ISO RFK protein results in increased abundance of Flavin-Adenine Dinucleotide CTD PMID:21308351 NCBI chr 1:224,226,632...224,234,185
Ensembl chr 1:224,226,628...224,235,698
Ensembl chr  X:224,226,628...224,235,698 		JBrowse link
G Slc52a3 solute carrier family 52 member 3 multiple interactions EXP Flavin-Adenine Dinucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] CTD PMID:19122205 NCBI chr 3:160,959,233...160,976,170
Ensembl chr 3:160,965,302...160,974,692 		JBrowse link
FMN term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Flavin Mononucleotide] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Rfk riboflavin kinase increases abundance ISO RFK protein results in increased abundance of Flavin Mononucleotide CTD PMID:21308351 NCBI chr 1:224,226,632...224,234,185
Ensembl chr 1:224,226,628...224,235,698
Ensembl chr  X:224,226,628...224,235,698 		JBrowse link
G Slc52a3 solute carrier family 52 member 3 multiple interactions EXP Flavin Mononucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] CTD PMID:19122205 NCBI chr 3:160,959,233...160,976,170
Ensembl chr 3:160,965,302...160,974,692 		JBrowse link
GDP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fut8 fucosyltransferase 8 multiple interactions
decreases activity 		ISO Guanosine Diphosphate inhibits the reaction [Mersalyl results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [Phenylglyoxal results in decreased activity of FUT8 protein]
Guanosine Diphosphate results in decreased activity of FUT8 protein 		CTD PMID:12770769 NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase affects binding ISO Guanosine Diphosphate binds to GMDS protein CTD PMID:25526675 NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,304,056...32,830,706 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Guanosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]] CTD PMID:25825487 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions EXP Guanosine Diphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]] CTD PMID:21126535 NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760 		JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions
affects binding 		ISO KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]
Guanosine Diphosphate binds to KRAS protein; Guanosine Diphosphate binds to KRAS protein mutant form 		CTD PMID:28154176 NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320 		JBrowse link
G Pgp phosphoglycolate phosphatase decreases phosphorylation ISO PGP protein results in decreased phosphorylation of Guanosine Diphosphate CTD PMID:24338473 NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408 		JBrowse link
G Rab3a RAB3A, member RAS oncogene family affects binding
multiple interactions 		EXP Guanosine Diphosphate binds to RAB3A protein
[alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein] 		CTD PMID:7929154 NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,718,167...18,721,842 		JBrowse link
G Sos1 SOS Ras/Rac guanine nucleotide exchange factor 1 multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]]; KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein] CTD PMID:25825487 PMID:28154176 NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Guanosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
GDP-alpha-D-glucose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of guanosine diphosphate glucose] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
GDP-beta-S term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acat1 acetyl-CoA acetyltransferase 1 multiple interactions ISO guanosine 5'-O-(2-thiodiphosphate) inhibits the reaction [Serotonin results in increased expression of ACAT1 protein] CTD PMID:16157345 NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:62,876,003...62,905,042 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 decreases activity ISO guanosine 5'-O-(2-thiodiphosphate) results in decreased activity of TRPC6 protein CTD PMID:11179201 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
glutaryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138 		JBrowse link
G Acot8 acyl-CoA thioesterase 8 affects hydrolysis ISO ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:173,950,531...173,962,570 		JBrowse link
GTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases hydrolysis ISO ABCB1 protein results in increased hydrolysis of Guanosine Triphosphate CTD PMID:2900677 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions EXP Guanosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G App amyloid beta precursor protein increases secretion ISO Guanosine Triphosphate results in increased secretion of APP protein modified form CTD PMID:22906069 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Cdc42 cell division cycle 42 multiple interactions ISO
EXP 		Resveratrol promotes the reaction [CDC42 protein binds to Guanosine Triphosphate]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased expression of [CDC42 protein binds to Guanosine Triphosphate]
Ethanol results in decreased expression of [CDC42 protein binds to Guanosine Triphosphate]
Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein] 		CTD PMID:15217905 PMID:16734383 PMID:20829428 PMID:28871336 NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:154,839,631...154,876,627 		JBrowse link
G Crh corticotropin releasing hormone decreases activity EXP Guanosine Triphosphate results in decreased activity of CRH protein CTD PMID:2153673 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]] CTD PMID:16734383 NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468 		JBrowse link
G Fut8 fucosyltransferase 8 decreases activity ISO Guanosine Triphosphate results in decreased activity of FUT8 protein CTD PMID:12770769 NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775 		JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions ISO [dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate CTD PMID:22171090 NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737 		JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions ISO [dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate CTD PMID:22171090 NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987 		JBrowse link
G Gypa glycophorin A increases expression ISO Guanosine Triphosphate results in increased expression of GYPA protein CTD PMID:17002868 NCBI chr19:44,354,669...44,370,304
Ensembl chr19:44,354,706...44,370,291 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Guanosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] inhibits the reaction [HRAS protein binds to Guanosine Triphosphate] CTD PMID:25825487 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Hrh1 histamine receptor H 1 multiple interactions ISO Guanosine Triphosphate analog affects the reaction [Histamine inhibits the reaction [Pyrilamine binds to HRH1 protein]] CTD PMID:2419744 NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:149,120,039...149,208,248 		JBrowse link
G Hrh3 histamine receptor H3 multiple interactions
affects binding 		ISO
EXP 		6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one inhibits the reaction [alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein]]; alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein] CTD PMID:21634396 NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:187,569,175...187,574,259 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions EXP Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]; Guanosine Triphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese inhibits the reaction [Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]] CTD PMID:21126535 NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760 		JBrowse link
G Kras KRAS proto-oncogene, GTPase affects binding
multiple interactions
increases hydrolysis 		ISO Guanosine Triphosphate binds to KRAS protein; Guanosine Triphosphate binds to KRAS protein mutant form
KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]
KRAS protein mutant form results in increased hydrolysis of Guanosine Triphosphate; KRAS protein results in increased hydrolysis of Guanosine Triphosphate 		CTD PMID:28154176 NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320 		JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 affects binding
multiple interactions 		ISO LRRK2 protein binds to Guanosine Triphosphate
sodium arsenite inhibits the reaction [LRRK2 protein binds to Guanosine Triphosphate] 		CTD PMID:24942733 NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:124,706,080...124,867,239 		JBrowse link
G Mtnr1b melatonin receptor 1B multiple interactions ISO Guanosine Triphosphate inhibits the reaction [Carbaryl inhibits the reaction [Melatonin binds to MTNR1B protein]]; Guanosine Triphosphate inhibits the reaction [Carbofuran inhibits the reaction [Melatonin binds to MTNR1B protein]] CTD PMID:28027439 NCBI chr 8:20,919,593...20,934,109
Ensembl chr 8:20,919,593...20,934,109 		JBrowse link
G Oprm1 opioid receptor, mu 1 affects binding
multiple interactions 		EXP Guanosine Triphosphate binds to OPRM1 protein
Dronabinol promotes the reaction [Guanosine Triphosphate binds to OPRM1 protein] 		CTD PMID:16823391 NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756 		JBrowse link
G P2rx5 purinergic receptor P2X 5 affects transport EXP GTP affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935 		JBrowse link
G P2ry4 pyrimidinergic receptor P2Y4 multiple interactions EXP Guanosine Triphosphate binds to and results in increased activity of P2RY4 protein CTD PMID:15654852 NCBI chr  X:69,722,604...69,757,726
Ensembl chr  X:69,721,753...69,753,510 		JBrowse link
G Panx1 Pannexin 1 decreases activity ISO Guanosine Triphosphate results in decreased activity of PANX1 protein CTD PMID:19023039 NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200 		JBrowse link
G Pgp phosphoglycolate phosphatase decreases phosphorylation ISO PGP protein results in decreased phosphorylation of Guanosine Triphosphate CTD PMID:24338473 NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,999,331...14,002,408 		JBrowse link
G Pomc proopiomelanocortin multiple interactions ISO [Guanosine Triphosphate co-treated with Lithium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Potassium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Sodium Chloride] results in decreased activity of POMC protein modified form CTD PMID:2550106 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Rab3a RAB3A, member RAS oncogene family affects binding
increases cleavage
multiple interactions 		EXP [RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein; Guanosine Triphosphate binds to RAB3A protein; RAB3A protein binds to Guanosine Triphosphate; SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]
RAB3A protein results in increased cleavage of Guanosine Triphosphate
[alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; manganese chloride results in increased expression of [RAB3A protein binds to Guanosine Triphosphate]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] 		CTD PMID:7929154 PMID:29289693 NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,718,167...18,721,842 		JBrowse link
G Rabgap1 RAB GTPase activating protein 1 multiple interactions
affects binding 		EXP manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] CTD PMID:29289693 NCBI chr 3:41,617,784...41,735,795
Ensembl chr 3:41,617,793...41,735,791 		JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions ISO
EXP 		Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased expression of [RAC1 protein binds to Guanosine Triphosphate]
Ethanol results in decreased expression of [RAC1 protein binds to Guanosine Triphosphate]
CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; GGTI 298 results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein] 		CTD PMID:16734383 PMID:20829428 PMID:28871336 NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109 		JBrowse link
G Rap1b RAP1B, member of RAS oncogene family multiple interactions ISO
EXP 		[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] CTD PMID:21693435 NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217 		JBrowse link
G Rasa1 RAS p21 protein activator 1 multiple interactions ISO KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate] CTD PMID:28154176 NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:17,593,136...17,676,161 		JBrowse link
G Rhoa ras homolog family member A multiple interactions
affects binding 		ISO
EXP 		Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one promotes the reaction [Guanosine Triphosphate binds to RHOA protein]
Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Cadmium Chloride promotes the reaction [RHOA protein binds to Guanosine Triphosphate]; Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; tempol inhibits the reaction [Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Zoledronic Acid results in increased expression of [RHOA protein binds to Guanosine Triphosphate] 		CTD PMID:16734383 PMID:21257924 PMID:25268128 PMID:26220685 PMID:28871336 More... NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302 		JBrowse link
G Snca synuclein alpha multiple interactions
affects binding 		EXP manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] CTD PMID:29289693 NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315 		JBrowse link
G Sos1 SOS Ras/Rac guanine nucleotide exchange factor 1 multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] inhibits the reaction [HRAS protein binds to Guanosine Triphosphate] CTD PMID:25825487 NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350 		JBrowse link
G Tgm2 transglutaminase 2 affects binding ISO Guanosine Triphosphate binds to TGM2 protein CTD PMID:15556610 NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Guanosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
guanosine 5'-[beta,gamma-imido]triphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions ISO Guanylyl Imidodiphosphate inhibits the reaction [Carbachol inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]] CTD PMID:20708676 NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions
decreases activity 		EXP CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]
Guanylyl Imidodiphosphate results in decreased activity of CRH protein 		CTD PMID:2153673 NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386 		JBrowse link
G Csnk2a1 casein kinase 2 alpha 1 affects binding ISO Guanylyl Imidodiphosphate binds to CSNK2A1 protein CTD PMID:34344863 NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase affects binding ISO Guanylyl Imidodiphosphate binds to GMDS protein CTD PMID:25526675 NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,304,056...32,830,706 		JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP] CTD PMID:2153673 NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445 		JBrowse link
G Pomc proopiomelanocortin multiple interactions ISO [Guanylyl Imidodiphosphate co-treated with Sodium Chloride] results in decreased activity of POMC protein modified form CTD PMID:2550106 NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173 		JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO Guanylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873 		JBrowse link
guanosine 5'-[gamma-thio]triphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adora2a adenosine A2a receptor multiple interactions ISO ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)] CTD PMID:14756803 NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802 		JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions
affects binding 		ISO (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; XLR-11 metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)] CTD PMID:28087785 PMID:29549157 PMID:32510591 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions
affects binding 		ISO (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; afimoxifene inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 281 inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; cannabinoid CB2 receptor agonist ABK5 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; iodopravadoline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; ridaifen-B inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Tamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; XLR-11 metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)] CTD PMID:27936172 PMID:28087785 PMID:29549157 PMID:29906493 PMID:30951717 More... NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961 		JBrowse link
G Gna13 G protein subunit alpha 13 affects binding
multiple interactions 		ISO Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein] 		CTD PMID:17876302 NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,836,444...94,874,968 		JBrowse link
G Gnai1 G protein subunit alpha i1 affects binding ISO GNAI1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) CTD PMID:29748632 NCBI chr 4:17,706,061...17,790,176
Ensembl chr 4:17,706,025...17,789,198 		JBrowse link
G Gnai3 G protein subunit alpha i3 affects binding ISO GNAI3 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) CTD PMID:29748632 NCBI chr 2:198,430,920...198,468,874 JBrowse link
G Gnao1 G protein subunit alpha o1 affects binding ISO GNAO1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) CTD PMID:29748632 NCBI chr19:11,040,788...11,198,437
Ensembl chr19:11,040,788...11,198,437 		JBrowse link
G Gnas GNAS complex locus affects binding ISO GNAS protein binds to Guanosine 5'-O-(3-Thiotriphosphate) CTD PMID:29748632 NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536 		JBrowse link
G Gnaz G protein subunit alpha z affects binding ISO GNAZ protein binds to Guanosine 5'-O-(3-Thiotriphosphate) CTD PMID:29748632 NCBI chr20:13,642,853...13,693,616
Ensembl chr20:13,644,020...13,669,287 		JBrowse link
G Gpr55 G protein-coupled receptor 55 multiple interactions ISO [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein] CTD PMID:17876302 NCBI chr 9:94,037,748...94,081,426
Ensembl chr 9:94,036,162...94,088,707 		JBrowse link
G Hrh4 histamine receptor H4 affects binding
multiple interactions 		ISO Guanosine 5'-O-(3-Thiotriphosphate) binds to HRH4 protein
Histamine promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to HRH4 protein] 		CTD PMID:11181941 NCBI chr18:4,440,977...4,457,132
Ensembl chr18:4,440,977...4,457,132 		JBrowse link
G Myl9 myosin light chain 9 multiple interactions EXP [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] CTD PMID:29660437 NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:165,742,046...165,748,410 		JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO [7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [clocinnamox binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate)
[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate); ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)] 		CTD PMID:11413242 PMID:14756803 NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756 		JBrowse link
G Plcb1 phospholipase C beta 1 multiple interactions
increases activity 		EXP [3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein; Caffeine inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Caffeine inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein] CTD PMID:15998294 NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646 		JBrowse link
G Plcg2 phospholipase C, gamma 2 multiple interactions ISO [[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] CTD PMID:25903139 PMID:27542411 NCBI chr19:62,456,196...62,592,684
Ensembl chr19:62,453,259...62,592,684 		JBrowse link
G Plek pleckstrin increases phosphorylation
multiple interactions 		ISO Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein
dioleoylphosphatidic acid analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; Oleic Acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; phosphatidylethanol analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein] 		CTD PMID:8928743 NCBI chr14:95,598,650...95,631,326
Ensembl chr14:95,598,654...95,655,721 		JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A multiple interactions
increases phosphorylation 		EXP Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein]
Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PPP1R12A protein 		CTD PMID:29660437 NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157 		JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873 		JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions ISO Methohexital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Pentobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Secobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Thiamylal inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein] CTD PMID:15263067 NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109 		JBrowse link
G Rac2 Rac family small GTPase 2 multiple interactions ISO [[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] CTD PMID:25903139 PMID:27542411 NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267 		JBrowse link
G Rhoa ras homolog family member A affects localization
multiple interactions 		EXP Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein]; Sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein] 		CTD PMID:12960549 PMID:29660437 NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302 		JBrowse link
G Rock2 Rho-associated coiled-coil containing protein kinase 2 affects localization
multiple interactions 		EXP Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein
sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein] 		CTD PMID:12960549 NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:45,407,965...45,502,771 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 increases activity ISO Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of TRPC6 protein CTD PMID:11179201 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
guanosine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fut8 fucosyltransferase 8 decreases activity ISO Guanosine Monophosphate results in decreased activity of FUT8 protein CTD PMID:12770769 NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase affects binding ISO Guanosine Monophosphate binds to GMDS protein CTD PMID:25526675 NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,304,056...32,830,706 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [NR1I2 protein affects the susceptibility to Pregnenolone Carbonitrile] which affects the abundance of Guanosine Monophosphate CTD PMID:38971454 NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380 		JBrowse link
hexanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806 		JBrowse link
IDP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G H2ax H2A.X variant histone multiple interactions ISO Inosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Inosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
IMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G App amyloid beta precursor protein multiple interactions
increases abundance 		ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate]
APP protein mutant form results in increased abundance of Inosine Monophosphate
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Inosine Monophosphate] 		CTD PMID:39172838 NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971 		JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]] CTD PMID:20868668 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Impdh2 inosine monophosphate dehydrogenase 2 affects binding
multiple interactions 		ISO Inosine Monophosphate binds to IMPDH2 protein
berberrubine inhibits the reaction [Inosine Monophosphate binds to IMPDH2 protein] 		CTD PMID:37871880 NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions
affects abundance 		ISO PF-06840003 affects the reaction [MAPT protein mutant form affects the abundance of Inosine Monophosphate] CTD PMID:39172838 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108 		JBrowse link
G Mpo myeloperoxidase multiple interactions EXP [potassium oxonate co-treated with Inosine Monophosphate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]] CTD PMID:20868668 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate] CTD PMID:39172838 NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]] CTD PMID:20868668 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Tp73 tumor protein p73 affects abundance ISO TP73 protein affects the abundance of Inosine Monophosphate CTD PMID:25554796 NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552 		JBrowse link
isobutyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO isobutyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
lauroyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806 		JBrowse link
malonyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mlycd malonyl-CoA decarboxylase multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
methacrylyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506 		JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886 		JBrowse link
myristoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dbi diazepam binding inhibitor affects binding ISO S-tetradecanoyl-coenzyme A binds to DBI protein CTD PMID:17044054 NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
N(6)-butyryl-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] CTD PMID:18467523 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein CTD PMID:18467523 NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339 		JBrowse link
G Crem cAMP responsive element modulator multiple interactions
increases expression
decreases response to substance 		EXP CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein]
monobutyryl cyclic AMP results in increased expression of CREM mRNA
CREM protein results in decreased susceptibility to monobutyryl cyclic AMP 		CTD PMID:25381014 NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160 		JBrowse link
G Cyp51 cytochrome P450, family 51 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] CTD PMID:18467523 NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] CTD PMID:18467523 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions EXP CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; monobutyryl cyclic AMP results in increased expression of and affects the localization of and results in increased activity of HIF1A protein CTD PMID:25381014 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Irs2 insulin receptor substrate 2 increases expression
multiple interactions 		EXP monobutyryl cyclic AMP results in increased expression of IRS2 mRNA
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA] 		CTD PMID:25381014 NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein] CTD PMID:18467523 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18467523 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Nr4a2 nuclear receptor subfamily 4, group A, member 2 increases expression
multiple interactions 		EXP monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA] 		CTD PMID:25381014 NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions 		EXP monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA] 		CTD PMID:25381014 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Prkar2b protein kinase cAMP-dependent type II regulatory subunit beta multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of PRKAR2B protein CTD PMID:18467523 NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:54,291,151...54,381,411 		JBrowse link
G Rps6 ribosomal protein S6 increases expression EXP monobutyryl cyclic AMP results in increased expression of RPS6 protein modified form CTD PMID:25381014 NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions 		EXP monobutyryl cyclic AMP results in increased expression of VEGFA protein
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein] 		CTD PMID:25381014 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
NAD zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c13 aldo-keto reductase family 1, member C13 multiple interactions EXP AKR1C13 protein results in increased metabolism of [4-chlorobenzaldehyde co-treated with NAD]; AKR1C13 protein results in increased metabolism of [Hydroxysteroids co-treated with NAD] CTD PMID:16788056 NCBI chr17:70,874,110...70,907,518
Ensembl chr17:70,874,917...70,907,824 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity 		ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein 		CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance 		ISO
EXP 		[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD 		CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity 		ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein 		CTD PMID:10856427 PMID:21256123 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714 		JBrowse link
G Atp6v1e1 ATPase H+ transporting V1 subunit E1 multiple interactions ISO NAD promotes the reaction [SIRT1 protein results in decreased acetylation of ATP6V1E1 protein] CTD PMID:39695235 NCBI chr 4:155,694,534...155,716,660
Ensembl chr 4:155,694,534...155,716,678 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636 		JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:226,376,346...226,397,010
Ensembl chr 2:226,376,356...226,397,006 		JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:33,625,734...33,695,067
Ensembl chr16:33,617,399...33,656,832 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:42,588,948...42,595,669
Ensembl chr14:42,588,948...42,595,669 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:51,972,611...52,006,477
Ensembl chr19:51,972,547...52,026,980 		JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions 		ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine 		CTD PMID:16469290 PMID:25170804 NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:116,186,729...116,204,306 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:106,504,730...106,506,619 JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122 		JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:74,555,606...74,581,376 		JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:133,148,813...133,470,914
Ensembl chr  X:133,148,813...133,470,891 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing 		ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD 		CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP 		[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] 		CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions 		ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein] 		CTD PMID:25246272 PMID:25536389 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:222,462,049...222,504,446 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:9,200,971...9,241,377
Ensembl chr14:9,188,275...9,241,754 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions 		EXP
ISO 		HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD] 		CTD PMID:26859423 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:24,568,551...24,571,012
Ensembl chr  X:24,568,551...24,574,681 		JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:5,997,893...6,047,816
Ensembl chr14:5,997,906...6,047,811 		JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:6,056,708...6,071,463
Ensembl chr14:6,056,774...6,072,823 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:105,165,695...105,176,510 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:831,407...850,950
Ensembl chr 7:831,421...850,873 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,828,608...4,830,634 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:191,842,688...191,845,919
Ensembl chr 1:191,842,636...191,845,921 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions 		ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD] 		CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions 		ISO NAD results in increased expression of IGFBP1 mRNA
NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] 		CTD PMID:32781018 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803 		JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Mir34a microRNA 34a decreases abundance
multiple interactions 		ISO MIR34A mRNA results in decreased abundance of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] 		CTD PMID:23834033 NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:165,815,952...165,816,053 		JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:98,854,235...98,894,208
Ensembl chr13:98,871,289...98,894,252 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781 		JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:206,225,775...206,261,280
Ensembl chr 1:206,229,035...206,261,280 		JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:171,427,973...171,458,586
Ensembl chr 5:171,428,000...171,458,579 		JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions 		ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] 		CTD PMID:23834033 PMID:25505128 PMID:33949241 NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544 		JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:47,684,420...47,794,914
Ensembl chr 2:47,684,406...47,794,931 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions 		EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] 		CTD PMID:27558805 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance 		ISO
EXP 		[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD 		CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:109,829,721...109,839,054
Ensembl chr 7:109,829,722...109,843,566 		JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:112,731,803...112,771,978
Ensembl chr 7:112,731,803...112,771,609 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
decreases activity 		EXP 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] CTD PMID:18815186 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:140,406,318...140,427,201
Ensembl chr 5:140,406,214...140,427,200 		JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:7,969,931...7,998,834
Ensembl chr 5:7,971,705...7,999,019 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:65,499,763...65,510,304 JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:1,912,120...1,931,836
Ensembl chr 7:1,925,335...1,936,049 		JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions 		ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein 		CTD PMID:18926804 PMID:25526675 NCBI chr 5:21,816,394...21,841,596
Ensembl chr 5:21,816,394...21,838,551 		JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:65,588,726...65,607,534
Ensembl chr 7:65,593,000...65,605,630 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance 		ISO
EXP 		6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; NAD promotes the reaction [SIRT1 protein results in decreased acetylation of ATP6V1E1 protein]
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] 		CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:46,568,627...46,571,741
Ensembl chr20:46,568,629...46,571,741 		JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:101,581,765...101,602,779
Ensembl chr15:101,582,227...101,602,718 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression 		ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein 		CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation 		ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction
multiple interactions 		ISO XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] 		CTD PMID:30998386 PMID:35778544 NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613 		JBrowse link
NAD(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acmsd aminocarboxymuconate semialdehyde decarboxylase increases abundance EXP ACMSD protein results in increased abundance of NAD CTD PMID:17896587 NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c13 aldo-keto reductase family 1, member C13 multiple interactions EXP AKR1C13 protein results in increased metabolism of [4-chlorobenzaldehyde co-treated with NAD]; AKR1C13 protein results in increased metabolism of [Hydroxysteroids co-treated with NAD] CTD PMID:16788056 NCBI chr17:70,874,110...70,907,518
Ensembl chr17:70,874,917...70,907,824 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] CTD PMID:25446855 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] CTD PMID:25536389 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions
increases activity 		ISO [ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein 		CTD PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 multiple interactions ISO [ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde CTD PMID:7779080 NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions
affects binding
affects abundance 		ISO
EXP 		[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD 		CTD PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More... NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity 		ISO [ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein 		CTD PMID:10856427 PMID:21256123 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 multiple interactions EXP NAD binds to and affects the activity of ALDH5A1 protein CTD PMID:18926807 NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714 		JBrowse link
G Atp6v1e1 ATPase H+ transporting V1 subunit E1 multiple interactions ISO NAD promotes the reaction [SIRT1 protein results in decreased acetylation of ATP6V1E1 protein] CTD PMID:39695235 NCBI chr 4:155,694,534...155,716,660
Ensembl chr 4:155,694,534...155,716,678 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO NAD results in decreased expression of BAX protein CTD PMID:12390773 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO NAD results in increased expression of BCL2 protein CTD PMID:12390773 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] CTD PMID:11461765 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO NAD binds to and results in increased activity of BDH1 protein CTD PMID:25526675 NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636 		JBrowse link
G Bdh2 3-hydroxybutyrate dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of BDH2 protein CTD PMID:25526675 NCBI chr 2:226,376,346...226,397,010
Ensembl chr 2:226,376,356...226,397,006 		JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 decreases oxidation ISO BMAL1 gene mutant form results in decreased oxidation of NAD CTD PMID:27056296 NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] CTD PMID:24040102 PMID:24491677 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] CTD PMID:10334203 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cbr4 carbonyl reductase 4 multiple interactions ISO NAD binds to and results in increased activity of CBR4 protein CTD PMID:25526675 NCBI chr16:33,625,734...33,695,067
Ensembl chr16:33,617,399...33,656,832 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] CTD PMID:22561310 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] CTD PMID:22561310 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit multiple interactions ISO CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr14:42,588,948...42,595,669
Ensembl chr14:42,588,948...42,595,669 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO [NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein CTD PMID:11752025 NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031 		JBrowse link
G Cyb5b cytochrome b5 type B multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr19:51,972,611...52,006,477
Ensembl chr19:51,972,547...52,026,980 		JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 affects binding
multiple interactions 		ISO CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine 		CTD PMID:16469290 PMID:25170804 NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:116,186,729...116,204,306 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO 1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] CTD PMID:28595002 NCBI chr10:106,504,730...106,506,619 JBrowse link
G Dek DEK proto-oncogene increases oxidation ISO DEK protein results in increased oxidation of NAD CTD PMID:28558019 NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122 		JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO NAD binds to and results in increased activity of DHRS9 protein CTD PMID:25526675 NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:74,555,606...74,581,376 		JBrowse link
G Enox2 ecto-NOX disulfide-thiol exchanger 2 multiple interactions ISO [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD CTD PMID:20518072 NCBI chr  X:133,148,813...133,470,914
Ensembl chr  X:133,148,813...133,470,891 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing 		ISO ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD 		CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G Gale UDP-galactose-4-epimerase multiple interactions ISO NAD binds to and results in increased activity of GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO NAD results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO
EXP 		[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] 		CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions EXP NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] CTD PMID:22561310 NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance
multiple interactions 		ISO GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein] 		CTD PMID:25246272 PMID:25536389 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] CTD PMID:24491677 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase increases metabolic processing ISO HADH protein results in increased metabolism of NAD CTD PMID:10600649 NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:222,462,049...222,504,446 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein CTD PMID:25526675 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hpse heparanase increases expression EXP NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein CTD PMID:19429930 NCBI chr14:9,200,971...9,241,377
Ensembl chr14:9,188,275...9,241,754 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] CTD PMID:10334203 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions ISO [Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein CTD PMID:25526675 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 increases reduction
multiple interactions 		EXP
ISO 		HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD] 		CTD PMID:26859423 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein CTD PMID:25526675 NCBI chr  X:24,568,551...24,571,012
Ensembl chr  X:24,568,551...24,574,681 		JBrowse link
G Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 multiple interactions ISO NAD binds to and results in increased activity of HSD17B11 protein CTD PMID:25526675 NCBI chr14:5,997,893...6,047,816
Ensembl chr14:5,997,906...6,047,811 		JBrowse link
G Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 multiple interactions ISO NAD binds to and results in increased activity of HSD17B13 protein CTD PMID:25526675 NCBI chr14:6,056,708...6,071,463
Ensembl chr14:6,056,774...6,072,823 		JBrowse link
G Hsd17b14 hydroxysteroid (17-beta) dehydrogenase 14 multiple interactions ISO NAD binds to and results in increased activity of HSD17B14 protein CTD PMID:25526675 NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:105,165,695...105,176,510 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD17B2 protein CTD PMID:25526675 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions ISO NAD binds to and results in increased activity of HSD17B4 protein CTD PMID:25526675 NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 multiple interactions ISO NAD binds to and results in increased activity of HSD17B6 protein CTD PMID:25526675 NCBI chr 7:831,407...850,950
Ensembl chr 7:831,421...850,873 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO [Gossypol co-treated with NAD] binds to HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,828,608...4,830,634 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO NAD binds to and results in increased activity of HSD3B1 protein CTD PMID:25526675 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 multiple interactions ISO NAD binds to and results in increased activity of HSD3B2 protein CTD PMID:25526675 NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO NAD binds to and results in increased activity of HSD3B7 protein CTD PMID:25526675 NCBI chr 1:191,842,688...191,845,919
Ensembl chr 1:191,842,636...191,845,921 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions 		ISO IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD] 		CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions
increases expression 		ISO NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA 		CTD PMID:32781018 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Insr insulin receptor multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] CTD PMID:25536389 NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803 		JBrowse link
G Ldha lactate dehydrogenase A increases oxidation EXP LDHA protein results in increased oxidation of NAD CTD PMID:8632003 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Mir34a microRNA 34a multiple interactions
decreases abundance 		ISO [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] CTD PMID:23834033 NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:165,815,952...165,816,053 		JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 multiple interactions ISO [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] CTD PMID:25170804 PMID:29856598 NCBI chr13:98,854,235...98,894,208
Ensembl chr13:98,871,289...98,894,252 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 multiple interactions ISO [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine CTD PMID:25170804 NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781 		JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming increases expression ISO NAD results in increased expression of MUC2 mRNA CTD PMID:29935245 NCBI chr 1:206,225,775...206,261,280
Ensembl chr 1:206,229,035...206,261,280 		JBrowse link
G Nadk NAD kinase increases phosphorylation ISO NADK protein results in increased phosphorylation of NAD CTD PMID:22954684 NCBI chr 5:171,427,973...171,458,586
Ensembl chr 5:171,428,000...171,458,579 		JBrowse link
G Nadsyn1 NAD synthetase 1 multiple interactions ISO [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD CTD PMID:12547821 NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase increases chemical synthesis
multiple interactions 		ISO NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] 		CTD PMID:23834033 PMID:25505128 PMID:33949241 NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544 		JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects abundance ISO NDUFS4 protein affects the abundance of NAD CTD PMID:21383081 NCBI chr 2:47,684,420...47,794,914
Ensembl chr 2:47,684,406...47,794,931 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases oxidation
multiple interactions 		EXP NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] 		CTD PMID:27558805 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G P2ry1 purinergic receptor P2Y1 multiple interactions ISO P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:147,390,681...147,398,027 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases abundance
affects abundance 		ISO
EXP 		[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
PARP1 protein results in decreased abundance of NAD
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD 		CTD PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 decreases abundance ISO PARP10 protein results in decreased abundance of NAD CTD PMID:33051211 NCBI chr 7:109,829,721...109,839,054
Ensembl chr 7:109,829,722...109,843,566 		JBrowse link
G Pla2g6 phospholipase A2 group VI multiple interactions ISO PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 7:112,731,803...112,771,978
Ensembl chr 7:112,731,803...112,771,609 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases activity
multiple interactions 		EXP NAD results in decreased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] 		CTD PMID:18815186 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppt1 palmitoyl-protein thioesterase 1 affects abundance ISO PPT1 gene mutant form affects the abundance of NAD CTD PMID:21224254 NCBI chr 5:140,406,318...140,427,201
Ensembl chr 5:140,406,214...140,427,200 		JBrowse link
G Rdh10 retinol dehydrogenase 10 multiple interactions ISO NAD binds to and results in increased activity of RDH10 protein CTD PMID:25526675 NCBI chr 5:7,969,931...7,998,834
Ensembl chr 5:7,971,705...7,999,019 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO NAD binds to and results in increased activity of RDH16 protein CTD PMID:25526675 NCBI chr 7:65,499,763...65,510,304 JBrowse link
G Rdh5 retinol dehydrogenase 5 multiple interactions ISO NAD binds to and results in increased activity of RDH5 protein CTD PMID:25526675 NCBI chr 7:1,912,120...1,931,836
Ensembl chr 7:1,925,335...1,936,049 		JBrowse link
G Sdr16c5 short chain dehydrogenase/reductase family 16C, member 5 affects activity
multiple interactions 		ISO NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein 		CTD PMID:18926804 PMID:25526675 NCBI chr 5:21,816,394...21,841,596
Ensembl chr 5:21,816,394...21,838,551 		JBrowse link
G Sdr9c7 short chain dehydrogenase/reductase family 9C, member 7 multiple interactions ISO NAD binds to and results in increased activity of SDR9C7 protein CTD PMID:25526675 NCBI chr 7:65,588,726...65,607,534
Ensembl chr 7:65,593,000...65,605,630 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases activity
decreases abundance 		ISO
EXP 		6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; NAD promotes the reaction [SIRT1 protein results in decreased acetylation of ATP6V1E1 protein]
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] 		CTD PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More... NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Smpd2 sphingomyelin phosphodiesterase 2 affects activity ISO NAD affects the activity of SMPD2 protein CTD PMID:20518072 NCBI chr20:46,568,627...46,571,741
Ensembl chr20:46,568,629...46,571,741 		JBrowse link
G Sphk1 sphingosine kinase 1 decreases activity ISO NAD results in decreased activity of SPHK1 protein CTD PMID:20518072 NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance ISO TALDO1 gene mutant form results in decreased abundance of NAD CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tgds TDP-glucose 4,6-dehydratase multiple interactions ISO NAD binds to and results in increased activity of TGDS protein CTD PMID:25526675 NCBI chr15:101,581,765...101,602,779
Ensembl chr15:101,582,227...101,602,718 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression 		ISO [2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein 		CTD PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tyr tyrosinase multiple interactions
increases oxidation 		ISO ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] CTD PMID:20685355 NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases reduction
multiple interactions 		ISO XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] 		CTD PMID:30998386 PMID:35778544 NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613 		JBrowse link
NADP zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases abundance 		EXP Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP] CTD PMID:38356441 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions
increases activity
affects binding 		ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat 		CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction 		ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP 		CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847 		JBrowse link
G Akr1b15 aldo-keto reductase family 1 member B15 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-Butanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-hexanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-nonanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Benzyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of n-decyl alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Nicotinyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the reduction of 1-phenyl-1,2-propanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 16-ketoestrone; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-hexanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-pentanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-decadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-hexenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol; [AKR1B8 protein co-treated with NADP] affects the reduction of 3-deoxyglucosone; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-nitrobenzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Acrolein; [AKR1B8 protein co-treated with NADP] affects the reduction of benzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of butyraldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Diacetyl; [AKR1B8 protein co-treated with NADP] affects the reduction of glycolaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Glyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Isatin; [AKR1B8 protein co-treated with NADP] affects the reduction of Phenylglyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Pyruvaldehyde CTD PMID:18845131 NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c14 aldo-keto reductase family 1, member C14 multiple interactions EXP [[AKR1C14 protein co-treated with NADP] results in increased metabolism of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased abundance of quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 9,10-Dimethyl-1,2-benzanthracene; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of benzo(a)pyrene-6,12-quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of Chrysenes; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of Naphthalenes; [AKR1C14 protein co-treated with NADP] results in increased metabolism of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr17:71,066,197...71,083,184
Ensembl chr17:71,066,200...71,083,157 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity 		ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein 		CTD PMID:10856427 PMID:21256123 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821 		JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760 		JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478 		JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821 		JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:16,030,596...16,065,065
Ensembl chr  X:16,030,596...16,065,065 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP 		NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein 		CTD PMID:15720144 PMID:24713513 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730 		JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:91,391,492...91,417,158
Ensembl chr 1:91,391,502...91,417,158 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 1:90,646,098...90,669,762 JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:90,780,468...90,859,852 JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:115,815,212...115,819,281
Ensembl chr 7:115,815,212...115,819,281 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP 		[acetylhydrazine co-treated with NADP] results in decreased activity of CYP2E1 protein; [hydrazine co-treated with NADP] results in decreased activity of CYP2E1 protein; [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein] 		CTD PMID:11181492 PMID:24713513 PMID:39047805 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP
ISO 		[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] 		CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813 		JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:21,511,763...21,547,598
Ensembl chr12:21,471,542...21,547,598 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:106,504,730...106,506,619 JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033 		JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,609,389...15,617,779
Ensembl chr10:15,611,092...15,617,397 		JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:25,320,895...25,346,004 JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:33,206,449...33,213,776
Ensembl chr15:33,206,451...33,213,734 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:70,195,637...70,205,735
Ensembl chr10:70,195,637...70,205,893 		JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:63,418,790...63,424,005
Ensembl chr10:63,418,798...63,424,004 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity 		ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein 		CTD PMID:25451588 PMID:25526675 NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653 		JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:32,924,482...32,948,103
Ensembl chr15:32,936,522...32,948,101 		JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744 		JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:46,003,845...46,036,498
Ensembl chr10:46,003,845...46,036,499 		JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:52,994,205...53,012,281
Ensembl chr10:52,994,205...53,012,281 		JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:177,078,973...177,140,363
Ensembl chr 1:177,079,150...177,161,696 		JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:182,705,499...182,819,290
Ensembl chr 4:182,705,381...182,825,279 		JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP 		[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol] 		CTD PMID:20369854 NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression 		ISO
EXP 		G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein 		CTD PMID:1922005 PMID:5432368 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:109,492,808...109,497,719
Ensembl chr 7:109,492,809...109,497,662 		JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,646,509...9,680,210 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,304,056...32,830,706 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation 		ISO
EXP 		NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP] 		CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation 		ISO
EXP 		NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP] 		CTD PMID:25526675 PMID:26859423 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:100,445,393...100,568,898
Ensembl chr 3:100,445,400...100,568,938 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO 		NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein 		CTD PMID:20522127 PMID:25526675 NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,828,608...4,830,634 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:64,524,435...64,540,527
Ensembl chr19:64,525,891...64,540,762 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815 		JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 multiple interactions EXP NADP promotes the reaction [Ethylmaleimide results in decreased activity of IDH1 protein] CTD PMID:8486157 NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:74,027,892...74,049,555 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions 		ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP] 		CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:42,410,099...42,425,414
Ensembl chr 1:42,410,130...42,426,386 		JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions 		EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite 		CTD PMID:19013139 PMID:21296056 NCBI chr 5:168,182,228...168,270,760
Ensembl chr 5:168,184,613...168,270,760 		JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:23,374,101...23,408,779
Ensembl chr13:23,376,779...23,408,897 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Mat2b methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions ISO [Resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,609,202...25,626,694
Ensembl chr10:25,609,204...25,625,176 		JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:171,427,973...171,458,586
Ensembl chr 5:171,428,000...171,458,579 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation 		ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP 		CTD PMID:21775727 PMID:29950142 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:11,348,080...11,356,621
Ensembl chr10:11,348,213...11,356,620 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP 		[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] 		CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nsdhl NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:155,817,301...155,848,224
Ensembl chr  X:155,817,340...155,848,220 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806 		JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029 		JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing 		EXP
ISO 		NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] 		CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809 		JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954 		JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein] 		CTD PMID:16990274 PMID:19149680 NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436 		JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:78,579,057...78,597,811 		JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:69,882,776...69,896,378
Ensembl chr14:69,882,612...69,896,379 		JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:103,712,373...103,728,247
Ensembl chr 6:103,712,374...103,729,741 		JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:103,748,457...103,761,379
Ensembl chr 6:103,748,427...103,761,380 		JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:78,415,765...78,444,116
Ensembl chr 1:78,415,782...78,490,102 		JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:38,875,693...38,880,836
Ensembl chr 6:38,875,693...38,880,836 		JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:27,629,380...27,636,651
Ensembl chr 8:27,629,380...27,636,651 		JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:33,348,057...33,350,892
Ensembl chr15:33,348,059...33,354,600 		JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:62,624,130...62,636,652
Ensembl chr19:62,624,150...62,636,756 		JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:119,229,447...119,233,320
Ensembl chr 4:119,229,447...119,233,179 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions 		ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP] 		CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586 		JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance 		EXP
ISO 		NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
TIGAR protein results in increased abundance of NADP 		CTD PMID:32057834 PMID:33359019 NCBI chr 4:161,613,306...161,632,248
Ensembl chr 4:161,613,306...161,632,229 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction 		ISO
EXP 		[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] 		CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817 		JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:59,338,402...60,269,323
Ensembl chr19:59,341,233...60,269,441 		JBrowse link
NADP(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP [Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein CTD PMID:11684353 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases abundance 		EXP Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP] CTD PMID:38356441 NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944 		JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] CTD PMID:32057834 NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:21910479 NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions
increases activity
affects binding 		ISO [AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B1 protein
NADP binds to AKR1B1 protein binds to fidarestat 		CTD PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 multiple interactions
increases activity
affects binding
decreases reduction 		ISO [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP 		CTD PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227 NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847 		JBrowse link
G Akr1b15 aldo-keto reductase family 1 member B15 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-Butanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-hexanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-nonanol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Benzyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of n-decyl alcohol; [AKR1B8 protein co-treated with NADP] affects the oxidation of Nicotinyl Alcohol; [AKR1B8 protein co-treated with NADP] affects the reduction of 1-phenyl-1,2-propanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 16-ketoestrone; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-hexanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,3-pentanedione; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-decadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-hexenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol; [AKR1B8 protein co-treated with NADP] affects the reduction of 3-deoxyglucosone; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [AKR1B8 protein co-treated with NADP] affects the reduction of 4-nitrobenzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Acrolein; [AKR1B8 protein co-treated with NADP] affects the reduction of benzaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of butyraldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Diacetyl; [AKR1B8 protein co-treated with NADP] affects the reduction of glycolaldehyde; [AKR1B8 protein co-treated with NADP] affects the reduction of Glyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Isatin; [AKR1B8 protein co-treated with NADP] affects the reduction of Phenylglyoxal; [AKR1B8 protein co-treated with NADP] affects the reduction of Pyruvaldehyde CTD PMID:18845131 NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:21910479 PMID:23261716 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c14 aldo-keto reductase family 1, member C14 multiple interactions EXP [[AKR1C14 protein co-treated with NADP] results in increased metabolism of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased abundance of quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 9,10-Dimethyl-1,2-benzanthracene; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of benzo(a)pyrene-6,12-quinone; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of Chrysenes; [AKR1C14 protein co-treated with NADP co-treated with quinone] results in increased reduction of and affects the activity of Naphthalenes; [AKR1C14 protein co-treated with NADP] results in increased metabolism of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr17:71,066,197...71,083,184
Ensembl chr17:71,066,200...71,083,157 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] CTD PMID:14672942 PMID:21910479 PMID:23261716 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone CTD PMID:25500266 NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes CTD PMID:21910479 NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione CTD PMID:21910479 NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions ISO 1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein] CTD PMID:9585485 NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 multiple interactions
increases activity 		ISO [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein 		CTD PMID:10856427 PMID:21256123 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Atg5 autophagy related 5 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] CTD PMID:32057834 NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821 		JBrowse link
G Bche butyrylcholinesterase multiple interactions ISO [diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] CTD PMID:23085349 NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760 		JBrowse link
G Becn1 beclin 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] CTD PMID:32057834 NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002 		JBrowse link
G Cat catalase multiple interactions EXP CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein CTD PMID:21910479 PMID:25526675 PMID:25541467 NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO NADP binds to and results in increased activity of CBR3 protein CTD PMID:25526675 NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558 		JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Ctsb cathepsin B multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] CTD PMID:32057834 NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478 		JBrowse link
G Ctsd cathepsin D multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] CTD PMID:32057834 NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821 		JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions ISO [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] CTD PMID:22390216 NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:17275678 NCBI chr  X:16,030,596...16,065,065
Ensembl chr  X:16,030,596...16,065,065 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO
EXP 		NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein 		CTD PMID:15720144 PMID:24713513 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] CTD PMID:15720144 PMID:16120791 PMID:19463925 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 multiple interactions ISO [NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog CTD PMID:27137136 NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730 		JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 multiple interactions EXP [CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr 1:91,391,492...91,417,158
Ensembl chr 1:91,391,502...91,417,158 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein CTD PMID:11805216 PMID:16485904 NCBI chr 1:90,646,098...90,669,762 JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein] CTD PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941 NCBI chr 1:90,780,468...90,859,852 JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:24120545
G Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein] CTD PMID:24713513 NCBI chr 7:115,815,212...115,819,281
Ensembl chr 7:115,815,212...115,819,281 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO [CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] CTD PMID:20825217 PMID:24120545 PMID:32198085 NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO
EXP 		[acetylhydrazine co-treated with NADP] results in decreased activity of CYP2E1 protein; [hydrazine co-treated with NADP] results in decreased activity of CYP2E1 protein; [vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein; NADP promotes the reaction [Isoniazid results in decreased activity of CYP2E1 protein] 		CTD PMID:11181492 PMID:24713513 PMID:39047805 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 multiple interactions ISO NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein] CTD PMID:30965050 NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP
ISO 		[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] 		CTD PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More... NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine CTD PMID:20825217 NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813 		JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 multiple interactions EXP [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein CTD PMID:24713513 NCBI chr12:21,511,763...21,547,598
Ensembl chr12:21,471,542...21,547,598 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions ISO [2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] CTD PMID:21910479 PMID:25526675 PMID:28595002 NCBI chr10:106,504,730...106,506,619 JBrowse link
G Decr1 2,4-dienoyl-CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DECR1 protein CTD PMID:25526675 NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033 		JBrowse link
G Decr2 2,4-dienoyl-CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of DECR2 protein CTD PMID:25526675 NCBI chr10:15,609,389...15,617,779
Ensembl chr10:15,611,092...15,617,397 		JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO NADP analog results in decreased activity of DHFR protein CTD PMID:22954684 NCBI chr 2:25,320,895...25,346,004 JBrowse link
G Dhrs1 dehydrogenase/reductase 1 multiple interactions ISO NADP binds to and results in increased activity of DHRS1 protein CTD PMID:25526675 NCBI chr15:33,206,449...33,213,776
Ensembl chr15:33,206,451...33,213,734 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 multiple interactions ISO NADP binds to and results in increased activity of DHRS11 protein CTD PMID:25526675 NCBI chr10:70,195,637...70,205,735
Ensembl chr10:70,195,637...70,205,893 		JBrowse link
G Dhrs13 dehydrogenase/reductase 13 multiple interactions ISO NADP binds to and results in increased activity of DHRS13 protein CTD PMID:25526675 NCBI chr10:63,418,790...63,424,005
Ensembl chr10:63,418,798...63,424,004 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions ISO [NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein CTD PMID:16685466 PMID:25526675 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases activity 		ISO NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein 		CTD PMID:25451588 PMID:25526675 NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653 		JBrowse link
G Dhrs4 dehydrogenase/reductase 4 multiple interactions ISO NADP binds to and results in increased activity of DHRS4 protein CTD PMID:25526675 NCBI chr15:32,924,482...32,948,103
Ensembl chr15:32,936,522...32,948,101 		JBrowse link
G Dhrs7 dehydrogenase/reductase 7 multiple interactions ISO NADP binds to and results in increased activity of DHRS7 protein CTD PMID:25526675 NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744 		JBrowse link
G Dhrs7b dehydrogenase/reductase 7B multiple interactions ISO NADP binds to and results in increased activity of DHRS7B protein CTD PMID:25526675 NCBI chr10:46,003,845...46,036,498
Ensembl chr10:46,003,845...46,036,499 		JBrowse link
G Dhrs7c dehydrogenase/reductase 7C multiple interactions ISO NADP binds to and results in increased activity of DHRS7C protein CTD PMID:25526675 NCBI chr10:52,994,205...53,012,281
Ensembl chr10:52,994,205...53,012,281 		JBrowse link
G Far1 fatty acyl CoA reductase 1 multiple interactions ISO NADP binds to and results in increased activity of FAR1 protein CTD PMID:25526675 NCBI chr 1:177,078,973...177,140,363
Ensembl chr 1:177,079,150...177,161,696 		JBrowse link
G Far2 fatty acyl CoA reductase 2 multiple interactions ISO NADP binds to and results in increased activity of FAR2 protein CTD PMID:25526675 NCBI chr 4:182,705,499...182,819,290
Ensembl chr 4:182,705,381...182,825,279 		JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO NADP binds to and results in increased activity of FASN protein CTD PMID:25526675 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO
EXP 		[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol] 		CTD PMID:20369854 NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases reduction
increases expression 		ISO
EXP 		G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein 		CTD PMID:1922005 PMID:5432368 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions ISO NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] CTD PMID:15788719 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] CTD PMID:32057834 NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685 		JBrowse link
G Gfus GDP-L-fucose synthase multiple interactions ISO NADP binds to and results in increased activity of GFUS protein CTD PMID:25526675 NCBI chr 7:109,492,808...109,497,719
Ensembl chr 7:109,492,809...109,497,662 		JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO [GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]] CTD PMID:26639393 NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,646,509...9,680,210 		JBrowse link
G Gmds GDP-mannose 4, 6-dehydratase multiple interactions ISO NADP binds to and results in increased activity of GMDS protein CTD PMID:25526675 NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,304,056...32,830,706 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases abundance ISO GSK3B protein mutant form results in increased abundance of NADP metabolite CTD PMID:25246272 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
increases oxidation 		ISO
EXP 		NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP] 		CTD PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases reduction
increases oxidation 		ISO
EXP 		NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP] 		CTD PMID:25526675 PMID:26859423 NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions ISO NADP binds to and results in increased activity of HSD11B2 protein CTD PMID:25526675 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein CTD PMID:21232530 PMID:25526675 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of HSD17B12 protein CTD PMID:25526675 NCBI chr 3:100,445,393...100,568,898
Ensembl chr 3:100,445,400...100,568,938 		JBrowse link
G Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 multiple interactions EXP
ISO 		NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein 		CTD PMID:20522127 PMID:25526675 NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 multiple interactions ISO NADP binds to and results in increased activity of HSD17B7 protein CTD PMID:25526675 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of HSD17B8 protein CTD PMID:25526675 NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,828,608...4,830,634 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 multiple interactions ISO [Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein CTD PMID:25526675 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsdl1 hydroxysteroid dehydrogenase like 1 multiple interactions ISO NADP binds to and results in increased activity of HSDL1 protein CTD PMID:25526675 NCBI chr19:64,524,435...64,540,527
Ensembl chr19:64,525,891...64,540,762 		JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein CTD PMID:25526675 NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 multiple interactions ISO NADP binds to and results in increased activity of HTATIP2 protein CTD PMID:25526675 NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815 		JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 multiple interactions EXP NADP promotes the reaction [Ethylmaleimide results in decreased activity of IDH1 protein] CTD PMID:8486157 NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:74,027,892...74,049,555 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions 		ISO IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP] 		CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682 		JBrowse link
G Iyd iodotyrosine deiodinase increases oxidation ISO IYD protein results in increased oxidation of NADP CTD PMID:33352258 NCBI chr 1:42,410,099...42,425,414
Ensembl chr 1:42,410,130...42,426,386 		JBrowse link
G Kcnab2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 affects binding
multiple interactions 		EXP NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite 		CTD PMID:19013139 PMID:21296056 NCBI chr 5:168,182,228...168,270,760
Ensembl chr 5:168,184,613...168,270,760 		JBrowse link
G Kdsr 3-ketodihydrosphingosine reductase multiple interactions ISO NADP binds to and results in increased activity of KDSR protein CTD PMID:25526675 NCBI chr13:23,374,101...23,408,779
Ensembl chr13:23,376,779...23,408,897 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects abundance ISO KEAP1 protein affects the abundance of NADP CTD PMID:21775727 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 multiple interactions ISO NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] CTD PMID:33359019 NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:32057834 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Mat2b methionine adenosyltransferase 2 non-catalytic beta subunit multiple interactions ISO [resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein CTD PMID:25526675 NCBI chr10:25,609,202...25,626,694
Ensembl chr10:25,609,204...25,625,176 		JBrowse link
G Nadk NAD kinase multiple interactions ISO [3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP CTD PMID:22954684 NCBI chr 5:171,427,973...171,458,586
Ensembl chr 5:171,428,000...171,458,579 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects abundance
affects oxidation 		ISO NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP 		CTD PMID:21775727 PMID:29950142 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nmral1 NmrA like redox sensor 1 multiple interactions ISO [Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein CTD PMID:25526675 NCBI chr10:11,348,080...11,356,621
Ensembl chr10:11,348,213...11,356,620 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO
EXP 		[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] 		CTD PMID:20545351 PMID:21910479 PMID:27558805 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nsdhl NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL multiple interactions ISO NADP binds to and results in increased activity of NSDHL protein CTD PMID:25526675 NCBI chr  X:155,817,301...155,848,224
Ensembl chr  X:155,817,340...155,848,220 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP] CTD PMID:17669606 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein CTD PMID:25526675 NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:81,347,173...81,375,806 		JBrowse link
G Pgd phosphogluconate dehydrogenase increases expression EXP NADP results in increased expression of PGD protein CTD PMID:1922005 NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029 		JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
increases metabolic processing 		EXP
ISO 		NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] 		CTD PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More... NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809 		JBrowse link
G Ppif peptidylprolyl isomerase F multiple interactions EXP [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein] CTD PMID:26975474 NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954 		JBrowse link
G Prnp prion protein multiple interactions ISO [NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein] 		CTD PMID:16990274 PMID:19149680 NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436 		JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions EXP [PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene CTD PMID:11524419 PMID:21939268 NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:78,579,057...78,597,811 		JBrowse link
G Qdpr quinoid dihydropteridine reductase multiple interactions ISO NADP binds to and results in increased activity of QDPR protein CTD PMID:25526675 NCBI chr14:69,882,776...69,896,378
Ensembl chr14:69,882,612...69,896,379 		JBrowse link
G Rdh11 retinol dehydrogenase 11 multiple interactions ISO NADP binds to and results in increased activity of RDH11 protein CTD PMID:25526675 NCBI chr 6:103,712,373...103,728,247
Ensembl chr 6:103,712,374...103,729,741 		JBrowse link
G Rdh12 retinol dehydrogenase 12 multiple interactions ISO NADP binds to and results in increased activity of RDH12 protein CTD PMID:25526675 NCBI chr 6:103,748,457...103,761,379
Ensembl chr 6:103,748,427...103,761,380 		JBrowse link
G Rdh13 retinol dehydrogenase 13 multiple interactions ISO NADP binds to and results in increased activity of RDH13 protein CTD PMID:25526675 NCBI chr 1:78,415,765...78,444,116
Ensembl chr 1:78,415,782...78,490,102 		JBrowse link
G Rdh14 retinol dehydrogenase 14 multiple interactions ISO NADP binds to and results in increased activity of RDH14 protein CTD PMID:25526675 NCBI chr 6:38,875,693...38,880,836
Ensembl chr 6:38,875,693...38,880,836 		JBrowse link
G Rdh8 retinol dehydrogenase 8 multiple interactions ISO NADP binds to and results in increased activity of RDH8 protein CTD PMID:25526675 NCBI chr 8:27,629,380...27,636,651
Ensembl chr 8:27,629,380...27,636,651 		JBrowse link
G Sdr39u1 short chain dehydrogenase/reductase family 39U, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR39U1 protein CTD PMID:25526675 NCBI chr15:33,348,057...33,350,892
Ensembl chr15:33,348,059...33,354,600 		JBrowse link
G Sdr42e1 short chain dehydrogenase/reductase family 42E, member 1 multiple interactions ISO NADP binds to and results in increased activity of SDR42E1 protein CTD PMID:25526675 NCBI chr19:62,624,130...62,636,652
Ensembl chr19:62,624,150...62,636,756 		JBrowse link
G Spr sepiapterin reductase multiple interactions ISO NADP binds to and results in increased activity of SPR protein CTD PMID:25526675 NCBI chr 4:119,229,447...119,233,320
Ensembl chr 4:119,229,447...119,233,179 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] CTD PMID:32057834 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Taldo1 transaldolase 1 decreases abundance
multiple interactions 		ISO TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP] 		CTD PMID:19436114 NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase affects abundance EXP TDO2 protein affects the abundance of NADP CTD PMID:7306070 NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586 		JBrowse link
G Tigar TP53 induced glycolysis regulatory phosphatase multiple interactions
increases abundance 		EXP
ISO 		NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
TIGAR protein results in increased abundance of NADP
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] 		CTD PMID:32057834 PMID:33359019 NCBI chr 4:161,613,306...161,632,248
Ensembl chr 4:161,613,306...161,632,229 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein] CTD PMID:10942736 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions EXP [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] CTD PMID:20457604 NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases reduction 		ISO
EXP 		[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] 		CTD PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More... NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817 		JBrowse link
G Wwox WW domain-containing oxidoreductase multiple interactions ISO NADP binds to and results in increased activity of WWOX protein CTD PMID:25526675 NCBI chr19:59,338,402...60,269,323
Ensembl chr19:59,341,233...60,269,441 		JBrowse link
nicotinic acid-adenine dinucleotide phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Edn1 endothelin 1 increases metabolic processing
multiple interactions 		ISO EDN1 protein results in increased metabolism of NAADP
NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP] 		CTD PMID:23940720 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Faslg Fas ligand multiple interactions
increases abundance 		ISO CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503 		JBrowse link
G Mcoln1 mucolipin TRP cation channel 1 increases activity
multiple interactions 		ISO NAADP results in increased activity of MCOLN1 protein
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium 		CTD PMID:21613607 NCBI chr12:6,357,851...6,372,151
Ensembl chr12:6,357,807...6,372,151 		JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP] CTD PMID:23940720 NCBI chr  X:101,572,338...101,625,571
Ensembl chr  X:101,572,340...101,595,520 		JBrowse link
NMN zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadm acyl-CoA dehydrogenase medium chain multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA] CTD PMID:23834033 NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of ACP5 protein] CTD PMID:30292833 NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:34752167 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Axin1 axin 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in increased expression of AXIN1 protein] CTD PMID:32005247 NCBI chr10:15,667,894...15,720,092
Ensembl chr10:15,667,958...15,720,092 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in increased expression of BAX mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in increased expression of BAX protein]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in increased expression of BAX mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in increased expression of BAX protein] CTD PMID:40372707 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of BCL2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of BCL2 protein]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of BCL2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of BCL2 protein] CTD PMID:40372707 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions EXP
ISO 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased activity of BGLAP protein]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein] CTD PMID:30292833 NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO
EXP 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of CASP1 protein modified form] CTD PMID:30292833 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275 		JBrowse link
G Cat catalase multiple interactions ISO [Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of CAT protein CTD PMID:38159578 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CCND1 protein] CTD PMID:32005247 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD36 mRNA] CTD PMID:38159578 NCBI chr 4:18,209,088...18,302,142 JBrowse link
G Cd38 CD38 molecule multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD38 mRNA] CTD PMID:38159578 NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein] CTD PMID:37640247 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein] CTD PMID:37640247 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:34752167 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CPT1A mRNA] CTD PMID:38159578 NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CTNNB1 protein] CTD PMID:32005247 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT1 mRNA] CTD PMID:38159578 NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT2 mRNA] CTD PMID:38159578 NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566 		JBrowse link
G Elovl3 ELOVL fatty acid elongase 3 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of ELOVL3 mRNA] CTD PMID:38159578 NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:254,938,731...254,942,559 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance ISO ERCC6 gene mutant form results in decreased abundance of Nicotinamide Mononucleotide CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of FASN mRNA] CTD PMID:38159578 NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583 		JBrowse link
G Foxo4 forkhead box O4 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA] CTD PMID:36336710 NCBI chr  X:70,425,218...70,432,120
Ensembl chr  X:70,425,563...70,432,120 		JBrowse link
G Galnt1 polypeptide N-acetylgalactosaminyltransferase 1 increases expression ISO Nicotinamide Mononucleotide results in increased expression of GALNT1 mRNA CTD PMID:29935245 NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of GJA1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of GJA1 protein] CTD PMID:40372707 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] CTD PMID:34752167 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of H2AX protein] CTD PMID:36756972 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hk2 hexokinase 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of HK2 mRNA] CTD PMID:40372707 NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO
EXP 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL18 protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA] CTD PMID:30292833 PMID:38159578 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA] CTD PMID:30292833 PMID:38159578 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of LDHA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of LDHA protein] CTD PMID:40372707 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Lpin1 lipin 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of LPIN1 protein] CTD PMID:38159578 NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK1 protein] CTD PMID:38159578 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK3 protein] CTD PMID:38159578 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mir34a microRNA 34a multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA] CTD PMID:23834033 NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:165,815,952...165,816,053 		JBrowse link
G Nampt nicotinamide phosphoribosyltransferase affects binding
multiple interactions 		EXP
ISO 		NAMPT protein binds to Nicotinamide Mononucleotide
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] 		CTD PMID:16901503 PMID:23834033 PMID:32005247 NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO
EXP 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein] 		CTD PMID:30292833 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394 		JBrowse link
G Nnt nicotinamide nucleotide transhydrogenase multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:53,144,160...53,237,310 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions 		ISO Nicotinamide Mononucleotide results in increased expression of NQO1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide results in increased expression of NQO1 protein] 		CTD PMID:37640247 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Ocln occludin multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of OCLN mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of OCLN protein] CTD PMID:40372707 NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 affects abundance
multiple interactions 		ISO PARP1 protein affects the abundance of Nicotinamide Mononucleotide
[Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PARP1 mRNA] 		CTD PMID:19426698 PMID:34089817 PMID:38159578 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of PCNA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of PCNA protein] CTD PMID:40372707 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of PGK1 protein] CTD PMID:38159578 NCBI chr  X:75,336,988...75,352,962
Ensembl chr  X:75,336,687...75,352,959 		JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of PKM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of PKM protein] CTD PMID:40372707 NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396 		JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PNPLA2 protein] CTD PMID:38159578 NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA] CTD PMID:23834033 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARD mRNA] CTD PMID:23834033 PMID:38159578 NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARG mRNA] CTD PMID:38159578 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA] CTD PMID:36336710 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions EXP Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of PYCARD protein] CTD PMID:30292833 NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Retn resistin multiple interactions ISO [resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] CTD PMID:23827175 NCBI chr12:6,508,653...6,511,115
Ensembl chr12:6,508,801...6,511,116 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SCD1 mRNA] CTD PMID:38159578 NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785 		JBrowse link
G Shank2 SH3 and multiple ankyrin repeat domains 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA] CTD PMID:36336710 NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:208,598,772...209,018,736 		JBrowse link
G Shbg sex hormone binding globulin multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of SHBG mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[uranyl acetate results in increased abundance of Uranium] which results in decreased expression of SHBG protein] CTD PMID:40372707 NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760 		JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions 		EXP
ISO 		Nicotinamide Mononucleotide results in increased expression of SIRT1 mRNA
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SIRT1 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 protein] 		CTD PMID:32087266 PMID:38159578 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
G Slc12a8 solute carrier family 12, member 8 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SLC12A8 mRNA] CTD PMID:38159578 NCBI chr11:80,622,000...80,771,674
Ensembl chr11:80,622,000...80,771,659 		JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:46,490,262...46,532,954
Ensembl chr10:46,489,831...46,533,425 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SOD1 protein] CTD PMID:38159578 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of SOD2 mRNA CTD PMID:38159578 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of SOX9 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of SOX9 protein] CTD PMID:40372707 NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] CTD PMID:36336710 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:34752167 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of TNF mRNA] CTD PMID:38159578 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Txnip thioredoxin interacting protein multiple interactions ISO
EXP 		Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein] 		CTD PMID:30292833 NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731 		JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions EXP
ISO 		Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in increased expression of UCP2 protein]
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of UCP2 mRNA] 		CTD PMID:32087266 PMID:38159578 NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743 		JBrowse link
G Wt1 WT1 transcription factor multiple interactions ISO Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of WT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[Uranyl Nitrate results in increased abundance of Uranium] which results in decreased expression of WT1 protein] CTD PMID:40372707 NCBI chr 3:112,019,721...112,068,454
Ensembl chr 3:112,021,641...112,068,444 		JBrowse link
nucleoside pentaphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2rx5 purinergic receptor P2X 5 affects transport EXP diinosine pentaphosphate affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935 		JBrowse link
oleoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
P(1),P(4)-bis(5'-adenosyl) tetraphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 multiple interactions EXP diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] CTD PMID:19442829 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Nudt2 nudix hydrolase 2 increases hydrolysis ISO NUDT2 protein results in increased hydrolysis of diadenosine tetraphosphate CTD PMID:20533549 NCBI chr 5:61,424,176...61,439,018
Ensembl chr 5:61,424,053...61,439,015 		JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in decreased expression of TH protein] CTD PMID:19442829 NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227 		JBrowse link
P(1),P(5)-bis(5'-adenosyl) pentaphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cftr CF transmembrane conductance regulator multiple interactions ISO P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] CTD PMID:15684079 NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643 		JBrowse link
G Nudt11 nudix hydrolase 11 multiple interactions
increases metabolic processing 		ISO [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] CTD PMID:12121577 NCBI chr  X:18,998,587...19,005,208
Ensembl chr  X:18,998,461...19,005,208 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA] CTD PMID:22892143 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000 		JBrowse link
P(1),P(6)-bis(5'-adenosyl)hexaphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nudt11 nudix hydrolase 11 multiple interactions
increases metabolic processing 		ISO [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate CTD PMID:12121577 NCBI chr  X:18,998,587...19,005,208
Ensembl chr  X:18,998,461...19,005,208 		JBrowse link
palmitoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acox1 acyl-CoA oxidase 1 increases metabolic processing
multiple interactions 		ISO ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A
[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide] 		CTD PMID:10497882 NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136 		JBrowse link
G Ces1d carboxylesterase 1D increases hydrolysis EXP CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A CTD PMID:8611161 NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions EXP valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] CTD PMID:19854160 NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326 		JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 multiple interactions ISO DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] CTD PMID:16214399 NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein CTD PMID:17992261 NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein
Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] 		CTD PMID:11139385 PMID:18812576 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Shbg sex hormone binding globulin decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein CTD PMID:17992261 NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760 		JBrowse link
sofosbuvir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Klrc1 killer cell lectin like receptor C1 decreases expression ISO sofosbuvir co-treated with ledipasvir decreased expression of NCR1 protein in natural killer cells RGD PMID:31218578 RGD:40400920 NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:164,828,163...164,838,464 		JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 affects expression ISO sofosbuvir co-treated with ledipasvir affects expression of NCR1 protein in natural killer cells RGD PMID:31218578 RGD:40400920 NCBI chr 1:78,657,409...78,665,255
Ensembl chr 1:78,659,262...78,703,273 		JBrowse link
stearoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
succinyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of succinyl-coenzyme A CTD PMID:16141203 NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138 		JBrowse link
UDP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein] CTD PMID:18523137 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G Cysltr1 cysteinyl leukotriene receptor 1 multiple interactions ISO [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein] CTD PMID:20083671 NCBI chr  X:75,734,281...75,762,873
Ensembl chr  X:75,734,270...75,763,050 		JBrowse link
G Gpr17 G protein-coupled receptor 17 multiple interactions ISO cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions 		ISO IDH2 protein mutant form results in increased abundance of Uridine Diphosphate
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate] 		CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression 		ISO MRS 2211 inhibits the reaction [Uridine Diphosphate results in increased expression of IL6 protein]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] CTD PMID:18523137 PMID:24849676 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions 		ISO Uridine Diphosphate results in increased phosphorylation of MAPK1 protein
P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein] 		CTD PMID:15034929 PMID:18523137 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions 		ISO Uridine Diphosphate results in increased phosphorylation of MAPK3 protein
P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] 		CTD PMID:15034929 PMID:18523137 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G P2ry6 pyrimidinergic receptor P2Y6 multiple interactions
affects response to substance 		ISO P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein]
P2RY6 gene affects the susceptibility to Uridine Diphosphate 		CTD PMID:18523137 NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:164,706,116...164,743,588 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
UDP-alpha-D-galactose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate Galactose binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Gpr17 G protein-coupled receptor 17 increases activity ISO Uridine Diphosphate Galactose results in increased activity of GPR17 protein CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
UDP-alpha-D-glucose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate Glucose binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Gpr17 G protein-coupled receptor 17 increases activity ISO Uridine Diphosphate Glucose results in increased activity of GPR17 protein CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
UDP-alpha-D-glucuronic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] CTD PMID:35101544 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G B3gat3 beta-1,3-glucuronyltransferase 3 affects binding
multiple interactions 		ISO B3GAT3 protein binds to Uridine Diphosphate Glucuronic Acid
Uridine Diphosphate Glucuronic Acid inhibits the reaction [Diacetyl results in decreased activity of B3GAT3 protein] 		CTD PMID:11986319 NCBI chr 1:215,246,453...215,253,033
Ensembl chr 1:215,246,482...215,266,876 		JBrowse link
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate Glucuronic Acid binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Uridine Diphosphate Glucuronic Acid results in increased expression of PPARGC1A mRNA CTD PMID:23056435 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol CTD PMID:18098064 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with UGT1A3 protein] results in increased metabolism of Lithocholic Acid CTD PMID:36473578 NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] CTD PMID:18098064 PMID:36473578 NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
UDP-D-galactose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate Galactose binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Gpr17 G protein-coupled receptor 17 increases activity ISO Uridine Diphosphate Galactose results in increased activity of GPR17 protein CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
UDP-D-glucose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate Glucose binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
G Gpr17 G protein-coupled receptor 17 increases activity ISO Uridine Diphosphate Glucose results in increased activity of GPR17 protein CTD PMID:18974869 NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702 		JBrowse link
G Uxs1 UDP-glucuronate decarboxylase 1 multiple interactions ISO [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein CTD PMID:25526675 NCBI chr 9:740,929...818,310
Ensembl chr 9:740,724...818,319 		JBrowse link
UDP-N-acetyl-alpha-D-galactosamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gale UDP-galactose-4-epimerase affects binding ISO Uridine Diphosphate N-Acetylgalactosamine binds to GALE protein CTD PMID:25526675 NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:153,478,325...153,481,922 		JBrowse link
UDP-N-acetyl-alpha-D-glucosamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance 		ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate N-Acetylglucosamine] CTD PMID:27469509 NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248 		JBrowse link
uridine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bsg basigin decreases expression ISO Uridine Monophosphate results in decreased expression of BSG protein CTD PMID:36574092 NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005 		JBrowse link
UTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions EXP Uridine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] CTD PMID:1848756 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions EXP Uridine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein] CTD PMID:12044622 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Egfr epidermal growth factor receptor increases phosphorylation EXP Uridine Triphosphate results in increased phosphorylation of EGFR protein CTD PMID:14676212 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Gnaq G protein subunit alpha q multiple interactions EXP Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]] CTD PMID:14676212 NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] CTD PMID:32941855 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions ISO [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids] CTD PMID:16674924 NCBI chr12:38,387,163...38,389,149
Ensembl chr12:38,387,230...38,389,391 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression 		ISO NF157 compound inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]
MRS 2211 inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] 		CTD PMID:24793913 PMID:24849676 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein
RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Uridine Triphosphate results in increased phosphorylation of MAPK1 protein 		CTD PMID:14676212 PMID:15034929 PMID:16674924 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO
EXP 		2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein
RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Uridine Triphosphate results in increased phosphorylation of MAPK3 protein 		CTD PMID:14676212 PMID:15034929 PMID:16674924 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Myl2 myosin light chain 2 multiple interactions EXP Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein] CTD PMID:14676212 NCBI chr12:40,114,964...40,126,236
Ensembl chr12:40,114,958...40,129,149 		JBrowse link
G Myocd myocardin multiple interactions EXP Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein] CTD PMID:14676212 NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819 		JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases expression 		EXP Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]; Uridine Triphosphate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
Uridine Triphosphate results in increased expression of NPPA mRNA 		CTD PMID:14676212 NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493 		JBrowse link
G P2rx1 purinergic receptor P2X 1 affects binding EXP UTP binds to P2rx1 protein RGD PMID:12237343 RGD:727431 NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164 		JBrowse link
G P2ry2 purinergic receptor P2Y2 multiple interactions EXP
ISO 		Uridine Triphosphate binds to and results in increased activity of P2RY2 protein
Endocannabinoids inhibits the reaction [Uridine Triphosphate binds to and results in increased activity of P2RY2 protein]; Uridine Triphosphate binds to and results in increased activity of P2RY2 protein 		CTD PMID:15654852 PMID:30102254 NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:164,759,213...164,781,852 		JBrowse link
G P2ry4 pyrimidinergic receptor P2Y4 multiple interactions EXP Uridine Triphosphate binds to and results in increased activity of P2RY4 protein CTD PMID:15654852 NCBI chr  X:69,722,604...69,757,726
Ensembl chr  X:69,721,753...69,753,510 		JBrowse link
G Panx1 Pannexin 1 decreases activity ISO Uridine Triphosphate results in decreased activity of PANX1 protein CTD PMID:19023039 NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:20,132,165...20,171,200 		JBrowse link
G Sftpb surfactant protein B increases secretion ISO Uridine Triphosphate results in increased secretion of SFTPB protein CTD PMID:14565945 NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646 		JBrowse link
G Sftpc surfactant protein C increases secretion ISO Uridine Triphosphate results in increased secretion of SFTPC protein CTD PMID:14565945 NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] CTD PMID:32941855 NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747 		JBrowse link
G Trpc3 transient receptor potential cation channel, subfamily C, member 3 multiple interactions
increases activity 		ISO ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Uridine Triphosphate results in increased activity of TRPC3 protein] CTD PMID:19289841 NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:121,409,436...121,475,823 		JBrowse link
G Trpc5 transient receptor potential cation channel, subfamily C, member 5 increases activity ISO Uridine Triphosphate results in increased activity of TRPC5 protein CTD PMID:19289841 NCBI chr  X:112,742,828...113,027,638
Ensembl chr  X:112,742,828...113,027,638 		JBrowse link
G Trpc6 transient receptor potential cation channel, subfamily C, member 6 increases activity ISO Uridine Triphosphate results in increased activity of TRPC6 protein CTD PMID:19289841 NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304 		JBrowse link
G Trpc7 transient receptor potential cation channel, subfamily C, member 7 increases activity ISO Uridine Triphosphate results in increased activity of TRPC7 protein CTD PMID:19289841 NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,714,505...7,838,745 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20874
    chemical entity 20872
      atom 20872
        nonmetal atom 20781
          nitrogen atom 19576
            nitrogen molecular entity 19576
              nucleobase-containing molecular entity 5651
                nucleoside phosphate 1639
                  adenosine phosphate + 274
                  cytidine phosphate + 5
                  deoxyadenosine phosphate + 0
                  deoxycytidine phosphate + 3
                  deoxyguanosine phosphate + 2
                  deoxyinosine phosphate + 0
                  deoxyuridine phosphate + 2
                  dinucleotide analogue + 0
                  guanosine phosphate + 39
                  inosine phosphate + 10
                  nucleoside 5'-diphosphate + 68
                  nucleoside 5'-monophosphate + 26
                  nucleoside 5'-triphoshate + 268
                  nucleoside bisphosphate + 7
                  nucleoside diphosphate analogue + 2
                  nucleoside monophosphate analogue + 12
                  nucleoside pentaphosphate + 2
                  nucleoside tetraphosphate + 0
                  nucleoside triphosphate analogue + 44
                  nucleotide + 1600
                  nucleotide derivative + 49
                  oxetanocin A 4-(dihydrogen phosphate) 0
                  thymidine phosphate + 4
                  uridine phosphate + 29
                  xanthosine phosphate + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20874
    subatomic particle 20883
      composite particle 20883
        hadron 20872
          baryon 20883
            nucleon 20872
              atomic nucleus 20883
                atom 20872
                  main group element atom 20796
                    p-block element atom 20796
                      pnictogen 19695
                        phosphorus atom 14760
                          phosphorus molecular entity 14760
                            phosphorus oxoacids and derivatives 14745
                              phosphorus oxoacid derivative 14118
                                phosphoric acid derivative 13866
                                  phosphate 13865
                                    organic phosphate 13865
                                      nucleoside phosphate 1639
                                        adenosine phosphate + 274
                                        cytidine phosphate + 5
                                        deoxyadenosine phosphate + 0
                                        deoxycytidine phosphate + 3
                                        deoxyguanosine phosphate + 2
                                        deoxyinosine phosphate + 0
                                        deoxyuridine phosphate + 2
                                        dinucleotide analogue + 0
                                        guanosine phosphate + 39
                                        inosine phosphate + 10
                                        nucleoside 5'-diphosphate + 68
                                        nucleoside 5'-monophosphate + 26
                                        nucleoside 5'-triphoshate + 268
                                        nucleoside bisphosphate + 7
                                        nucleoside diphosphate analogue + 2
                                        nucleoside monophosphate analogue + 12
                                        nucleoside pentaphosphate + 2
                                        nucleoside tetraphosphate + 0
                                        nucleoside triphosphate analogue + 44
                                        nucleotide + 1600
                                        nucleotide derivative + 49
                                        oxetanocin A 4-(dihydrogen phosphate) 0
                                        thymidine phosphate + 4
                                        uridine phosphate + 29
                                        xanthosine phosphate + 0
paths to the root